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1.1      INTRODUCTION 
 
           The pyrimidine fragment is present in the molecules of a series of biologically 
active compounds, many of which have found use in medical practice (soporific, anti-
inflammatory, antitumor, and other products).1,2 In this connection, great attention has 
recently been paid to derivatives of pyrimidine, including their hydrogenation 
products. The first investigations into the synthesis of such compounds appeared more 
than a hundred years ago (e.g., the Biginelli reaction),3  and for a long time they 
remained unused. Only in the last decade have methods been developed specifically 
for the production of hydrogenated pyrimidine systems and their physicochemical 
properties been studied. This is explained by the high reactivity and wide range of 
biological activity with these scaffolds. Thus, for example, 2-substituted 5-
alkoxycarbonyl-4-aryl-l,4-dihydropyrimidines, which are structural analogs of 
Hantzsch esters, are modulators of the transport of calcium through membranes.4-7 
Many hydrogenated pyrimidines exhibit antimicrobial,8 hypoglemic,9  herbicidal,10 
and pesticidal11 activity. Publications devoted to these problems have been 
summarized in a number of reviews.9-14 
 Pyrimidines have a long and distinguished history extending from the days of their 
discovery as important constituents of nucleic acids to their current use in the 
chemotherapy of AIDS.   
Alloxan (1) is known for its diabetogenic action in a number of animals.15 Uracil (2), 
thymine (3) and cytosine (4) are the three important constituents of nucleic acids 
(Figure 1). 
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(1) Alloxan (2) Uracil (3) Thymine (4) Cytosine
 
Figure 1 
The pyrimidine ring is found in vitamins like thiamine (5), riboflavin (6) (Figure 2) 
and folic acid (7)16 Barbitone (8), (Figure 3) the first barbiturate hypnotic, sedative 
and anticonvulsant are pyrimidine derivatives. 
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Figure 3 
 
1.2 Pharmacological Profile 
 
       4-Aryl-1,4-dihydropyridines (DHPs, e.g. nifedipine) are the most studied class of 
organic calcium channel modulators. More than 30 years after the introduction of 
nifedipine many DHP analogs have now been synthesized and numerous second-
generation commercial products have appeared on the market.17,18 
 
Nowadays, interest has also focused on aza-analogs such as dihydropyrimidines 
(DHPMs) which shows a very similar pharmacological profile to classical 
dihydropyridine calcium channel modulators.5-7,19-20 Over the past few years several 
lead-compounds were developed (i.e. SQ 32,926) that are superior in potency and 
duration of antihypertensive activity to classical DHP drugs, and compare favorable 
with second-generation analogs such as amlodipine and nicardipine (Figure 4). 
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Figure 4 
 
Barrow et al reported in vitro and in vivo evaluation of dihydropyrimidinone C-5 
amides as potent and selective r1A receptor antagonists for the treatment of benign 
prostatic hyperplasia (Figure 5). R1 Adrenergic receptors mediate both vascular and 
lower urinary tract tone, and R1 receptor antagonists such as terazosin are used to 
treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three 
different subtypes of this receptor have been identified, with the R1A receptor being 
most prevalent in lower urinary tract tissue. Barrow et al reported 4-
aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C5 
amide as selective R1A receptor subtype antagonists. In receptor binding assays, these 
types of compounds generally display Ki values for the R1a receptor subtype <1 nM 
while being greater than 100-fold selective versus the R1b and R1d receptor subtypes. 
Many of these compounds were also evaluated in vivo and found to be more potent 
than terazosin in both a rat model of prostate tone and a dog model of intra-urethral 
pressure without significantly affecting blood pressure. While many of the 
compounds tested displayed poor pharmacokinetics, one compound was found to 
have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs. Due 
to its selectivity for the R1a over the R1b and R1d receptors as well as its favorable 
pharmacokinetic profile, it has the potential to relieve the symptoms of BPH without 
eliciting effects on the cardiovascular system.21,22 
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The 4-aryldihydropyrimidinone heterocycles attached to an aminopropyl-4-
arylpiperidine via a C5 amide has proved to be an excellent template for selective 
R1A receptor subtype antagonists. These types of compounds are exceptionally potent 
in both cloned receptor binding studies as well as in vivo pharmacodynamic models of 
prostatic tone. 
 
Atwal et al have examined a series of novel dihydropyrimidine calcium channel 
blockers that contain a basic group attached to either C5 or N3 of the heterocyclic ring 
(Figure 6). Structure-activity studies show that l-(phenylmethyl)-4-piperidinyl 
carbamate moiety at N3 and sulfur at C2 are optimal for vasorelaxant activity in vitro 
and impart potent and long-acting antihypertensive activity in vivo. One of these 
compounds was identified as a lead, and the individual enantiomers were synthesized. 
Two key steps of the synthesis were (1) the efficient separation of the diastereomeric 
ureido derivatives and (2) the high-yield transformation of 2-methoxy intermediate to 
the (p-methoxybenzyl)thio intermediates. Chirality’s was demonstrated to be a 
significant determinant of biological activity, with the DHP receptor recognizing the 
enamines ester moiety but not the carbamate moiety. DHPM is equipotent to 
nifidepine and amlodipine in vitro. In the spontaneously hypertensive rat, DHPM is 
more potent and longer acting than both nifidepine and the long-acting amlodipine 
(DHP derivative). DHPM has the potential advantage of being a single 
enantiomer.23,24 
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Figure 6 
 
In order to explain the potent antihypertensive activity of the modestly active (ICw = 
3.2 pM) DHPM calcium channel blocker, Atwal et al carried out drug metabolism 
studies in the rat and found it is metabolized. Two of the metabolites (ICw = 16 nM) 
and (ICw = 12 nM), were found to be responsible for the antihypertensive activity of 
compound. Potential metabolism in vivo precluded interest in pursuing compounds  
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related to it. Structure-activity studies aimed at identifying additional aryl-substituted 
analogues led to comparable potential in vivo, though these compounds were less 
potent in vitro. To investigate the effects of absolute stereochemistry on potency, 
authors resolved via diastereomeric ureas, prepared by treatment with (R)-α-
methylbenzylamine. The results demonstrate that the active R-(-)-enantiomer is more 
potent and longer acting than nifedipine as an antihypertensive agent in the SHR. The 
in vivo potency and duration is comparable to the long-acting DHP amlodipine. The 
superior oral antihypertensive activity compared to that of previously described 
carbamates (R2=COOEt) could be explained by its improved oral bioavailability, 
possibly resulting from increased stability of the urea functionality (Figure 7).6 
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Figure 7 
 
Authors modified the structure of previously described DHPM i.e. 3-substituted 1,4-
dihydropyrimidines. Structure-activity studies using potassium-depolarized rabbit 
aorta show that ortho, meta-disubstituted aryl derivatives are more potent than either 
ortho or meta-monosubstituted compounds. While vasorelaxant activity was critically 
dependent on the size of the C5 ester group, isopropyl ester being the best, a variety 
of substituents (carbamate, acyl, sulfonyl, and alkyl) were tolerated at N3. The results 
show DHPMs are significantly more potent than corresponding 2- heteroalkyl-l,4-
dihydropyrimidines and only slightly less potent than similarly substituted 2-
heteroalkyl-1-4-dihydropyridines (Figure 8). Where as DHP enantiomer usually show 
10-15-fold difference in activity, the enantiomer of DHPM show more than a 1000-
fold difference in activity. These results strengthen the requirement of an 
enaminoester for binding to the dihydropyridine receptor and indicate a nonspecific 
role for the N3-substituent 
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Figure 8 
 
2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboxylicesters 
(Figure 9), which lack the potential symmetry of DHP calcium channel blockers, 
were prepared and evaluated for biological activity. Biological assays using 
potassium-depolarized rabbit aorta and radio ligand binding techniques showed that 
some of these compounds are potent mimics of DHP calcium channel blockers.25 
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Figure 9 
 
Bryzgalov A. O. et al has studied the antiarrhythmic activity of 4,6-di(het)aryl-5-
nitro-3,4-dihydropyrimidin-(1H)-2-ones (Figure 10) toward two types of 
experimental rat arrhythmia. With CaCl2 induced arrhythmia model, several agents 
have demonstrated high antiarrhythmic activity and the lack of influence on arterial 
pressure of rats.26 
HN
N
H
Ar
NO2
O
 
 
Figure 10 
 
Remennikov G. Y. et al27 has synthesized some novel 4-aryl-5-nitro substituted 
DHPMs (Figure 11) using nitro acetone and screened as calcium modulators. They 
have studied the pharmacological properties of 6-methyl- and 1,6-dimethyl-4-aryl-5- 
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nitro-2-oxo-l,2,3,4-tetrahydropyrimidines with different substituents in the aryl 
fragment, i.e. unsubstituted, ortho, meta, para, di, and tri-substituted compounds and 
observed that 5-nitro DHPMs bearing unsubstituted, ortho and tri-substitution on aryl 
moieties at C4 position reduced blood pressure and inhibited myocardial contractile 
activity. The second group consisted meta, para and di-substituted aryl moieties with 
DHPMs increased blood pressure and had positive inotropic effects. The compounds 
with the highest hypotensive activity were containing substituents in the ortho 
position of the phenyl fragment. Thus, compounds having substitution on aryl 
moieties which had pronounced vasodilator and weak cardio depressive actions, 
increased cardiac pump function (SV). When inhibition of myocardial contractile 
function predominated, there was a reduction in SV. The effect of compounds of the 
first group on heart rate was variable, though most reduced heart rate. In addition, a 
reflex increase in heart rate might be expected because of the reduction in blood 
pressure. The reference preparation for compounds of this group was the calcium 
antagonist nifedipine. The pharmacological profile of compounds of the first group 
was analogous to that of nifedipine. This suggests that they share a common 
mechanism of action - blockade of calcium ion influx 
 
HN
N
H
O
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R3
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R1= H, OMe, NO2
R2= H, OMe, OH, Cl
R3= H, OMe
R4= H, OMe, NO2, CF3, OCHF2
 
 
Figure 11 
 
Brain C. Shook et al28 has synthesized a novel series of                        
arylindenopyrimidines (Figure 12) were identified as A2A and A1 receptor 
antagonists. The series was optimized for vitroactivit by substituting the 8-and-9- 
positions with methylene amine substituents. The compounds show excellent activity 
in mouse models of perkinson’s disease when dosed orally. 
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1.3. Alternative synthetic routes for better yield, shorter reaction                        
time and to synthesize new analogs  
  
           Various modifications have been applied to Biginelli reaction to get better 
yield and to synthesize biologically active analogs. Different catalysts have been 
reported to increase the yield of the reaction. Microwave synthesis strategies have 
also been applied to shorten the reaction time. Solid phase synthesis and 
combinatorial chemistry has made possible to generate library of DHPM analogs. The 
various modifications are discussed in the following section. 
 
? Catalysts 
 Min Yang and coworkers29 have synthesized the different DHPMs by using 
different inorganic salts as a catalyst (Figure 13). They found that the yields of the 
one-pot Biginelli reaction can be increased from 20-50% to 81-99%, while the 
reaction time shorted for 18-24 h to 20-30 min. This report a new and simple 
modification of the Biginelli type reaction by using Yb(OTf)3 and YbCl3 as a catalyst 
under solvent free conditions. One additional important feature of this protocol is the 
catalyst can be easily recovered and reused.  
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100 o C
N
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NH
R
O
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Figure 13 
Indium (III) chloride was emerged as a powerful Lewis catalyst imparting high region 
and chemo selectivity in various chemical transformations. B. C. Ranu and co-
workers30 reported indium (III) chloride (InCl3) as an efficient catalyst for the  
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synthesis of 3,4-dihydropyrimidn-2(1H)-ones (Figure 14). A variety of substituted 
aromatic, aliphatic and heterocyclic aldehydes have been subjected to this 
condensation very efficiently.  Thiourea has been used with similar success to provide 
the corresponding dihydropyrimidin-2(1H)-thiones. 
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O
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O
R
NH2
XH2N
InCl3
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R
X
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R2
O
O
THF
X= O or S  
                                                          Figure 14 
 
Majid M. Heravi et al have reported a simple, efficient and cost-effective method for 
the synthesis of 3,4-dihydropyrimidin-2(1H)-ones/thiones by one pot three-
component cyclocondensation reaction of a 1,3-dicarbonyl compound, an aldehyde 
and urea or thiourea using 12-tungstophosphoric acid31 and 12-molybdophosphoric 
acid32 as  recyclable catalyst (Figure 15). 
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X
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O
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Figure 15 
 
An improved approach has been found to carry out the Biginelli reaction for the 
synthesis of 3,4- dihydropyrimidine- 2(1H)-one derivatives. This synthesis was 
performed in the presence of hydrochloric acid and β-cyclodextrin in ethanol solution. 
Compared with the classical Biginelli reaction conditions, this new approach has the 
advantage of excellent yields and short reaction time.33 
 
An efficient synthesis of 3,4-DHPMs from the aldehyde, β-keto ester and urea in 
ethanol, using ferric chloride hexahydrate or nickel chloride hexahydrate as the 
catalyst, was described. Compared with the classical Biginelli reaction conditions, this 
new method has the advantage of excellent yields (53-97%) and short reaction time  
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(4-5 h).34 5-Alkoxycarbonyl-4-aryl-3,4-dihydropyrimidin-2-ones were synthesized by 
the one-pot reactions of aldehydes, β-ketoesters and urea using a catalytic amount of 
phosphotungstic acid (PTA) in ethanol. The modified Biginelli cyclocondensation not 
only shortens the reaction period and simplifies the operation, but also improves the 
yields.35 
 
Ruthenium (III) chloride efficiently catalyzes the three-component Biginelli reaction 
of an aldehyde, a β-keto ester, and urea or thiourea under solvent-free conditions to 
afford the corresponding 3,4-dihydropyrimidine-2-(1H)-ones in excellent yields.36 
 
The Biginelli reaction, a one-pot condensation of aldehydes, urea or thiourea and β-
dicarbonyl compounds, is efficiently catalyzed by samarium diiodide. The 
biologically active dihydropyrimidinones are easily synthesized in moderate to 
excellent yields under solvent-free conditions.37 
 
Hydroxyapatite doped with ZnCl2, CuCl2, NiCl2 and CoCl2 efficiently catalyses the 
three components Biginelli reaction between an aldehyde, ethyl acetoacetate and urea 
in refluxing toluene to afford the corresponding dihydropyrimidinones in high 
yields.38 
 
Sc(III)triflate efficiently catalyzes the three-component condensation reaction of an 
aldehyde, a β-ketoester and urea in refluxing acetonitrile to afford the corresponding 
3,4-dihydropyrimidin-2(1H)-ones in excellent yields (Figure 16). The catalyst can be 
recovered and reused, making this method friendly and environmentally acceptable.39 
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Figure 16 
Recently, chiral phosphoric acid is reported as highly enantioselective catalyst for 
Biginelli reaction. Reaction is reported in presence of 10 mol % of chiral phosphoric 
acid to produce desired enantioselective product. This is the first organocatalytic 
asymmetric Biginelli reaction. The optimal chiral phosphoric acid  
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afforded the reaction in high yields with excellent enantioselectivities of up to 97%.  
A wide variety of substrates, including aldehydes and α-keto esters, could be 
tolerated. This reaction has an advantage of avoiding the contamination of transition 
metals in the manufacture of the medicinally relevant chiral 3,4-dihydropyrimidin-2-
(1H)-ones (Figure 17).40 
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Figure 17 
 
Shkurko, O. P. et al have  synthesized 4,6-diaryl-5- nitro-3,4-dihydropyrimidin-
2(1H)-ones and N-benzoyl-N'-(1-aryl-2-nitroethyl)urea (Figure 18) using ω-nitro 
acetophenone, aromatic aldehydes and urea in the presence of iron(III), cobalt(II), 
nickel(II), and copper(II) salts as catalyst with moderate to poor yields.41 
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O
NO2 H2N NH2
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ArCH2O HN
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O
FeCl3 6H2O
 
Figure 18 
An efficient three-component synthesis of 3,4-dihydropyrimidinones using 
trichloroisocyanuric acid (TCCA) as mild, homogeneous and neutral catalyst for 
Biginelli reaction in ethanol or DMF under reflux condition.42 Many researchers43-44 
have investigated Biginelli reaction under solvent-free conditions for one-pot 
synthesis of 3,4-dihydropyrimidine-2-(1H)ones/thiones using various catalyst as 
described under.  
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? Solid phase synthesis 
 The generation of combinatorial libraries of heterocyclic compounds by solid 
phase synthesis is of great interest for accelerating lead discovery and lead 
optimization in pharmaceutical research. Multi-component reactions (MCRs)45,46-47 
leading to heterocycles are particularly useful for the creation of diverse chemical 
libraries, since the combination of any 3 small molecular weight building blocks in a 
single operation leads to high combinatorial efficiency. Therefore, solid phase 
modifications of MCRs are rapidly become the cornerstone of combinatorial synthesis 
of small-molecule libraries.  
 
The first solid-phase modification of the Biginelli condensation was reported by Wipf 
and Cunningham48 in 1995 (Figure 19). In this sequence, γ-aminobutyric acid derived 
urea was attached to Wang resin using standard procedures. The resulting polymer-
bound urea was condensed with excess β-ketoester and aromatic aldehydes in THF at 
55 °C in the presence of a catalytic amount of HCl to afford the corresponding 
immobilized DHPMs. Subsequent cleavage of product from the resin by 50 % 
trifluoroacetic acid (TFA) provided DHPMs in high yields and excellent purity. 
 
O
O
R2 CH3
R1
R
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O
O
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O
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O
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Figure 19 
 
Li W. and Lam Y.77 have described the synthesis of 3,4-dihydropyrimidin-2- 
(1H)ones/thiones using sodium benzenesulfinate as a traceless linker (Figure 20). The 
key steps involved in the solid-phase synthetic procedure were sulfinate acidification, 
condensation of urea or thiourea with aldehydes and sulfinic acid and traceless 
product release by a one-pot cyclization-dehydration process. Since a variety of 
reagents can be used, the overall strategy appears to be applicable to library 
generation. 
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Figure 20 
 
Gross et al78 developed a protocol to increase the diversity of DHPM which based on 
immobilized α-ketoamides (Figure 21). The resulting synthetic protocol proved to be 
suitable for the preparation of a small library using different building blocks. They 
found that the aromatic aldehyde and α-ketoamide building blocks were formed the 
expected DHPM derivatives in high purity and yield. The usage of an aliphatic 
aldehyde leads to an isomeric DHPM mixture. Purities and yields were not affected, 
when thiourea was used instead of urea. 
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H
O
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Figure 21 
 
? Liquid phase synthesis 
 In the solid phase synthesis there are some disadvantages of this methodology 
compared to standard solution-phase synthesis, such as difficulties to monitor reaction 
progress, the large excess of reagents typically used in solid-phase supported 
synthesis, low loading capacity and limited solubility during the reaction progress and 
the heterogeneous reaction condition with solid phase.51 Recently, organic synthesis 
of small molecular compounds on soluble polymers, i.e. liquid phase chemistry has 
increasingly become attractive field.52 It couples the advantages of homogeneous 
solution chemistry with those of solid phase chemistry. 
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Moreover, owing to the homogeneity of liquid-phase reactions, the reaction 
conditions can be readily shifted from solution-phase systems without large changes 
and the amount of excessive reagents is less than that in solid-phase reactions. In the 
recent years, Task Specific room temperature Ionic Liquids (TSILs) has emerged as a 
powerful alternative to conventional molecular organic solvents or catalysts. Liu Z. et 
al53 have reported cheap and reusable TSILs for the synthesis of 3,4-
dihydropyrimidin-2(1H)-ones via one-pot three component Biginelli reaction. 
 
Ionic liquid-phase bound acetoacetate reacts with thiourea and various aldehydes with 
a cheap catalyst to afford ionic liquid-phase supported 3,4-dihydropyrimidin-2(1H)-
thiones, which reported by Bazureau J. P. and co-workers54 (Figure 22). 3,4-
Dihydropyrimidinones were synthesized in one-pot, by the reaction of aldehydes, β-
dicarbonyl compounds and urea, catalyzed by non-toxic room temperature ionic 
liquid 1-n-butyl-3-methylimidazolium saccharinate (BMImSac).55 
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Figure 22 
 
? Microwave assisted synthesis 
 In general, the standard procedure for the Biginelli condensation involves one 
pot condensation of the three building blocks in a solvent such as ethanol using a 
strongly acidic catalyst that is hydrochloric acid. One major drawback of this 
procedure, apart from the long reaction time involving reflux temperature, is the 
moderate yields frequently observed when using more complex building blocks. 
Microwave irradiation (MW) has become accepted tool in organic synthesis, because 
the rate enhancement, higher yields and often, improved selectivity with respect to 
conventional reaction conditions.56 The publication by Dandia A. et al57 described 
microwave-enhanced solution-phase Biginelli reactions employing ethyl acetoacetate, 
thiourea and a wide variety of aromatic aldehydes as building blocks (Figure 23). 
Upon irradiation of the individual reaction mixtures (ethanol, catalytic HCl) in an  
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open glass beaker inside the cavity of a domestic microwave oven the reaction times 
were reduced from 2–24 hours of conventional heating 80 °C, reflux to 3–11 minutes 
under microwave activation (ca. 200 –300 W). At the same time the yields of DHPMs 
obtained were distinctly improved compared to those reported earlier using 
conventional conditions. 
 
 
Ar
O
H NH2CONH2
EtOH, H+
N
H
NHH3C O
O
H3C O OH3C
O
O Ar
 
Figure 23 
 
In recent years, solvent free reactions using either organic or inorganic solid supports 
have received more attention.58 There are several advantages to perform synthesis in 
dry media: (i) short reaction times, (ii) increased safety, (iii) economic advantages due 
to the absence of solvent. In addition, solvent free MW processes are also clean and 
efficient. Gopalakrishnan M. and co-workers have reported Biginelli reaction under 
microwave irradiation in solvent-free conditions using activated fly ash as catalyst, an 
industrial waste (pollutant) is an efficient and novel catalyst for some selected organic 
reactions in solvent free conditions under microwave irradiation.59 
 
 
? Ultrasound assisted synthesis 
 
 Ultrasound as a green synthetic approach has gradually been used in organic 
synthesis over the last three decades. Compared with the traditional methods, it is 
more convenient, easier to be controlled and consumes less power. With the use of 
ultrasound irradiation, a large number of organic reactions can be carried out in milder 
conditions with shorter reaction time and higher product yields.60 Ultrasound 
irradiated and amidosulfonicacid (NH2SO3H) catalyzed synthesis of 3,4-
dihydropyrimidi-2-(1H)ones have reported by Li J. T. and co-workers61 using 
aldehydes, β-ketoester and urea. 
 
 
 
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
16 
 
 
Liu C. et al62 have synthesized a novel series of 4-substituted pyrazolyl- 3,4-
dihydropyrimidin-2(1H)-thiones under ultrasound irradiation using magnesium 
perchlorate [Mg(ClO4)2] as catalyst (Figure 24), by the condensation of 5-
chloro/phenoxyl-3-methyl-1-phenyl-4-formylpyrazole, 1,3-dicarbonyl compound and 
urea or thiourea in moderate yields. The catalyst exhibited remarkable reactivity and 
can be recycled. 
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Figure 24 
Sonication of aromatic aldehydes, urea and ethyl acetoacetate in presence of solvent 
(ethanol) or solvent-less dry media (bentonite clay) by supporting-zirconium chloride 
(ZrCl4)  as catalyst at 35 kHz gives 6-methyl-4-substitutedphenyl-2-oxo-1,2,3,4- 
tetrahydropyrimidine-5-carboxylic acid ethyl esters proficiently in high yields, which 
reported by Harish Kumar et al. (Figure 25).63 
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Figure 25 
? Synthesis of substituted pyrimidines using various ketene dithio acetals. 
           Junjappa and coworkers64 extended the generality of this strategy by using 
guandine and thiourea s the nucleophilic reagents. Reaction of α-unsubstituted β,β’-
bis(alkylthio)-α,β-enones with guanidinium nitrate in refluxing methanolic sodium 
methoxide affords the 2-amino-4-methoxy pyrimidines (Figure 26,27). While 
utilization of thiourea affords the corresponding 2-mercapto-4-alkoxy analogs. This 
procedure is particularly useful for the synthesis of the latter compounds, which     
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would be difficult to prepare by alkylation of a free hydroxyl group in the presence of 
thiol functionality. These procedures have been extended to α-aryl substituted β,β’-
bis(alkylthio)-α,β-enones and to α-oxo ketene dithioacetals derived from cyclic 
ketones 
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 Figure 26 
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Figure 27 
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A. Kumar and V. Agrawal et al65 have synthesized a novel series of 2-amino-4-(N-
alkyl-N-arylamino)-pyrimidines using polarized ketene S,S-and S,N-acetals (Figure 
28.) by reaction of ketene S,S-acetal 1 with aniline 2 in boiling ethanol the 
corresponding S,N-acetal 3 was obtained in good yield. Treatment of 3 with guanidine 
nitrarte in the presence of sodium ethoxide followed by refluxing in ethanol, yielded 
2-amino-4-anilino-5-cyno-1,6-dihydro-6-oxopyrimidine 4 in 57% yield. 
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Figure 28 
 
H. Ila and H. Junjappa et al66 have synthesized a novel series of 2-amino-4-ethoxy 
dibenz[b,f]oxepino-[4,5-d]pyrimidine (Figure 29). Guanidine nitrate was added to a 
stirred solution of sodium ethoxide then after 5 min ketene dithioacetal was added and 
reflux the reaction mix for 5-12 h which yielded pyrimidine. 
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Figure 29 
 
 
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
19 
 
 
U. K. Syamkumar et al67 have reported a heteroannulation of 2-[Bis (methylthio) 
methylene]-1-methyl-3-oxoindole with guanidine nitrate and sodium methoxide or 
ethoxide in 50b ml of the respective alcohol and the reaction mix was refluxed for 12-
15 h which yielded 2-amino-5-N-methyl-4-(alkoxy)pyrimido[5,4-b]indole (Figure 
30) in good yield. 
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Figure 30 
 
M. A. Ebraheem et al68 have  reported a novel synthesis of polysubstituted 
pyrimidines (2) via the reaction of α,α -oxoketene dithioacetals (1) with urea and 
thiourea in EtOH reflux 3 h which yielded pyrimidine (Figure 31) in good yield. 
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            Figure 31 
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1.4.  CURRENT RESEARCH WORK 
 
        Nitrogen containing heterocyclic compounds has received considerable attention 
due to their wide range of pharmacological activity. In this context, the pyrimidine 
derivatives have been reported to possess a variety of potent biological activity, 
among which are the analgesic, antihypertensive, antipyretic, antiviral and anti-
inflammatory activity. These are also associated with nucleic acid, antibiotic, 
antimalarial and anti cancer drugs. Many of the pyrimidine derivatives are reported to 
possess potential CNS depressant properties. The tremendous biological potential of 
pyrimidine derivatives encouraged us to synthesize some novel carboxamide 
functionalized pyrimidine derivatives. Various methodologies have been described for 
the synthesis of pyrimidine derivatives. However, the existing methods have suffered 
with some drawbacks, such as yield, time and product isolation.    
 
During the course of our ongoing interest on the synthesis various heterocycles we 
observed that functionalized ketene dithioacetals are versatile intermediates in organic 
synthesis for the construction of substituted heterocycles. Thus, we have synthesized 
some novel ketene dithioacetals starting from, 4-methyl-3-oxo-N-aryl pentanamide 
for the construction of small molecule library of 2-amino-4-isopropyl-6-alkoxy-N-
arylpyrimidine-5-carboxamide. The newly synthesized compounds were characterized 
by IR, Mass, 1H NMR, 13C NMR spectroscopy and elemental analysis. All 
synthesized compounds were evaluated for their antimicrobial activity. 
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1.5. RESULTS AND DISCUSSION                   
Scheme:-1 Synthesis of substituted pyrimidines using ketene dithioacetals. 
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Scheme:-2 
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Various substituted 4-methyl-3-oxo-N-arylpentanamide 2a-t were prepared by 
reacting substituted amines (1) and methyl-4-methyl-3-oxopentanoate in toluene with 
a catalytic amount of NaOH or KOH (Scheme 1). The reaction mixture was reflux for 
15-20 h. Various acetoacetanilide were synthesized bearing different electron 
donating and electron withdrawing groups like 2,3-diCH3; 3,4-diCH3; 4-CH3; H; 2,5-
diCH3; 2,4-diCH3; 3-Cl-4-F; 4-F; 4-Cl; 2-Cl; 2-F; 4-OCH3; 2,5-diCl and 3-NO2 on the 
phenyl ring.           
       
Thus, it has been found that reaction of substituted acetoacetanilide 2a-t derivatives 
(Scheme 1) with carbon disulfide in the presence of potassium carbonate followed by 
the alkylation with methyl iodide gives the novel ketene dithioacetals 3a-t, when 3a-t 
was reacted with guanidine nitrate in refluxing methanolic sodium methoxide or 
ethanolic sodium ethoxide (scheme 2) affords the 2-amino-4-isopropyl-6-alkoxy-N-
arylpyrimidine-5-carboxamide derivatives PVP-1a-t was obtained in excellent yield.       
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The structures of PVP-1a-t were established on the basis of their elemental analysis 
and spectral data (MS, IR, and 1H NMR). The analytical data for 3m revealed a 
molecular formula C16H21NO2S2 (m/z 323). The 1H NMR spectrum revealed a two 
singlet at δ = 1.18-1.20 ppm assigned to isopropyl-CH3, a singlet at δ = 1.57 ppm 
assigned to the –CH3 protons, a singlet at δ = 2.44 ppm assigned to (2 × SCH3), a 
multiplet at δ = 3.17-3.24 ppm assigned to the isopropyl-CH protons, a multiplet at δ 
= 6.99–7.54 ppm assigned to the aromatic protons, and one broad singlets at δ = 8.38 
ppm assigned to -CONH groups.  
 
  
Table 1: Synthesis of substituted pyrimidines using ketene dithioacetals. 
 
Entry R R1 Yield % Time h. 
PVP-1a 4-BrC6H4 C2H5 92 6.0 
PVP-1b 4-OCH3C6H4 CH3 91 6.0 
PVP-1c C6H5 CH3 84 5.7 
PVP-1d C6H11 C2H5 90 5.0 
PVP-1e 2,5-di-CH3C6H3 CH3 86 5.5 
PVP-1f C6H11 CH3 92 5.6 
PVP-1g 4-FC6H4 CH3 90 6.0 
PVP-1h 4-ClC6H4 C2H5 86 5.8 
PVP-1i 3-Cl,4-FC6H3 CH3 93 5.5 
PVP-1j 3,4-di-FC6H3 CH3 91 6.0 
PVP-1k 3-ClC6H4 CH3 88 5.4 
PVP-1l 3,4-di-ClC6H3 CH3 92 5.7 
PVP-1m 4-CH3C6H4 CH3 90 5.6 
PVP-1n 2-CH3C6H4 CH3 87 5.8 
PVP-1o 2-OCH3C6H4 CH3 85 5.5 
PVP-1p 2-FC6H4 CH3 93 6.0 
PVP-1q 2-BrC6H4 CH3 90 5.6 
PVP-1r C6H5 C2H5 89 6.0 
PVP-1s 4-ClC6H4 CH3 85 5.7 
PVP-1t 3-ClC6H4 C2H5 92 5.4 
 
 
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
23 
 
 
The reaction of compounds 3a-t with guanidine nitrate in refluxing methanolic 
sodium methoxide or ethanolic sodium ethoxide afforded the 2-amino-4-isopropyl-6-
alkoxy-N-arylpyrimidine-5-carboxamide derivatives PVP-1a-t.  
 
The structures of PVP-1a were established on the basis of their elemental analysis 
and spectral data (MS, IR, 1H NMR, and 13C NMR). Structure PVP-1a was supported 
by its mass (m/z 379), which agrees with its molecular formula C16H19BrN4O2, its 1H 
NMR spectrum had signals at δ= 1.18-1.20 (d, 6H 2 x iprCH3), 1.29-1.33 (t, 3H, 
CH3), 3.07-3.13 (m, 1H, CH), assigned to the isopropyl-CH protons, 4.32-4.37 (q, 2H, 
CH2), 5.86 (s, 2H, NH2), 7.38-7.40 (d, 2H, Ar-H,  j=8.8Hz ), 7.63-7.65 (d, 2H, Ar-H,  
j=8.8Hz ), 9.97 (br, s, 1H,  -CONH). 
 
The mechanism (Figure 35), in ketene dithioacetal system the carbonyl carbon and β-
carbon atoms regarded as hard and soft electrophilic centers, since the carbonyl 
carbon is adjacent to the hard-base oxygen while the β-carbon is flanked by the soft-
base methylthio groups. Thus, the binucleophile guanidine in the presence of base 
attacks on carbonyl carbon of systems and formed heterocyclic product by removal of 
water molecule followed by methylthio as good leaving group.  
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Figure 35: Proposed mechanism for the formation of pyrimidine. 
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1.6. ANTIMICROBIAL SENSITIVITY TESTING 
 
WELL DIFFUSION / AGAR CUP METHOD (Lt. General Raghunath D. 1998, 
Ashok Rattan, 1998; Patel R., Patel K. 2004,) 
In vitro effectivity of antimicrobial agents can be demonstrated by observing their 
capacity to inhibit bacterial growth on suitable media. The production of a zone 
depends on two factors namely bacterial growth and concentration of antimicrobial 
agent. The hole/well punch method was first used by Bennett. This diffusion method 
has proved more effective then many other methods. According to Lt. General 
Raghunath the well technique is 5-6 times more sensitive then using disk method. 
 
Principle  
 
When antimicrobial substance is added in agar cup (made in a medium previously 
inoculated with test organism) the redial diffusion of an antimicrobial agent through 
the agar, produces a concentration gradient. The test organism is inhibited at the 
minimum inhibitory concentration (MIC), giving rise to a clear zone of inhibition.  
 
Requirements 
 
1. Young broth culture of a standard test organism  
2. Sterile Mueller Hinton Agar plate 
3. Solution of antimicrobial substance 
4. Cup borer  
5. Alcohol etc. 
 
Inoculum preparation 
 
Inoculum was prepared by selecting 4-5 colonies from slope of stock culture of the 
indicator organism and emulsifying them in a suitable broth. The inoculated broth was 
incubated at 37ºC till it equals turbidity of a 0.5 McFarland standard. This happens in 
2-8 h. 
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Procedure 
1. Inoculate test organism on the top of Mueller Hinton Agar plate with help of 
sterile swab. (it can be inoculated in melted agar also ) 
2. The swab was dipped in the inoculum and surface of plate was streaked with 
swab. 
3. Streaking was repeated for 3 times and each time the plate was rotated at angle 
of 60º.  
4. Sterilize the cup-borer make four cups of the diameter of 8-10 mm. at equal 
distance in the plate previously inoculated with seed culture. 
5. The depth of well was 2.5-5.0 mm.  
6. The wells have been clearly punched so the surrounding medium is not lifted 
when the plug was removed out. 
7. The plates were incubated at 37ºC for 24 h. Then the zone of inhibition 
measured and the size of zone cited in table.  
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? Antibiotic Sensitivity Assay 
   
(Concentration250/500/ 1000 µG/ml) 
Sr. 
No. 
CODE 
No. 
Pseudomonas 
aeruginosa 
Proteus 
vulgaris 
Escherichia  
coli 
Staphylococcu
s aureus 
Candida 
albicans 
  250 500 1000 250 500 1000 250 500 1000 250 500 1000 250 500 1000 
1.  1a R 1.1 1.2 R 1.1 1.3 R R R R R R R 1 1.2 
2.  1b 1.2 1.4 2 1.1 1.3 1.6 R R R R 1 1.2 R 1.2 1.5 
3.  1c 1.2 1.3 1.7 1.1 1.4 1.6 R R R 1.2 1.3 1.6 1 1.3 1.8 
4.  1d 1.1 1.3 1.5 R 1.1 1.4 1.1 1.2 1.3 R 1 1.2 1.1 1.5 2 
5.  1e 1.1 1.2 1.4 1 1.3 1.6 R R R 1.3 1.4 1.6 1.1 1.4 1.8 
6.  1f 1.2 1.3 1.6 R 1.2 1.4 R R R 1.2 1.4 1.6 1 1.3 1.7 
7.  1g 1.1 1.2 1.3 R 1 1.2 R R R 1.2 1.3 1.5 1 1.1 1.3 
8.  1h 1 1.3 1.5 1.1 1.4 1.7 1.2 1.4 1.8 1.1 1.3 1.4 R 1.1 1.4 
9.  1i 1.1 1.3 1.6 1.2 1.6 2 1.3 1.5 1.9 1.1 1.5 2.2 1.2 1.6 2.3 
10.  1j 1.3 1.5 1.9 1 1.2 1.3 1.3 1.4 1.7 1.1 1.4 1.5 1.1 1.4 1.8 
11.  1k 1.3 1.5 1.8 1.1 1.4 1.7 1.2 1.4 1.8 1.4 1.5 2 1.2 1.4 1.7 
12.  1l 1.4 1.7 2 1.1 1.3 1.5 1.1 1.1 1.3 1.4 1.6 2 1.1 1.3 1.5 
13.  1m 1.1 1.3 1.5 R R R R R R 1.3 1.4 1.7 R 1.3 1.7 
14.  1n 1.3 1.5 1.5 1.9 R R 1.5 1.5 1.7 R 1.3 R 1.3 R 1 
15.  1o 1.5 1.6 1.3 1.1 1.4 1.3 1.4 1.7 1 R 1.2 1.7 1.1 1.5 1.3 
16.  1p 1.7 1.8 1.5 1 1.6 1.2 1.3 1.9 1.1 1.7 1.5 1.5 R 1.1 1.4 
17.  1q 1.6 1 1.2 1.5 1.4 1.2 1.2 1.5 1.4 1.6 1.8 1.3 1.5 1.3 1.8 
18.  1r 2 1.8 1.3 1.1 1.3 1.5 1 1.2 1.5 1.1 1 1.4 1.8 1.1 1.6 
19.  1s 1.2 1.1 1.1 1.7 1.8 1.4 1.1 1 1.3 1.5 1.6 1.9 1.6 1 2 
20.  1t R 1 2 1.3 1.3 1.2 1.5 1.7 1.2 1.3 1.2 1 1.2 1.8 1.7 
21.  A 1.8 1.8 1.9 1.9 - 
22.  CPD 2.2 2.1 2.1 2.2 - 
23.  GF 1.8 1.9 2.0 2.0 - 
24.  GRF - - - - 2.6 
25.  FLC - - - - 2.8 
 
Note: Zone of inhibition interpretation is as follows. 
 
1. ZONE SIZE <1.0 C.M.- RESISTENT(R)  
2. ZONE SIZE  1.0 To 1.5 – INTERMEDIATE 
3. ZONE SIZE >1.5 – SENSITIVE 
STD Antibiotic Sensitivity Assay Concentration 40 µG/ml 
     A: AMPICILLIN     
 CPD: CEFPODOXIME 
   GF: GATIFLOXACIN 
 GRF: GRESIOFULVIN 
  FLC: FLUCONAZOLE 
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1.7 CONCLUSION 
 
     In summary, we have described the synthesis of substituted pyrimidine 
derivatives in excellent yields. The reaction of various ketene dithioacetals with 
guanidine nitrate in refluxing methanolic sodium methoxide or ethanolic sodium 
ethoxide affords the 2-amino-4-isopropyl-6-alkoxy-N-arylpyrimidine-5-carboxamide 
derivatives with good yields. All the synthesized compounds were evaluated for their 
antimicrobial activity. The investigation of antibacterial and antifungal screening 
data revealed that all the tested compounds PVP-1a-t showed moderate to potent 
activity. The compounds PVP -1i, 1k and 1l showed comparatively good activity 
against all the bacterial strains. 
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1.8 EXPERIMENTAL SECTION 
 
      Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (400 MHz) and 13C (100 MHz) NMR spectra were recorded on a 
Bruker AVANCE II spectrometer in CDCl3. Chemical shifts are expressed in δ ppm 
downfield from TMS as an internal standard. Mass spectra were determined using 
direct inlet probe on a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were 
evaporated with a BUCHI rotary evaporator. Melting points were measured in open 
capillaries and are uncorrected. 
 
? General synthesis of 4-methyl-3-oxo-N-arylpentanamide 2a-t. 
            A mixture containing the primary amine (10 mmol), methyl isobutyrylacetate 
(10 mmol), and catalytic amount of sodium or potassium hydroxide lie (10 %) was 
reflux at 110oC for the approximately 15-20 h. The reaction was monitored by TLC. 
After completion of reaction, the solvent was removed under vaccuo when the 
reaction was completed. The solid or oil was crystallized from methanol to give pure 
product 2a-t. 
 
? General synthesis of ketene dithioacetals 3a-t. 
           A 100mL conical flask equipped with magnetic stirrer and septum was charged 
with a solution of 4-methyl-3-oxo-N-arylpentanamide 2a-t, (10 mmol) in DMF (10 
mL). Dried K2CO3 (10 mmol) was added and the mixture was stirred for 2 h at room 
temperature. CS2 (30 mmol) was added and the mixture was stirred for an additional 2 
h at room temperature. Methyl iodide (20 mmol) was added at 0-5 oC and the mixture 
was stirred for 4 h before being poured onto water (40 mL). The precipitated crude 
product was purified by filtration followed by crystallization from EtOH. When the 
product was oil, the organic phase was extracted with Et2O (3 × 10 mL). The 
combined organic extracts were washed with H2O (2 × 10 mL), dried (MgSO4), and 
concentrated in vaccuo to afford ketene dithioacetals directly used for the next step. 
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? General procedure for the synthesis of substituted pyrimidines PVP-1a-t. 
           To a well stirred mixture of guanidine nitrate (10 mmol) and sodium 
methoxide or sodium ethoxide (20 mmol) in methanol or ethanol was added the 
solution of ketene dithioacetals 3a-t (10 mmol) in methanol or ethanol within 10-15 
min. The resulting reaction mixture was further stirred at rt for 15 min. then, reflux 
the reaction mixtures for 6h on water bath. After completion of the reaction, the 
mixture was poured onto ice cold water. Thus, the obtained solid was filtered, wash 
with water and dried it and crystallization from EtOH to afford analytically pure 
products PVP-1a-t. 
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? Spectral data of the synthesized compounds 
 
2-(bis(methylthio)methylene)-4-methyl-3-oxo-N-p-tolylpentanamide 3m. yellow 
solid,  mp 155-157°C;  IR  (KBr): 3373, 3072, 2895, 2828, 1694, 1635, 1482, 1343, 
1298 cm-1; 1H NMR (400 MHz, DMSO): δ ppm 1.18-1.20 (d, 6H, 2 × iprCH3), 1.57 
(s, 3H, CH3),  2.44 (s, 6H, 2 × SCH3), 3.17-3.24 (m, 1H, iprCH), 6.99–7.54 (m, 4H, 
Ar-H), 8.38  (br, s, 1H, -CONH); MS (m/z): 323 (M+);  Anal. Calcd for C16H21NO2S2: 
C, 59.41; H, 6.54; N, 4.33; Found: C, 59.33; H, 6.45; N, 4.23. 
 
2-amino-N-(4-bromophenyl)-4ethoxy-6-isopropylpyrimidine-5-carboxamide 
(PVP-1a): White solid; Rf  0.45 (6:4 hexane-EtOAc); mp 185-187°C; IR (KBr): 3459, 
3327, 3193, 2999, 1648, 1586, 1261, 1061 cm-1; 1H NMR: δ 1.18-1.20 (d, 6H, 2 x 
iprCH3), 1.29-1.33 (t, 3H, CH3), 3.07-3.13 (m, 1H, iprCH),  4.32-4.37 (q, 2H, CH2), 
5.86 (s, 2H, NH2), 7.38-7.40 (d, 2H, Ar-H, j=8.8Hz), 7.63-7.65 (d, 2H, Ar-H,  
j=8.8Hz), 9.97 (br, s, 1H, -CONH); MS (m/z): 379 (M+); Anal. Calcd for 
C16H19BrN4O2: C, 50.67; H, 5.05; N, 14.77; Found: C, 50.48; H, 5.15; N, 14.52. 
 
2-amino-4isopropyl-6-methoxy-N-(4-methoxyphenyl)pyrimidine-5-carboxamide 
(PVP-1b): yellow solid; Rf  0.24 (6:4 hexane-EtOAc); mp 180-184°C; IR (KBr): 3452, 
3307, 3223, 2980, 1653, 1509, 1461, 1051 cm-1; 1H NMR: δ 1.19-1.25 (d, 6H, 2 x 
iprCH3), 3.07-3.13 (m, 4H, iprCH,), 3.78 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 5.69 (s, 
2H, NH2), 6.82-6.85 (d, 2H, Ar-H,  j=8.8Hz), 7.60-7.62 (d, 2H, Ar-H,  j=8.8Hz), 9.58 
(s, 1H, CONH);  MS (m/z): 316 (M+); Anal. Calcd for C16H20N4O3: C, 60.75; H, 6.37; 
N, 17.71; Found: C, 60.48; H, 6.15; N, 17.52. 
 
2-amino-4isopropyl-6-methoxy-N-phenylpyrimidine-5-carboxamide (PVP-1c): 
yellow solid; Rf  0.26 (6:4 hexane-EtOAc); mp 210-212°C; IR (KBr): 3412, 3317, 
3253, 2950, 1613, 15039, 1431, 1041 cm-1; MS (m/z): 286 (M+); Anal. Calcd for 
C15H18N4O2: C, 60.92; H, 6.34; N, 19.57; Found: C, 60.48; H, 6.15; N, 19.32. 
 
2-amino-N-cyclohexyl-4ethoxy-6-isopropylpyrimidine-5-carboxamide (PVP-1d): 
White solid; Rf  0.47 (6:4 hexane-EtOAc); mp 196-198°C; IR (KBr): 3429, 3307, 
3123, 2959, 1658, 1546, 1265, 1041 cm-1; 1H NMR: δ 1.19-1.20 (d, 6H, 2 x iprCH3),  
1.22-1.25 (t, 3H, CH3), 1.28-1.93 (m, 10H, 5 x CH2), 3.07-3.14 (m, 1H, iprCH), 3.79-
3.86 (m, 1H, CH), 4.26-4.31 (q, 2H, CH2), 5.73 (s, 2H, NH2), 7.21 (s, 1H, CONH);  
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MS (m/z): 306 (M+); Anal. Calcd for C16H26N4O2: C, 62.72; H, 8.55; N, 18.29; Found: 
C, 62.38; H, 8.10; N, 18. 
 
2-amino-4-isopropyl-6-methoxy-N-(2,5-dimethylphenyl)pyrimidine-5-           
carboxamide (PVP-1e): yellow solid; Rf  0.24 (6:4 hexane-EtOAc); mp 186-188°C; 
IR (KBr): 3420, 3341, 32631, 2930, 1610, 1553, 1411, 1060 cm-1; MS (m/z): 314 
(M+); Anal. Calcd for C17H22N4O2: C, 64.58; H, 7.05; N, 17.82; Found: C, 64.48; H, 
7.15; N, 17.62. 
 
2-amino-N-cyclohexyl-4isopropyl-6-methoxypyrimidine-5-carboxamide(PVP-1f): 
yellow solid; Rf  0.22 (6:4 hexane-EtOAc); mp 190-192°C; IR (KBr): 3462, 3307, 
3223, 2990, 1653, 1509, 1461, 1061 cm-1; 13C NMR: δ 21.20, 24.42, 25.02, 31.60, 
32.16, 38.90-40.16, 47.97, 53.01, 106.73, 161.89, 164.94, 166.47, 173.41.  MS (m/z): 
292 (M+); Anal. Calcd for C15H24N4O2: C, 61.62; H, 8.27; N, 19.16; Found: C, 61.58; 
H, 8.15; N, 19.12. 
 
2-amino-N-(4-fluorophenyl)-4isopropyl-6-methoxypyrimidine-5-carboxamide   
(PVP-1g): yellow solid; Rf  0.25 (6:4 hexane-EtOAc); mp 180-182°C; IR (KBr): 3459, 
3327, 3173, 2989, 1648, 1586, 1261, 1061 cm-1;  MS (m/z): 304 (M+); Anal. Calcd for 
C15H17 FN4O2: C, 59.20; H, 5.63; N, 18.41; Found: C, 59.13; H, 5.45; N, 18.52. 
 
2-amino-N-(4-chlorophenyl)-4ethoxy-6-isopropylpyrimidine-5-carboxamide 
(PVP-1h): White solid; Rf  0.42 (6:4 hexane-EtOAc); mp 194-196°C; IR (KBr): 3449, 
3331, 3182, 3055, 2952, 1651, 1568, 1491, 1247, 1049 cm-1; 1H NMR: δ 1.17-1.94 (d, 
6H, 2 x iprCH3), 1.28-1.31 (t, 3H, CH3), 3.05-3.09 (m, 1H, iprCH), 4.31-4.36 (q, 2H, 
CH2), 6.09 (s, 2H, NH2), 7.24-7.26 (d, 2H, Ar-H, j=8.8Hz), 7.68-7.71 (d, 2H, Ar-H, 
j=8.8Hz), 10.07 (s, 1H, CONH);  MS (m/z): 334 (M+); Anal. Calcd for C16H19ClN4O2: 
C, 57.40; H, 5.72; N, 16.73; Found: C, 57.41; H, 5.55; N, 16.63. 
 
2-amino-N-(3-chloro-4-fluorophenyl)-4isopropyl-6-methoxypyrimidine-5-
carboxamide (PVP-1i): yellow solid; Rf  0.21 (6:4 hexane-EtOAc); mp 185-187°C; 
IR (KBr): 3443, 3325, 3153, 2989, 1648, 1506, 1251, 1064 cm-1; MS (m/z): 338 (M+);  
Anal. Calcd for C15H16ClFN4O2: C, 53.18; H, 4.76; N, 16.54; Found: C, 53.13; H, 
4.65; N, 16.52. 
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
33 
 
 
2-amino-N-(3,4-di-fluorophenyl)-4isopropyl-6-methoxypyrimidine-5-
carboxamide   (PVP-1j): yellow solid; Rf  0.26 (6:4 hexane-EtOAc); mp 245-247°C; 
IR (KBr): 3442, 3226, 3143, 2986, 1642, 1566, 1241, 1061 cm-1; MS (m/z): 322 (M+); 
Anal. Calcd for C15H16F2N4O2: C, 55.90; H, 5.00; N, 17.38; Found: C, 55.73; H, 4.94; 
N, 17.32. 
 
2-amino-N-(3-chlorophenyl)-4isopropyl-6-methoxypyrimidine-5-carboxamide 
(PVP-1k): yellow solid; Rf  0.25 (6:4 hexane-EtOAc); mp 256-258°C; IR (KBr): 3459, 
3252, 3143, 2919, 1648, 1586, 1241, 1051 cm-1; MS (m/z): 320 (M+); Anal. Calcd for 
C15H17ClN4O2: C, 56.16; H, 5.34; N, 17.47; Found: C, 56.23; H, 5.25; N, 17.52. 
 
2-amino-N-(3,4-di-chlorophenyl)-4isopropyl-6-methoxypyrimidine-5-
carboxamide   (PVP-1l): yellow solid; Rf  0.23 (6:4 hexane-EtOAc); mp 240-242°C; 
IR (KBr): 3420, 3226, 3143, 2988, 1632, 1546, 1231, 1061 cm-1; MS (m/z): 354 (M+); 
Anal. Calcd for C15H16Cl2N4O2: C, 50.72; H, 4.54; N, 15.77; Found: C, 55.73; H, 
4.64; N, 15.62. 
 
2-amino-4isopropyl-6-methoxy-N-p-tolylpyrimidine-5-carboxamide (PVP-1m): 
yellow solid; Rf 0.27 (6:4 hexane-EtOAc); mp 194-196°C; IR (KBr): 3412, 3317, 
3253, 2950, 1613, 1539, 1431, 1061 cm-1; MS (m/z): 300 (M+); Anal. Calcd for 
C16H20N4O2: C, 63.98; H, 6.71; N, 18.65; Found: C, 63.88; H, 6.65; N, 18.52. 
 
2-amino-4isopropyl-6-methoxy-N-o-tolylpyrimidine-5-carboxamide (PVP-1n): 
yellow solid; Rf  0.21 (6:4 hexane-EtOAc); mp 185-187°C; IR (KBr): 3442, 3327, 
3253, 2980, 1623, 1569, 1431, 1051 cm-1; MS (m/z): 300 (M+); Anal. Calcd for 
C16H20N4O2: C, 63.98; H, 6.71; N, 18.65; Found: C, 63.88; H, 6.65; N, 18.52. 
 
2-amino-4isopropyl-6-methoxy-N-(2-methoxyphenyl)pyrimidine-5-carboxamide 
(PVP-1o): yellow solid; Rf  0.22 (6:4 hexane-EtOAc); mp 165-167°C; IR (KBr): 3462, 
3327, 3220, 2980, 1623, 1509, 1461, 1051 cm-1; MS (m/z): 316 (M+); Anal. Calcd for 
C16H20N4O3: C, 60.75; H, 6.37; N, 17.71; Found: C, 60.68; H, 6.55; N, 17.62. 
 
2-amino-N-(2-fluorophenyl)-4isopropyl-6-methoxypyrimidine-5-carboxamide 
(PVP-1p): yellow solid; Rf  0.25 (6:4 hexane-EtOAc); mp 178-180°C; IR (KBr): 3442,  
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3327, 3173, 2989, 1653, 1586, 1261, 1061 cm-1; MS (m/z): 304 (M+); Anal. Calcd for 
C15H17 FN4O2: C, 59.20; H, 5.63; N, 18.41; Found: C, 59.16; H, 5.55; N, 18.32. 
 
2-amino-N-(2-bromophenyl)-4isopropyl-6-methoxypyrimidine-5-carboxamide 
(PVP-1q): yellow solid; Rf  0.24 (6:4 hexane-EtOAc); mp 190-192°C; IR (KBr): 3459, 
3327, 3173, 2989, 1648, 1586, 1261, 1061 cm-1;  MS (m/z): 364 (M+); Anal. Calcd for 
C15H17BrN4O2: C, 49.33; H, 4.69; N, 15.34; Found: C, 49.13; H, 4.45; N, 15.22. 
 
2-amino-4-ethoxy-6-isopropyl-N-phenyl pyrimidine-5-carboxamide (PVP-1r): 
White solid; Rf  0.43 (6:4 hexane-EtOAc); mp 198-200°C; IR (KBr): 3459, 3327, 
3193, 2999, 1648, 1586, 1261, 1061 cm-1;  MS (m/z): 300 (M+); Anal. Calcd for 
C16H20N4O2: C, 63.98; H, 6.71; N, 18.65; Found: C, 63.92; H, 6.65; N, 18.56. 
 
2-amino-N-(4-chlorophenyl)-4isopropyl-6-methoxypyrimidine-5-carboxamide 
(PVP-1s): yellow solid; Rf  0.23 (6:4 hexane-EtOAc); mp 185-187°C; IR (KBr): 3459, 
3252, 3143, 2919, 1648, 1586, 1241, 1051 cm-1; MS (m/z): 320 (M+); Anal. Calcd for 
C15H17ClN4O2: C, 56.16; H, 5.34; N, 17.47; Found: C, 56.20; H, 5.25; N, 17.42. 
 
2-amino-N-(3-chlorophenyl)-4ethoxy-6-isopropylpyrimidine-5-carboxamide 
(PVP-1t): White solid; Rf  0.42 (6:4 hexane-EtOAc); mp 210-212°C; IR (KBr): 3449, 
3227, 3193, 2966, 1628, 1522, 1217, 1041 cm-1; MS (m/z): 334 (M+); Anal. Calcd for 
C16H19ClN4O2: C, 57.40; H, 5.72; N, 16.73; Found: C, 57.44; H, 5.65; N, 16.67. 
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? Spectral representation of synthesized compounds 
 1H NMR spectrum of compound 3m  
 
 
Expanded 1H NMR spectrum of compound 3m 
 
NHS
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1H NMR spectrums of compound PVP-1a  
 
 
Expanded 1H NMR spectrum of compound PVP-1a 
 
NH N
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1H NMR spectrums of compound PVP-1b  
 
 
Expanded 1H NMR spectrum of compound PVP-1b 
 
 
 
NH N
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1H NMR spectrum of compound PVP-1d 
 
 
Expanded 1H NMR spectrum of compound PVP-1d 
 
 
 
NH
 
Chapter 1                                                           Synthesis of functionalized pyrimidines 
39 
 
 
13C NMR spectrum of compound PVP-1f 
 
 
Expanded 13C NMR spectrum of compound PVP-1f 
 
 
 
NH
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1H NMR spectrum of compound PVP-1h  
 
 
Mass Spectrum of compound PVP-1b 
 
 
 
NH N
NH N
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Mass Spectrum of compound PVP-1c 
 
 
 
Mass Spectrum of compound PVP-1d 
 
 
NHN
NHN
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Mass Spectrum of compound PVP-1e 
 
 
 
Mass Spectrum of compound PVP-1j 
 
 
NHONCCH3
NHO NNOCHF
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IR Spectrum of compound PVP-1h 
 
 
 
IR Spectrum of compound PVP-1i 
 
 
 
NHO NNOCHF
NH
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2.1    INTRODUCTION 
 
        Biaryls and heterobiaryls have attracted significant attention from the scientific 
community because of their relevance in medicinal chemistry. Heterobiaryls 
frequently can be observed in numerous bioactive small molecules, and in particular, 
heterobiaryls fused with various heterocycles, such as pyrazole, pyridine, and 
pyrimidine, have been used as key pharmacophores.1 As shown in Figure 1, a 
blockbuster drug, sildenafil citrate (1),2 and a potent anticancer agent (2),3 contain 
heterobiaryls fused with privileged heterocycles as core skeletons. In addition, 1H-
pyrazolo[3,4-b]pyridine is recognized as a privileged substructural motif of drug-like 
molecules and potential drugs. Compound 3, which contains the heterobiaryl 
pyrazolopyridine substructure, stimulates soluble guanylate cyclase via a nitric oxide 
independent regulatory site and induces vasodilation.4 6-Aryl pyrazolo[3,4-
b]pyridines are also reported as potentinhibitors of glycogen synthase kinase-3 (4).5 
These examples emphasize the importance of pyrazol-fused heterobiaryls, as well as 
pyrazolopyridines, as key pharmacophores in bioactive small molecules. 
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2.2 Biological activity of several fused pyrazolopyridine and                        
pyrazolopyrimidine derivatives. 
 
      Several diverse biological activities have been reported for condensed 
polyazaaromatic ring systems which are described as below. 
 
Mitogen-activated protein kinases (MAP) are a family of praline-directed 
serine/threonie kinases that activate their substrates by dual phosphorylation. The 
kinases are activated by a variety of signals including nutritional and osmotic stress, 
UV light, growth factors, endotoxin and inflammatory cytokines. One group of MAP 
kinases is the p38 kinase group that includes various isoforms (ex. p38α, p39β, p38γ 
and p38δ). The p38 kinases are responsible for phosphorylating and activating 
transcription factors as well as other kinases, and are activated by physical and 
chemical stress, pro-inflammatory cytokines and bacterial lipopolysaccharide. More 
importantly, the products of the p38 phosphorylation have been shown to mediate the 
production of inflammatory cytokines, including TNF and IL-1, and cyclooxygenae-2. 
Each of these cytokines has been implicated in numerous disease states and 
conditions. The inhibition of these cytokines by inhibition of the p38 kinases of 
benefit in controlling, reducing and alleviating many of this disease states. In this 
context, some novel substituted pyrazolopyridones (Figure 2) have been synthesized 
and found potent for the treatment of disease associated with p38 MAP kinase.6 
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Figure 2 
 
Recently, Yassin F. A.7 has synthesized some pyrazolopyridine derivatives (Figure 3) 
and evaluated for their antimicrobial activity.  
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Figure 3 
 
Echevarri A. et al8 have developed three series of 4-anilino-1H-pyrazolo[3,4-
b]pyridine-5-carboxylic esters to study potential anti-Leishmania activity. These 
compounds were obtained by a condensation reaction of 4-chloro-1H-pyrazolo[3,4-
b]pyridine with several aniline derivatives. Some of them were also obtained by an 
alternative pathway involving a Mannich-type reaction. They were determined the 
hydrophobic parameter, log P, by shake-flask methodology, and using the Hansch-
Fujita addictive hydrophobic fragmental constants. Among them, compound (Figure 
4) shown most promising activity (IC50) 0.39 and 0.12 íM.  
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Figure 4 
 
Green N. J. et al9 have studied structure-activity relationship of a series of 
dipyrazolo[3,4-b:3’,4’-d]pyridin-3-ones binding to the immune regulatory protein 
B7.1. The interaction of co-stimulatory molecules on T cells with B7 molecules on 
antigen presenting cells plays an important role in the activation of naive T cells. 
Consequently, agents that disrupt these interactions should have applications in 
treatment of transplant rejection as well as autoimmune diseases. They have identified 
several leads that prevented the interaction of B7.1 with CD28 with activities in the 
nanomolar to low micromolar range. One of these, the dihydrodipyrazolopyridinone 
(Figure 5), was subsequently shown to bind the V-like domain of human B7.1 at 
equimolar stoichiometry. 
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Phosphodiesterase 9A (PDE9A) is one member of the wide family of 
phosphodiesterases (PDE). These kinds of enzymes modulate the levels of the cyclic 
nucleotides 5’-3’ cylic adenosine monophosphate (cAMP) and 5’-3’ cyclic guanosine 
monophosphate (cGMP). These cyclic nucleotides (cAMP and cGMP) are important 
second messengers and therefore play a central role in cellular signal transduction 
cascades. Each of them reactivates inter alia, but not exclusively, protein kinases. The 
protein kinase activated by cAMP is called protein kinase A (PKA), and the protein 
kinase activated by cGMP is called protein kinase G (PKG). Activated PKA and PKG 
are able in turn to phosphorylate a number of cellular effector proteins. It is possible 
in this way for the second messenger’s cAMP and c GMP to control a wide variety of 
physiological processes in a wide variety of organs. However, the cyclic nucleotides 
are also able to act directly on effector molecules. Thus, it is known, for example, the 
cGMP is able to act directly on ion channels and thus is able to influence the cellular 
ion concentration. The phosphodiesterases are a control mechanism for controlling the 
activity of cAMP and cGMP and thus in turn for the corresponding physiological 
processes. Thus, several phyrazolopyrimidones (Figure 6) have been synthesized and 
found potent PDE inhibitors.10 
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Chapter-2                                                  Synthesis of substituted pyrazolopyridones.  
51 
 
 
Fossa P. et al11 have synthesized substituted pyrazolopyridine and pyrazolopyrimidine 
derivatives and demonstrated its molecular modeling studies and pharmacological 
activity of selective A1 receptor antagonists (Figure 7). They were applied an 
approach combining pharmacophore mapping, molecular alignment, and 
pseudoreceptor generation to derive a hypothesis of the interaction pathway between a 
set of A1 AR antagonists taken from a model of the putative A1 receptor. The 
pharmacophore model consists of seven features and represents an improvement of 
the N6-C8 model, generally reported as the most probable pharmacophore model for 
A1 AR agonists and antagonists. It was used to build up a pseudoreceptor model able 
to rationalize the relationships between structural properties and biological data. All 
the synthesized compounds were tested for their affinity toward A1, A2a, and A3 AR, 
showing interesting antagonistic activity and A1 selectivity. 
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Figure 7 
 
Moreover, pyrazolopyrimidinones and their salts are also (Figure 8) important 
heterocycles due to their application for the treatment of impotency.12 
Pyrazolopyrimidones are also useful in the treatment of such diseases and adverse 
conditions as angina, hypertension, congestive heart failure, reduced blood vessel 
patency, peripheral vascular disease, stroke, bronchitis, chronic asthma, allergic 
asthma, allergic rhinitis, glaucoma, and gut motility (Figure 8).13 
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Figure 8 
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Das S. K. et al14 have designed, synthesized and evaluated several dual PPAR α/γ 
agonists with three different heterocycles, viz. pyrazolo[4,3-d]pyrimidin-7-one, 
quinazolin-4-one and benzo[e][1,3]oxazine-4-one for the treatment of type 2 diabetes 
and associated dyslipidemia. Among them, compounds (Figure 9) were found to 
possess a potent dual PPAR α/γ agonist property. It significantly reversed diabetic 
hyperglycemia while improving overall lipid homeostasis in preclinical animal 
models. 
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Figure 9 
 
Voelter W. et al15 have developed a simple high-yielding procedure for the synthesis 
of pyrazolopyrimidinones (Figure 10). They have also demonstrated its considerable 
utility for the production of intermediates for potential phosphodiesterase inhibitors. 
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Figure 10 
 
Dumaitre B. et al16 have synthesized a series of 6-phenylpyrazolo [3,4-d]pyrimidones 
for inhibitors of cGMP specific (type V) phosphodiesterase. Enzymatic and cellular 
activity as well as in vivo oral antihypertensive activity is evaluated. They have found 
that a n-propoxy group at the 2-position of the phenyl ring is necessary for activity. 
This position can accommodate many unrelated groups. Amino derivatives were very 
potent but lacked metabolic stability. Substitution by carbon-linked small heterocycles 
provided both high levels of activity and stability.  
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Cellular activity very often correlated with in vivo activity. Among the compounds, 
1,3-dimethyl-6-(2-propoxy-5-methanesulfonamidophenyl)-1,5-dihydropyrazolo[3,4d] 
pyrimidin-4-one and1-ethyl-3-methyl-6-(2-propoxy-5-(4-methylthiazol-2-yl)phenyl)-
1,5dihydropyrazolo[3,4-d]pyrimidin-4-one (Figure 11) displayed outstanding in vivo 
activities at 5 mg/kg/os and good metabolic stabilities.  
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Figure 11 
 
Synthesis of sildenafil analogues (Figure 12) from anacardic acid and their 
phosphodiesterase-5 inhibition activity have been reported by Rao S. A. and 
coworkers.17 Anacardic acid (6-pentadecylsalicylic acid), a major component of 
cashew nut shell liquid, consists of a heterogeneous mixture of monoenes, dienes, and 
trienes. The enes mixture of anacardic acid was hydrogenated to a saturated 
compound. Using saturated anacardic acid as a starting material, analogues of 
sildenafil [a potent phosphodiesterase-5 (PDE5) inhibitor and an orally active drug for 
the treatment of erectile dysfunction] were synthesized, to observe the effect of the 
pentadecyl side chain on PDE5 inhibition. 
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Magedov I. V. et al18 have synthesized some 4-aza-2,3-didehydro podophyllotoxin 
analogues (Figure 13). They were implementing a bioisosteric replacement of the 
methylenedioxybenzene subunit with a pyrazole moiety to afford tetracyclic 
dihydropyridopyrazoles. Libraries of these structurally simple analogues were 
prepared by a straightforward one-step multicomponent synthesis and demonstrated to 
display antiproliferative properties in a number of human cancer cell lines. These new 
heterocycles potently induce apoptosis in cancerous Jurkat cells even after a short 24 
h exposure. The ease of synthesis and encouraging biological activities make the 
presented library of dihydropyridopyrazoles promising new leads in anticancer drug 
design. 
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Figure 13 
 
Claudia M. et al19 have synthesized a series of ethyl-4-amino-1-(2-chloro-2-
phenylethyl)-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylates (Figure 
14) as potential A1 adenosine receptor (A1 AR) ligands.  Binding affinities of these 
compounds were determined for adenosine A1, A2A and A3 receptors.  Among these, 
two molecules showed good affinity (Ki = 299 μM and 517 μM) and selectivity 
towards A1 AR, whereas some showed good affinity for A2A AR (Ki = 290 μM), 
higher than towards A1 AR (Ki = 1000 μM).  The only arylamino derivatives of the 
series displayed high affinity (Ki = 4.6 nM) and selectivity for A3 AR.   
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Thierry sifferlen et al20 have been reported the synthesis and structure-activity 
relationship of a novel series of dual orexin reseptoar antagonists was prepared by  
heteroaromatic five-membered ring system replacement of dimethoxyphenl moiety 
contained in the tetrahydroquinoline core skeleton of almorexant.( Figure 15) Thus, 
replacement of the dimethoxyphenyl by a substituted pyrazole and additional 
optimization of the substitution pattern of the phenethyl motit allowed the 
identification of potent antagonists with nanomolar affinity for hOX1R and hOX2R. 
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                                Figure 15   
Raymond V. F. et al21 have  synthesized a series of 2-amino-pyrazolopyridines 
(Figure 16) was designed as polo-like kinase (plk) inhibitors based on a low micro 
molar hit.The SAR was developed to provide compounds exhibiting low nano molar 
inhibitory activity of plk 1; the phenotype of treated cells is consistent with plk1 
inhibition.  
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Figure 16 
Xiacong M. et al22 have discovered a series of pyrazolopiperidine sulfonamide based 
(Figure 17) γ-secretes Inhibitors and its SAR evolution is described. Significantly 
increases in APP potency on the pyrazolopipridine scaffold over the original N-
bicyclic sulfonamide scaffold were achieved and this potency increase translated in an 
improved in vivo efficacy.   
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2.3      Various synthetic approaches for substituted pyrazolopyridines and     
     pyrazolopyrmidines.  
 
Condensed polyazaaromatic ring systems are present in a variety of 
biologically active compounds (both naturally-occurring and synthetic). Although a 
large number of methods for their synthesis have been documented in the literature, 
many of them require multistep procedures using intermediates which are not readily 
available. Among them, few methods are discussed here.  
 
Adamo M. F. A. et al23 have described the preparation of two novel heterocyclic 
nuclei isoxazolopyridone and pyrazolopyridone (Figure 18) starting from NO2 
substituted isoxazole, arylaldehydes and nitro methane. The syntheses were modular 
in nature and fast to execute. The title compounds were obtained pure without 
intervention of chromatography. 
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Figure 18 
 
Sayed G. L. et al24 have prepared bifunctional pyrazolopyridine (2) derivatives by the 
reaction of 2-(2,4-dinitrophenyl)-5-methyl-2,4-dihydro-3H-pyrazol-3-one (1) with p-
methoxybenzaldehyde, malononitrile in the presence of ammonium acetate (Figure 
19). Further, compound 2 was used as the key intermediate to prepare the pyrazolo-
pyrido-pyrimidine derivatives through its reaction with formic acid, formamide-
formic acid-DMF, ammonium thiocyanate or reaction with triethyl orthoformate 
followed by cyclization with hydrazine hydrate. 
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Figure 19 
 
Attaby F. A. et al25 have synthesized some pyrazolopyridone derivatives (Figure 20). 
The reaction of α-β unsaturated nitrile derivatives with S-methylisothiourea was 
afforded the propene derivatives 1. Cyclization of 1 using ethanolic hydrochloric acid 
afforded the pyridine derivatives in good yields. This on reactions with hydrazine 
hydrate and of phenylhydrazine afforded the corresponding pyrazolopyridine 
derivatives 2.  
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Figure 20 
 
Junjappa H. et al26 have developed a novel process for the synthesis of substituted N-
methylpyrazolopyridones (Figure 21). The pyrazolopyridones were prepared by 
alkylation of the pyridones with dimethyl sulphate, followed by heating the mixture of 
N-methyl products with methyl iodide. Treatment of the pyridones (1) with hydrazine 
in refluxing propanol yielded the respective pyrazolo-[4,3-c]pyridone (2) derivatives 
in excellent yields. 
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Figure 21 
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Moreover, a variety of novel α-cyanoketene S,S-acetals, were readily prepared by the 
reaction of cyanoacetanilides or cyanothioacetamide with carbon disulfide, followed 
by alkylation, react smoothly with nucleophiles to afford variously substituted 
methylthio derivatives of pyrazolepyridine (Figure 22).27 
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Figure 22 
 
Additionally, a novel and efficient method for the synthesis of substituted 4-alkylthio-
N-arylsulphonylamino-2-pyridones via the reaction of ketene-S,S-acetals with N-
cyanoacetoarylsulfonylhydrazides has been developed by Elgemeie G. H. and 
coworkers.28 The arylsulfonylamino-pyrazolo[3,4-c]pyridine-2(1H)-ones have also 
been prepared from the reaction of 4-alkylthio-N-arylsulfonylamino-2-pyridones with 
hydrazines (Figure 23).  
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Figure 23 
 
Lacova M. et al29 have developed one-pot and facile preparations of 6-(2-hydroxy-5-
R-benzoyl)-4-methyl-2-aryl-pyrazolo[3,4-b]pyridines (Figure 24), using the reaction 
of 3-formyl chromones 1 with 5-amino-1-aryl-pyrazoles 2. An enamine-intermediate 
2-ethyloxy-6-R-3-(3-methyl-1-phenylpyrazol-5-ylaminomethylene)chroman-4-one 3  
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was isolated at lower temperatures. They were observed that reactions under 
microwave irradiation proceeded significantly faster and with high yields. 
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Figure 24 
 
Abass M. has synthesized several fused pyrazolopyrimidones (Figure 25) with 
quinolone scaffold. He has described the synthesis of amino-ester, its hydrolysis and 
chloroacetylatio, which were utilized for the synthesis of pyrazoloyridones.30 
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Hassanein E. M. et al31 have synthesized some pyrazolopyridone derivatives via the 
reaction of compound 1 with ketene dithioacetal 2, yielded compound 3 in good 
yields (Figure 26). Further, the reaction of 3 with hydrazine afforded 
pyrazolopyridones 4 in high yield. 
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Figure 26 
 
A mild one-step synthetic method to access privileged pyrazolearylpyrazole[3,4-
b]pyridines (Figure 27) from indole-3-carboxaldehyde derivatives and a variety of 
aminopyrazoles has been developed by Park S. B. and coworker.32 This novel method 
constructs heterobiaryls with the wide scope of substrate generality and excellent 
regioselectivity via indole ring opening.  
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Figure 27 
 
Rodrigues L. M. et al33 have synthesized some pyrazolopyridine derivatives (Figure 
28). The reaction of N-substituted-5-amino-4-cyanopyrazoles with malononitrile 
occurs with formation of 6-substituted pyrazole[3,4-b]pyridines respectively. 
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Figure 28 
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Recently, Yao H. et al34 have developed a synthesis of indeno[2’,1’:5,6]pyrido[2,3-
d]pyrazoles by the three-component reaction of aldehyde, 5-amino-3-methyl-1-
phenyl- pyrazole and 1,3-indenedione in the presence of SDS in aqueous media 
(Figure 29). 
  
N
HN
N
Ph
N
N
Ph
H2N
O
O
Ar CHO
SDS, H2O
90 oC
Ar O
 
 
Figure 29 
 
Li J. R. et al35 have developed synthesis of pyrazolopyrimidinones under microwave 
irradiation (Figure 30). They have demonstrated that the direct reaction of o-
aminopyrazocarbonitriles and carbonyl compounds afforded pyrazolopyrimidinones 
under microwave irradiation with high yields. 
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Figure 30 
 
Mekheimer R. et al36 have synthesized some benzoannulated pyrazolopyridones 2 by 
the reaction of 1 with hydrazine hydrate (Figure 31).  
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Figure 31 
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Swett L. R. et al37 have synthesized two isomeric pyrazolopyridones (Figure 32) 
which were identified as their tetrahydropyrazolopyridine derivatives by the reaction 
of 5-amino-1,3-dimethylpyrazole with ethyl acetoacetate.  
 
N
H
N
N
O
Ac
N
NH2N
O
EtO
O  
 
Figure 32 
 
Lynette A. Smyth et al,38 have synthesized 3-amino-1H-pyrazolo[4, 3-c]pyridine-4-
(5H)ones represent apotentially attractive heteroaromatic scaffold. (Figure 33) The 
reaction of bis(methylthio)but-3-en-2one 1 with cyanoacetamide to get 6-
arylpyridones 2 Further, the pyridones on reaction with hydrazine hydrated in 
isopropyl alcohol furnished the novel pyrazolopyridone 3 derivatives in excellent 
yields. 
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Figure 33 
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2.4     CURRENT RESEARCH WORK 
 
         The pyrazolopyridine and pyrazolopyrimidine derivatives have considerable 
chemical and pharmacological importance because of a broad range of biological 
activities displayed by these classes of molecules. As we demonstrated, the 
tremendous biological potential of pyrazolopyridine derivatives encouraged us to 
synthesize some pyrazolopyridone derivatives. Various methodologies have been 
described for the synthesis of pyrazolopyridone derivatives. However, the existing 
methods are suffer with some drawbacks, such as; yield, time, product isolation, 
isomer formation.  
 
During the course of our ongoing interest on the synthesis of various heterocyclic 
compounds using ketene dithioacetals, we observed that ketene dithioacetals are 
versatile intermediate for the synthesis of pyrazolopyridone derivatives. Thus, to 
synthesized target molecules, the reaction of various ketene dithioacetals with 
cyanoacetamide in the presence of base was afforded pyridones. Further, the 
pyridones on reaction with hydrazine hydrated in isopropyl alcohol furnished the 
novel pyrazolopyridone derivatives in excellent yields. The synthesized compounds 
were characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy and elemental 
analysis. All the synthesized compounds were evaluated for their anti microbial 
activity.  
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2.5  RESULTS AND DISCUSSION 
 
        Initially, the reaction of 2-(bis(methylthio)methylene)-3-oxo-N-arylbutanamide 
(1a) with cyanoacetamide 2 was carried out using sodium methoxide in methanol. 
The reaction of 1a with 2 in sodium methoxide was afforded the product 3a in 75 % 
yield with long reaction time (Table 1). To optimize the reaction condition for the 
synthesis of compound 3a, various sodium alkoxides were utilized in respective 
alcohol. As a result, we found the reaction of 1a with 2 was faster and afforded the 
pyridone 3a in good yield in the presence of sodium isopropoxide and isopropyl 
alcohol.  
 
Scheme 1: Synthesis of substituted pyrazolopyridones using ketene dithioacetals. 
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O
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H
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N2H4H2O
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1a-t 2 3a-t PVP -2a-t  
 
 
Table 1: Reaction of 1a with 2 using various bases. 
 
Entry Base Time h Yield % 
1 NaOMe 7 75 
2 NaOEt 6 82 
3 NaOiPr 4 88 
 
 
The resulting pyridones 3a-t were further reacted with hydrazine hydrate in isopropyl 
alcohol to afford the pyrazolopyridone PVP-2a-t derivatives in excellent yield with 
short reaction time. The results are gathered in table 2. The synthesized compounds 
were confirmed by IR, Mass, 1H and 13C NMR spectroscopy and elemental analysis. 
All the synthesized compounds were evaluated for their anti microbial activity.  
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Table 2: Synthesis of various pyrazolopyridones PVP-2a-t. 
 
Entry         R Time min Yield % mp oC 
     
PVP-2a 4-OCH3C6H4 50 89 280-282 
PVP-2b C6H5 65 86 270-272 
PVP-2c C6H11 40 89 283-285 
PVP-2d 2,5-di-CH3C6H3 45 87 265-277 
PVP-2e 4-BrC6H4 55 88 285-287 
PVP-2f 4-FC6H4 65 89 288-290 
PVP-2g 4-ClC6H4 60 85 270-272 
PVP-2h 3-Cl,4-FC6H3 45 84 290-292 
PVP-2i 3,4-di-FC6H3 50 84 280-285 
PVP-2j 3-ClC6H4 60 85 270-272 
PVP-2k 3,4-di-ClC6H3 65 87 275-287 
PVP-2l 4-CH3C6H4 70 88 288-290 
PVP-2m 2-CH3C6H4 60 89 290-292 
PVP-2n 2-OCH3C6H4 70 83 280-282 
PVP-2o 2-FC6H4 75 92 268-270 
PVP-2p 2-BrC6H4 75 84 268-270 
PVP-2q 4-NO2C6H4 60 85 284-286 
PVP-2r 3,4-di-C6H3 55 89 278-280 
PVP-2s 2-ClC6H4 60 85 275-277 
PVP-2t 3-CH3C6H4 55 84 290-292 
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In mechanism, the cyanoacetamide on the treatment with base generate an anion at 
active methylene group which attack on β carbon of ketene dithioacetal. The amine 
nucleophile attack on carbonyl carbon and form sodium salt of pyridine moiety by 
removal of methylthio and water molecule. The sodium salt on acidification affords 
pyridone. The binucleophile hydrazine hydrate on reaction with pyridone form 
pyrazolopyridone. 
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Figure 32: Proposed mechanism for the formation of pyrazolopyridone. 
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2.6   ANTIMICROBIAL SENSITIVITY TESTING 
 
WELL DIFFUSION / AGAR CUP METHOD (Lt. General Raghunath D. 1998, 
Ashok Rattan, 1998; Patel R., Patel K. 2004,) 
In vitro effectivity of antimicrobial agents can be demonstrated by observing their 
capacity to inhibit bacterial growth on suitable media. The production of a zone 
depends on two factors namely bacterial growth and concentration of antimicrobial 
agent. The hole/well punch method was first used by Bennett. This diffusion method 
has proved more effective then many other methods. According to Lt. General 
Raghunath the well technique is 5-6 times more sensitive then using disk method. 
 
Principle  
 
When antimicrobial substance is added in agar cup (made in a medium previously 
inoculated with test organism) the redial diffusion of an antimicrobial agent through 
the agar, produces a concentration gradient. The test organism is inhibited at the 
minimum inhibitory concentration (MIC), giving rise to a clear zone of inhibition.  
 
Requirements 
 
1. Young broth culture of a standard test organism  
2. Sterile Mueller Hinton Agar plate 
3. Solution of antimicrobial substance 
4. Cup borer  
5. Alcohol etc. 
 
Inoculum preparation 
 
Inoculum was prepared by selecting 4-5 colonies from slope of stock culture of the 
indicator organism and emulsifying them in a suitable broth. The inoculated broth was 
incubated at 37ºC till it equals turbidity of a 0.5 McFarland standard. This happens in 
2-8 h. 
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Procedure 
 
1. Inoculate test organism on the top of Mueller Hinton Agar plate with help of 
sterile swab. (it can be inoculated in melted agar also ) 
2. The swab was dipped in the inoculum and surface of plate was streaked with 
swab. 
3. Streaking was repeated for 3 times and each time the plate was rotated at angle 
of 60º.  
4. Sterilize the cup-borer make four cups of the diameter of 8-10 mm. at equal 
distance in the plate previously inoculated with seed culture. 
5. The depth of well was 2.5-5.0 mm.  
6. The wells have been clearly punched so the surrounding medium is not lifted 
when the plug was removed out. 
7. The plates were incubated at 37ºC for 24 h. Then the zone of inhibition 
measured and the size of zone cited in table.  
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? Antibiotic Sensitivity Assay 
   
(Concentration250/500/ 1000 µG/ml) 
Sr. 
No. 
COD
E No. 
Pseudomonas 
aeruginosa 
Proteus 
vulgaris 
Escherichia  
coli 
Staphylococcu
s aureus 
Candida 
albicans 
  250 500 1000 250 500 1000 250 500 1000 250 500 1000 250 500 1000 
1.  2a 1.1 1.2 1.3 R 1.1 1.2 1.1 1.2 1.3 R 1.1 1.2 1.2 1.5 2 
2.  2b R R R R R R 1.2 1.5 1.7 R R R R R R 
3.  2c 1.1 1.2 1.4 1 1.3 1.7 1.4 1.5 2 R R R R 1.2 1.5
4.  2d 1.3 1.4 1.8 1.2 1.5 1.9 1.2 1.7 2.1 R R R R 1 1.3
5.  2e 1.1 1.5 1.7 1.1 1.3 1.5 1.3 1.4 1.7 R R R R R R 
6.  2f 1.1 1.4 1.6 1 1.2 1.3 1.2 1.3 1.6 1.2 1.4 1.6 1.1 1.2 1.7
7.  2g 1.4 1.7 2 1.2 1.5 1.8 1.2 1.2 1.5 1.4 1.7 2.1 1 1.2 1.8
8.  2h 1.3 1.6 2 1.3 1.6 2 R R R 1.1 1.8 2.3 1.1 1.4 1.8
9.  2i 1.2 1.6 1.8 1.1 1.3 1.4 R R R 1.2 1.5 1.7 1.2 1.6 2.1
10.  2j R 1 1.1 1 1.2 1.8 1.1 1.1 1.3 R R R 1 1.4 2 
11.  2k R 1.1 1.3 1.1 1.3 1.7 R 1.6 2 R R R R 1.1 1.5
12.  2l 1.1 1.4 1.7 1 1.1 1.3 1.1 1.1 1.3 R R R 1 1.3 1.5
13.  2m 1.1 1.1 1.3 R 1.1 1.4 1.2 1.4 1.7 R R 1.2 1.1 1.5 2 
14.  2n 1.1 1.1 R 1.1 1.1 R 1.2 1.1 1.2 2 1.6 1.2 1.5 R 1.9
15.  2o 1.2 1.3 1.6 1.2 1.3 1.1 1.2 1.2 1.6 1.1 1.1 1.2 1.1 R 1.7
16.  2p 1.1 1.2 1.2 1.2 1.4 2 1.3 1.1 1.4 1.3 R 1.3 1.4 1.1 1.6
17.  2q 1.3 1.1 1.8 1.6 1.1 1.2 1.2 1.3 1.1 1.6 1.1 1.6 1.6 1.6 1.2
18.  2r 1.2 1.5 1.1 1.4 2 1.1 1.1 1.3 1.5 R 1.5 1.5 1.6 1.6 1.5
19.  2s 1.4 R 2 1.1 1.1 1.5 1.2 1.8 1.3 1.1 R R 1.1 1.5 1.7
20.  2t 1.5 2 1.3 1.1 1.1 1.9 1.1 1.7 1.1 1.1 1.2 1.7 1.8 1.3 1.9
21.  A 1.8 1.8 1.9 1.9 - 
22.  CPD 2.2 2.1 2.1 2.2 - 
23.  GF 1.8 1.9 2.0 2.0 - 
24.  GRF - - - - 2.6 
25.  FLC - - - - 2.8 
 
Note: Zone of inhibition interpretation is as follows. 
 
1. ZONE SIZE <1.0 C.M.- RESISTENT(R)  
2. ZONE SIZE  1.0 To 1.5 – INTERMEDIATE 
3. ZONE SIZE >1.5 - SENSITIVE 
STD Antibiotic Sensitivity Assay Concentration 40 µG/ml 
     A: AMPICILLIN     
 CPD: CEFPODOXIME 
   GF: GATIFLOXACIN 
 GRF: GRESIOFULVIN 
  FLC: FLUCONAZOLE 
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 2.7     CONCLUSION 
 
           In summary, we have described the synthesis substituted pyrazolopyridone 
derivatives in excellent yields. The reaction of various ketene dithioacetals with 
cyanoacetamide was afforded the pyridone derivatives with good yields in the 
presence of base. Sodium isopropoxide was found as an efficient base for the 
synthesis of pyridones. The pyridones were further reacted with hydrazine hydrate to 
furnished pyrazolopyridones in excellent yields with short reaction time. All the 
synthesized compounds were evaluated for their anti microbial activity. The 
investigation of antibacterial and antifungal screening data revealed that all the tested 
compounds PVP-2a-t showed moderate to potent activity. The compounds PVP- 2h 
and 2g showed comparatively good activity against all the bacterial strains. 
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2.8    EXPERIMENTAL SECTION 
 
         The solvents and chemicals were analytical grade. Analytical thin layer 
chromatography (TLC) was performed on 0.2-mm precoated plates of Silica Gel 60 
F254 precoated plates. 1H (400 MHz) and 13C NMR (100 MHz) spectra were recorded 
in DMSO, and TMS was used as an internal reference on a Bruker AVANCE II 
spectrometer. Mass spectra were determined using direct inlet probe on a 
GCMSQP2010 mass spectrometer. IR spectra were recorded on a FTIR-8400 
spectrophotometer using DRS prob. Melting points were measured in open capillaries 
and are uncorrected. 
 
? General procedure for the synthesis of pyridones 3a-t. 
To a well stirred mixture of cyanoacetamide (10 mmol) and sodium 
isopropoxide (10 mmol) in isopropyl alcohol was added the solution of ketene 
dithioacetals 1a-t (10 mmol) in isopropyl alcohol within 10-15 min. The resulting 
reaction mixture was further stirred at rt for 15 min. Then, reflux the reaction mixtures 
for 4-5 h on water bath. After completion of the reaction, the solvent was evaporated 
under vacuuo and the resulting solid was treated with dilute HCl solution. Thus, the 
obtained solid was filtered, wash with water and dried at room temperature to afford 
analytically pure products. The solid products were used for next step without further 
purification.  
 
? General procedure for the synthesis of pyrazolopyridones PVP-2a-t. 
The mixture of substituted pyridones 3a-t (5 mmol) and hydrazine hydrate 
(10mmol) in isopropyl alcohol was refluxed for appropriate time on water bath (Table 
2). After completion of the reaction, solid product was appeared in the reaction. Cool 
the reaction mixture upto room temperature and filter the separated product washed 
with iPA and dried at room temperature to furnished analytically pure products. 
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? Spectral data of the synthesized compounds 
 
2-(bis(methylthio)methylene)-N-(4-methoxyphenyl)-4-methyl-3-oxopentanamide 
3a: yellow solid; Rf 0.42 (9:1Chloroform: Methanol);IR (KBr): 3439, 3007, 2928, 
2808, 1599, 1462, 1327, 1255cm-1; 1H NMR: δ 1.18-1.20 (d, 6H, 2 × iprCH3), 2.44 (s, 
6H, 2 × SCH3), 3.17-3.24 (m, 1H, iprCH), 3.75 (s, 3H, OCH3), 6.99–7.54 (m, 4H, Ar-
H), 8.38  (br, s, 1H, -CONH); MS (m/z): 339 (M+); Anal. Calcd for C16H21NO3S2: C, 
56.61; H, 6.24; N, 4.13; Found: C, 56.53; H, 6.14; N, 4.06. 
 
3-amino-4,5-dihydro-6-isopropyl-N-(4-methoxyphenyl)-4-oxo-1H-pyrazolo[4,3-
c]pyridine-7-carboxamide (PVP-2a): Creamish solid; Rf 0.40 (9:1Chloroform: 
Methanol); IR (KBr): 3379, 3024, 2902, 1651, 1516,1483, 1332, 1166, 954 cm-1; 1H 
NMR: δ 1.29-1.31 (d, 6H, 2 × iprCH3), 3.79 (s, 3H, OCH3), 4.21 (m, 1H, iprCH), 5.64 
(s,  2H, NH2), 6.84-6.86 (d, 2H, Ar-H, J = 8.00 Hz), 7.59-7.61 (d, 2H, Ar-H, J = 8.00 
Hz), 9.50 (s, 1H, NH), 10.62 (s, 1H, CONH), 11.93 (s, 1H, NH) ; MS (m/z): 341 (M+); 
Anal. Calcd for C17H19N5O3: C, 59.81; H, 5.61; N, 20.52; Found: C, 59.61; H, 5.54; 
N, 20.29. 
 
3-amino-4,5-dihydro-6-isopropyl-4-oxo-N-phenyl-1H-pyrazolo[4,3-c]pyridine-7- 
carboxamide (PVP-2b): Creamish solid; Rf 0.40 (9:1Chloroform: Methanol); IR 
(KBr): 3347, 3104, 2842, 1681, 1496, 1331, 1152, 857 cm-1; MS (m/z): 311 (M+); 
Anal. Calcd for C16H17N5O2: C, 61.72; H, 5.50; N, 22.49; Found: C, 61.65; H, 5.40; 
N, 22.42. 
 
3-amino-N-cyclohexyl-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7- carboxamide (PVP-2c): Creamish solid; Rf 0.42 (9:1Chloroform: 
Methanol); IR (KBr): 3309, 3014, 2908, 1671, 1563, 1473,1287, 1246, 927 cm-1; 1H 
NMR: δ 1.29-1.31 (d, 6H, 2 × iprCH3), 2.31-2.56 (m, 10H, 5 x CH2), 3.44 (m,  1H, 
CH), 4.65 (m, 1H, iprCH), 5.92 (s, 2H, NH2), 9.90 (s, 1H, NH), 10.62 (s, 1H, CONH), 
12.13 (s, 1H, NH)  MS (m/z): 317 (M+); Anal. Calcd for C16H23N5O2: C, 60.55; H, 
7.30; N, 22.07; Found: C, 60.50; H, 7.23; N, 22.02. 
 
3-amino-4,5-dihydro-6-isopropyl-N-(2,5-dimethylphenyl)-4-oxo-1H-pyrazolo[4,3-
c]pyridine-7-carboxamide (PVP-2d): Creamish solid; Rf 0.41 (9:1Chloroform: 
Methanol); IR (KBr): 3406, 3115, 2902, 1660, 1514, 1483,1280, 1178, 952 cm-1; MS  
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(m/z): 339(M+); Anal. Calcd for C18H21N5O2: C, 63.70; H, 6.24; N, 20.64; Found: C, 
63.61; H, 6.20; N, 20.58. 
 
3-amino-N-(4-bromophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PVP-2e): Creamish solid; Rf 0.44 (9:1Chloroform: 
Methanol); IR (KBr): 3330, 3142, 2830, 1688, 1489, 1241, 1118, 827 cm-1; MS (m/z): 
389 (M+); Anal. Calcd for C16H16BrN5O2: C,49.25; H, 4.13; N, 17.95; Found: C, 
49.14; H, 4.04; N, 17.90. 
 
3-amino-N-(4-fluorophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PVP-2f): Creamish solid; Rf 0.39 (9:1Chloroform: 
Methanol);IR (KBr): 3324, 3143, 2812, 1675, 1532,1482, 1298, 1114, 897 cm-1; 13C 
NMR: δ 20.32, 38.89-40.14, 114.58, 114.80, 121.48, 121.55, 134.94, 160.50, 163.25, 
179.74, 187.97.  MS (m/z): 329 (M+); Anal. Calcd for C16H16FN5O2: C, 58.35; H, 
4.90; N, 21.27; Found: C, 58.24; H, 4.84; N, 21.18. 
 
3-amino-N-(4-chlorophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PVP-2g): Creamish solid; Rf 0.40 (9:1Chloroform: 
Methanol); IR (KBr): 3369, 3020, 2897, 1685, 1573, 1494, 1157, 854 cm-1; MS (m/z): 
345 (M+); Anal. Calcd for C16H16ClN5O2: C, 55.58; H, 4.66; N, 20.25.; Found: C, 
55.49; H, 4.61; N, 20.23. 
 
3-amino-N-(3-chloro-4-fluorophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-
pyrazolo[4,3-c] pyridine-7-carboxamide (PVP-2h): Creamish solid; Rf 0.42 
(9:1Chloroform: Methanol); IR (KBr): 3348, 323, 3126, 2993, 1670, 1471, 1267, 
1206, 1085, 956 cm-1; MS (m/z): 363 (M+); Anal. Calcd for C16H15ClFN5O2: C, 52.83; 
H, 4.16; N, 19.25; Found: C, 52.71; H, 4.08; N, 19.10. 
 
3-amino-N-(3,4-difluorophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-
c]pyridine-7-carboxamide (PVP-2i): Creamish solid; Rf 0.40 (9:1Chloroform: 
Methanol);IR (KBr): 3348, 3250, 3003, 2984, 1620, 1428, 1286, 1180, 897 cm-1; MS 
(m/z): 347 (M+); Anal. Calcd for C15H14F2N5O2: C, 55.33; H, 4.35; N, 20.16; Found: 
C, 55.26; H, 4.24; N, 20.09. 
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3-amino-N-(3-chlorophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PVP-2j): Creamish solid; Rf 0.44 (9:1Chloroform: 
Methanol);IR (KBr): 3347, 3041, 2820, 1681, 1546, 1473,1322, 1183, 974 cm-1; MS 
(m/z): 345 (M+); Anal. Calcd for C16H16ClN5O2: C, 55.58; H, 4.66; N, 20.25.; Found: 
C, 55.45; H, 4.61; N, 20.18. 
 
3-amino-N-(3,4-dichlorophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-
c] pyridine-7-carboxamide (PVP-2k): Creamish solid; Rf 0.41 (9:1Chloroform: 
Methanol);IR (KBr): 3358, 3108, 2920, 1698, 1543, 1481,1248, 1198, 854 cm-1; MS 
(m/z): 380 (M+); Anal. Calcd for C16H15Cl2N5O2: C, 50.54; H, 4.66; N,18.42; Found: 
C, 50.42; H, 4.55; N, 18.40. 
 
3-amino-4,5-dihydro-6-isopropyl-4-oxo-N-p-tolyl-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PVP-2l): Creamish solid; Rf 0.42 (9:1Chloroform: Methanol);IR (KBr): 
3364, 2927, 1674, 1533, 1462, 1281, 1112, 873 cm-1; 1H NMR: δ 1.29-1.37 (d, 6H, 2 
× iprCH3), 2.30 (s, 3H, CH3), 4.21 (m, 1H, iprCH), 5.61 (s,  2H, NH2), 7.09-7.11 (d, 
2H, Ar-H, J = 8.00 Hz), 7.56-7.58 (d, 2H, Ar-H, J = 8.00 Hz), 10.00 (s, 1H, NH), 
10.66 (s, 1H, CONH), 12.02 (s, 1H, NH); MS (m/z): 325 (M+); Anal. Calcd for 
C17H19N5O2: C, 62.75; H, 5.89; N, 21.52; Found: C, 62.65; H, 5.85; N, 21.49. 
 
3-amino-4,5-dihydro-6-isopropyl-4-oxo-N-o-tolyl-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PVP-2m): Creamish solid; Rf 0.40 (9:1Chloroform: Methanol);IR 
(KBr): 3379, 3124, 2857, 1685, 1426, 1212, 1106, 854 cm-1; MS (m/z): 325 (M+); 
Anal. Calcd for C17H19N5O2: C, 62.75; H, 5.89; N, 21.52; Found: C, 62.69; H, 5.71; 
N, 21.48. 
 
3-amino-4,5-dihydro-6-isopropyl-N-(2-methoxyphenyl)-4-oxo-1H-pyrazolo[4,3-
c]pyridine-7-carboxamide (PVP-2n): Creamish solid; Rf 0.38 (9:1Chloroform: 
Methanol); IR (KBr): 3369, 3024, 2952, 1651, 1516,1463, 1332, 1166, 954 cm-1; MS 
(m/z): 341 (M+); Anal. Calcd for C17H19N5O3: C, 59.81; H, 5.61; N, 20.52; Found: C, 
59.71; H, 5.52; N, 20.43. 
 
3-amino-N-(2-fluorophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PVP-2o): Creamish solid; Rf 0.41 (9:1Chloroform:  
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Methanol); IR (KBr): 3320, 3143, 2822, 1672, 1532,1486, 1298, 1114, 897 cm-1; MS 
(m/z): 329 (M+); Anal. Calcd for C16H16FN5O2: C, 58.35; H, 4.90; N, 21.27; Found: C, 
58.27; H, 4.88; N, 21.20. 
 
3-amino-N-(2-bromophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PVP-2p): Creamish solid; Rf 0.42 (9:1Chloroform: 
Methanol); IR (KBr): 3340, 3132, 2830, 1680, 1459, 1241, 1118, 827 cm-1; MS (m/z): 
389 (M+); Anal. Calcd for C16H16BrN5O2: C,49.25; H, 4.13; N, 17.95; Found: C, 
49.18; H, 4.10; N, 17.86. 
 
3-amino-4,5-dihydro-6-isopropyl-N-(4-nitrophenyl)-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PVP-2q): Creamish solid; Rf 0.40 (9:1Chloroform: 
Methanol);IR (KBr): 3391, 2902, 2802, 1692, 1596, 1473, 1176, 974 cm-1; MS (m/z): 
356 (M+); Anal. Calcd for C16H16N6O4: C, 53.93; H, 4.53; N, 23.58; Found: C, 53.87; 
H, 4.48; N, 23.51. 
 
3-amino-4,5-dihydro-6-isopropyl-N-(2,5-dimethylphenyl)-4-oxo-1H-pyrazolo[4,3-
c]pyridine-7-carboxamide (PVP-2r): Creamish solid; Rf 0.43 (9:1Chloroform: 
Methanol); IR (KBr): 3406, 3145, 2922, 1660, 1514, 1463,1280, 1178, 952 cm-1; MS 
(m/z): 339(M+); Anal. Calcd for C18H21N5O2: C, 63.70; H, 6.24; N, 20.64; Found: C, 
63.65; H, 6.18; N, 20.60. 
 
3-amino-N-(2-chlorophenyl)-4,5-dihydro-6-isopropyl-4-oxo-1H-pyrazolo[4,3-c] 
pyridine-7-carboxamide (PVP-2s): Creamish solid; Rf 0.39 (9:1Chloroform: 
Methanol); IR (KBr): 3327, 3141, 2860, 1681, 1546, 1478,1322, 1183, 974 cm-1; MS 
(m/z): 345 (M+); Anal. Calcd for C16H16ClN5O2: C, 55.58; H, 4.66; N, 20.25.; Found: 
C, 55.51; H, 4.51; N, 20.13. 
 
3-amino-4,5-dihydro-6-isopropyl-4-oxo-N-m-tolyl-1H-pyrazolo[4,3-c]pyridine-7-
carboxamide (PVP-2m): Creamish solid; Rf 0.40 (9:1Chloroform: Methanol);IR 
(KBr): 3379, 3124, 2847, 1685, 1456, 1212, 1106, 854 cm-1; MS (m/z): 325 (M+); 
Anal. Calcd for C17H19N5O2: C, 62.75; H, 5.89; N, 21.52; Found: C, 62.69; H, 5.65; 
N, 21.42. 
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? Spectral representation of synthesized compounds 
 
 1H NMR spectrum of compound 3a 
 
 
Expanded 1H NMR spectrum of compound 3a 
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1H NMR spectrum of compound PVP-2a 
 
 
 
Expanded 1H NMR spectrum of compound PVP-2a 
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1H NMR spectrum of compound PVP-2c 
 
 
 
Expanded 1H NMR spectrum of compound PVP-2c 
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13C NMR spectrum of compound PVP-2f 
 
 
 
Expanded 13C NMR spectrum of compound PVP-2f 
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1H NMR spectrum of compound PVP-2l 
 
 
 
Expanded 1H NMR spectrum of compound PVP-2l 
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Mass Spectrum of compound PVP-2a 
 
 
Mass Spectrum of compound PVP-2b 
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Mass Spectrum of compound PVP-2f 
 
 
Mass Spectrum of compound PVP-2j 
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IR Spectrum of compound PVP-2h 
 
 
IR Spectrum of compound PVP-2i 
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3.1      INTRODUCTION  
? Indazole 
            The systematic IUPAC name benzo[c]pyrazole is not used in the Ring Index or 
in Chemical Abstract and the heterocycle is normally referred to by its trivial name 
indazole or more correctly 1H-indazole (CAS registry number 271-244-3). 
Alternative names for indazole such as 1,2-benzodiazole, are not used. Benzo-fused 
derivatives are known as benzoindazoles. (Figure 1)The first indazoles were 
synthesized in 1880,1 and a systematic investigation of the heterocycle was performed 
by V. Auwers in 1924.2 Indeed, general synthetic pathways to indazoles were 
developed in the early years of the 20th century and many recent publications describe 
improvements of known methods. Methods for the synthesis of indazoles are 
described in Houben-Weyl,3 and well-tested procedures for the synthesis of 1H-
indazole,4-7 2-phenyl-2H-indazole8 and 5-nitro-1H-indazole,9 can be found in Organic 
Synthesis. 
 
Natural products bearing an indazole structure are rare10 and at present only two 
examples are known: nigellicine11 and nigellidine.12 However, many synthetic 
indazoles are known, and a number are important because of their pharmaceutical 
activity; some act as dopamine antagonists, anti-inflammatory, analgesic, or 
antipyretic agents.13-20 Others also exhibit CNS activity,21-23 and 6- and 7-
nitroindazoles are used to study the behavior of nitric oxide in vivo.24-26 1-Benzyl-1H-
indazole-3-carboxilic acids have antispermatogenetic and anticancer activity,27-29 the 
latter effect being shared by other indazole derivatives.30-32 1-Benzoyl-1H-indazoles 
behave as antiarthritic drugs,33 and 4-nitro- and 4-amino-2-ribofuranosyl-2H-indazole 
3',5'-cyclic monophosphates act as potent mimics of adenosine-3',5'-cyclic 
monophosphates.34 Cortivazol35 is an indazole-based drug possessing glucocorticoid 
properties. Many indazoles act as enzyme inhibitors,36-38 and some also show specific 
virucide,39  bronchodilatory,40-42 vasodilatory,43 or neuroprotectant44 activities; others 
are used in the treatment of diabetes.45 3-Trifluoromethyl-1H-indazoles possess 
trichomonacide properties,46 and fused indazoles with an azasteroid ring system show 
antimicrobial activity.47 Some 1H-indazole-4,7-quinones possess anthelmintic48 and 
diuretic activity.49 A series of indazole derivatives exhibit herbicide activity, behave  
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as growth inhibitors,50-52 or are used as bactericides and fungicides in polymer based 
paints.53 Guanidino-1H-indazoles are used as sweeteners.54 
 
N
H
N
N
NH
N
N
1H-indazole 2H-indazole 3H-indazole
                 Tautomeric forms of indazole
1 2 3
 
Figure 1 
 
Although many derivatives of indazole show biological activity, no special toxicity 
has been reported and no special handling precautions have been recommended. The 
biodegradability of indazole is included in an ecological survey of heterocyclic 
compounds.55 
 
? Oxadaizole 
            1,3,4-oxadiazole(1) is a thermally stable aromatic heterocycle and exist in two 
partially reduced forms; 2,3-dihydro-1,3,4-oxadiazole(1,3,4-oxadiazoline)(2) and 2,5-
dihydro-1,3,4-oxadiazole(1,3,4-oxadiazoline)(3) depending on the position of the 
double bond. The completely reduced form of the 1,3,4-oxadiazole is known as 
2,3,4,5-tetrahydro-1,3,4-oxadiazole (1,3,4-oxadiazolidine)(4).56(Figure 2) 
 
N
O
N N
O
NH N
O
N HN
O
NH
(1) (2) (3) (4)
 
Figure 2 
 
Bactericidal and/or fungicidal activity was reported for oxadiazole(5a), 
aminooxadiazole(5b)57 and oxadiazolinethiones(6a)58 (Figure 3) The tin derivatives 
(6b) is an effective fungicide and antimicrobial activity is shown by thiones(6c).59 
Antiinflammatory, sedative and analgesic properties were reported for 
aryloxadiazoles(5c).60 Amino-oxadiazoles(5d) show analgesic activity and amono-
oxadiazoles(5e) exhibit both antiinflammatory and antiproteolytic 
properties.61Anticonvulsant and nervous system depressant activity was reported for  
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amino-oxadiazoles(5f), where R is quinazolin-3-yl group.62 Aminooxadiazole( 5g) 
showlocalanaesthetic activity.63 The oxadiazolinone(6d) is an orally active 
antiallergic agent, for example in the treatment of asthma and allergy disease and is 
claimed to be more potent than sodium cromoglycate.64 Examples of the many 
oxadiazolones for the many herbicidal activity (week killers) are (6e,6f) and 
“oxadiazon”(6g), which is the subject of many regular reports in the literature. 
Insecticidal activity is shown by oxadiazolones(6h,6i the later is an aphicide), and 
oxadiazole(5h) 
 
N
O
N N
O
N
5(a-h) 6(a-i)
R2
XR1R1 R2
 
Figure 3 
 
 
? Triazole 
 
           Triazoles are well known five member heterocyclic compounds and several 
procedures for their synthesis have been extensively studied. Such studied have been 
stimulated by various promising application, especially in the case of nitrogen 
containing heterocyclic entities. In fact certain nitrogen containing heterocyclic 
containing are used as pharmaceuticals e.g. analgesic, anti-inflammatory, antipyretic, 
agrochemicals where as some other is being studied for their medicinal interest.                                   
 R1 
or 
R2  R1 R2 X 
5a Ar CH2CONHCONHR 6a heteroarylOCH2 H S 
5b AR OCH2 NHCOR 6b 1-methylcyclopropyl Sn(Ph)3 O 
5c trimethoxy 3,4-dimethoxyphenyl 6c 5-Cl-2-phenylindol-3-ylNH H S 
5d 2-pyridyl NR2HCl 6d 
3-Cl-benzo[b]thiophen-
2-yl H O 
5e 4-biphenylylmethyl 
NHAr 
 6e 4-cyclohexylphenoxy H O 
5f Ar NHCH2CONHR 6f 2,4-diCl-phenoxymethyl Bn O 
5g Ar NHCO(CH2)nNRR'HCl(n=2or3) 6g t-Bu 
2,4-diCl--5-
isopropoxyphenyl O 
   6h OCH3 o-methoxyphenyl O 
    6i CH3NH 
2,3-diH-2,2,4-
triMebenzofuran-7-
yl 
 
O 
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The knowledge of such applications has pointed out that nitrogen containing 
heterocyclic’s are important target to be prepared to our research. Triazoles have an 
important place in drug industries triazole are two types  1,2,3-triazoles (I) and 1,2,4-
triazoles (II) (Figure 4). 
N
H
N
N
N
NH
N
N
N
H
N
HN
N
N
N
N
NH
1,2,3-triazoles (I)
1,2,4-triazoles (II)  
Figure 4 
Hao Z.65 and Staben Steven66 have studied briefly with the chemistry of 1,2,4- 
triazoles.  Bladin67,68 is a pioneer scientist in the field of triazole, who had synthesized 
the first derivative of 1,2,4-triazole in 1885. 1,2,4-triazole derivatives not only known 
for their medicinal applications, but they are also used as analytical reagents,69 dyes 
and photographic chemicals70 corrosion inhibitors71,72 and in the preparation of 
polymers.73 
                       
3.2      Pharmacological Profile 
 
             Wolf A. D. et al74 reported the compounds of formula (Figure 5) as useful for 
the selective preemergence control of undesired vegetation e.g., barnyard grass, in 
crops such as rice, in particular paddy rice, wheat, and peanuts. These compounds 
also have utility for the post emergence control of weeds in certain crops, for 
example, rice. Furthermore, compounds of this invention can be used as directed 
treatments for the pre- or post-emergence control of weeds in various crops including 
soybeans, peanuts, cotton, garden beans and row planted rice. 
N
N
R
R1
n
n = 1,2,3
R = fluorine, chlorine, bromine or iodine
R1= fluorine, chlorine, bromine, iodine, cyano, methoxy or nitro
 
Figure 5 
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Metz, S. et al75 described fused pyrazolo compounds for the treatment of 
inflammation, while Bauer, V. J. et al76 described new fused bicyclic aminopyrazole 
and their physiologically acceptable salts possessing anti-inflammatory and analgesic 
properties (Figure 6, 7). 
 
A
NN NH2
O
H
N
A = O, NH, NCOCH3, NSO2CH3
R = o-Cl-Pyridine, o-Cl-Ph
OO
O
R
 
Figure 6 
m
n N
NR
NHR1 Where
R = H, alkyl of 1-4 carbon atoms, phenyl or
        halophenyl;
R1= alkyl of 1-4 carbon atoms, cycloalkyl of
        3-7 carbon atoms, phenyl or halophenyl;
m and n are 0 or 1.
 
Figure 7 
Corbera A. and Esteve, S.A. et al77 had reported some tetrahydroindazole and fused 
pyrazole derivatives  having pharmacological activity towards the sigma receptor, and  
their use in particular for the treatment of psychosis or pain(Figure 8). 
 
N
N
R1
n
R2
R3
R4
N
R5 R6
m
 
Figure 8 
Peter J. Connolly et al78 demonstrated the synthesis of some tetrahydroindazole, 
tetrahydrocyclopentapyrazole,(Figure 9) and hexahydrocycloheptapyrazole 
compounds  and their use as HMG-COA reductase inhibitors. 
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Z
(CH2)p
R1
R2
R3 n
Where
R1, R2 = H, C1-C8 alkyl or aryl
R3 = H
Y   = C1-C8 alkyl or C1-C8 alkenyl
n,p = 0 to 3
Z   =
O
O
OH
or
OHOH
OR
O
 
Figure 9 
1,3,4-Oxadiazole is a versatile scaffold and is being consistently used as a building 
block in organic chemistry as well as in heterocyclic chemistry for the synthesis of 
different heterocycles. The synthetic versatility of 1,3,4-oxadiazole has led to the 
extensive use of this compound in organic synthesis.  
 
2,5-Disubstituted-1,3,4-oxadiazole derivatives have tested for various 
pharmacological activities, which have been summarized as under  Antibacterial,79 
Antiinflammatory,80 Analgesic,81 Antiviral,anticancer,82 Antihypertensive,83 
Anticonvulsant,84 Antiproliferative,85 Antifungal,86 Cardiovascular,87 Herbicidal,88 
Hypoglycem,89  Hypnotic and Sedative,90 MAO inhibitor,91 Insecticidal.92  
 
Bishnoi S. R. et al93 have screened oxadiazoles for their antimicrobial activity. A. El-
Azzouny et al.94 have synthesized 1,3,4-oxadiazole derivatives and evaluated for their 
analgesic, anti-inflammatory, ulcerogenic effects and inhibitory activity on plasma 
prostaglandin E2  (PGE2) Level. 
 
Bhandari S. V. et al95 have reported 1,3,4-oxadiazoles (Figure 10). for their anti-
inflammatory activity. Song Cao et al96 have investigated some oxadiazoles 
possessing insecticidal activity. Suresh Kumar G. V. et al97 have discovered 
oxadiazole derivatives and reported their antimycobacterial activity. Ali Almasired et 
al98 have prepared 1,3,4- oxadiazoles of type as anticonvulsant agent. Meria Grazia 
Mamolo et al99 have synthesized 3-substituted-5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-
2-one of type and studied their antimycobacterial activity. 
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Figure 10 
Krishna K. J. et al100 have reported antimicrobial activity of oxadiazole derivatives. J. 
A. Christopher. et al101 have documented anti HIV activity of 1,3,4-oxadiazole 
derivatives. Gilani S. J. et al102 have synthesized some oxadiazoles as anti-
inflammatory and analgesic agents. (Figure 11). K. Subrahmanya Bhat et al103 have 
prepared new fluorine containing 1,3,4-oxadiazoles  and reported them as potential 
antibacterial and anticancer agents. T. P. Mohan et al.104 have synthesized 2,5-
disubstituted-1,3,4-oxadiazole derivatives and screened for their insecticidal activity. 
 
O
Cl
O
NN
R
Cl
F
CH3 CH2
N N
O R
 
Figure 11 
Ronald Kim et al105 have discovered oxadiazole derivatives useful as protease 
inhibitors. Mohd Amir and Kumar Shikha106 have documented anti-inflammatory, 
analgesic and ulcerogenic activity of some newly synthesized oxadiazoles. Ali A.et 
al.107 have investigated some oxadiazole derivatives possessing antimicrobial and anti-
HIV-1 activity. Sherif A. et al.108 have reported oxadiazoles as potential antitumor and 
anti-HIV agents. Afshin Zarghi et al.109 have synthesized R-substituted-5-(2-
benzyloxyphenyl)-1,3,4-oxadiazoles possessing anticonvulsant activity. Mahamud 
Tareq et al110 have synthesized 2,5-disubstituted-1,3,4-oxadiazoles useful as 
tyrosinase inhibitors. (Figure 12) 
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Figure 12 
Triazoles are potential bioactive agents due to their wide spectrum of therapeutic 
importance. Drug molecule having 1,2,4-triazole nucleus (Figure 13).with good 
activity are listed as under. 
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Figure 13 
 
Literature survey reveals that various 1,2,4-triazole derivatives display significant 
biological  activities.  3-Amino-1,2,4-triazole  was  the  first  1,2,4-triazole  to  
be manufactured  on  large  scale  from  amino guanidine  format,  useful  as  
herbicides111 therapeutic activity of 1,2,4-triazoles are as under. 
 
Bactericidal,112 Diuretic,113 Fungicidal,114 Herbicidal,115 Insecticidal and    
acaricidal,116 Plantgrowthregulator,117 Anticancer and Anti-HIV,118 
Antileshmanial,119 Antitumor.120 
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Yaseen A. et al121 have prepared 1,5-dialkyl-3-(5-marcepto-4-N-aryl-1H-1,2,4-
triazolo-3-yl-methylene)-1H-1,2,4-triazole which exhibited remarkable activity 
against nine type of cancer and also anti viral activity. Bozena et al,122 have 
synthesized triazole derivatives and tested for their anticonvulsant and 
antinoncicepative activity. Sylvie larrat et al,123 investigated that ribavarin in 
combination with alpha-2-interferon is the consensus treatment for chronic hepatitis 
C. and E. De Clercq et al124 screened ribavarin (Figure 14) for their antiviral and 
antimetabolic activities.  
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Figure 14 
Daniele Binchi et al125 have screened pure stereoisomer of two new triazole 
derivatives (Figure 15) for their antifungal activity against variety of fungi showing 
an activity ratio R-form and S-form up to 400. 
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Figure 15 
Krzyszotof  W. et al126 have discovered 1,2,4-triazole (Figure 16)  and reported their 
antimicrobial activity. Dae-Kee Kim et al have been synthesized 1,2,4-triazole 
derivatives to study their pesticidal and herbicidal activity.  
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Sherin M. El-Feky et al127 have reported a new series of 3,5-disubstituted triazoles 
(Figure 17) were synthesized and evaluated for invitro antifungal and antibacterial 
activity. All compounds tested showed significant antifungal activity against 
micromycetes compared to the commercial fungicide clotrimazole. 
N
N N
S
R S N
NHN
N
F
F
 
Figure 17 
 
Hakan Bekats et al128 have synthesized some novel 4,5-disubstituted-2,4-dihydro-3H-
1,2,4-triazole-3-one (Figure 18)  and all newly synthesized compounds were screened 
for their antimicrobial activities and some of which were found to possess good or 
moderate activities against the test microorganisms. 
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Figure 18 
 
 
3.3. Alternative synthetic routes for better yield, shorter reaction                        
time and to synthesize new analogs  
 
? Creation of a C-N bond 
                Diazotation of an o-toluidine followed by capture of the generated 
diazonium salt is an old yet common way of accessing 1H-indazoles. This can be 
realized following two routes: the first and most common proceeds by a phase 
transfer-catalyzed reaction from o-methyl-benzendiazonium tetrafluoroborates 
(Figure 19) (method of Bartsch and Yang)129 the second takes place via N-nitroso  
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derivatives (method of Kovach and Barnes).130 These two procedures are well 
illustrated in the following example.131 
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N
N
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R
R
R
R
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CH3
NH2
CH3
N
N
CH3
NH
NO
BF4
R= 5-Br, 5-F, 5-OMe
R= 5-OMe, 7-OMe
AcOK,
18-crown-6
CHCl3, rt
PhH at ref.
aq HBF4, 0oC
aq NaNO2
NaNO2
AcOH,conc HCl
 
Figure 19 
 
A different protocol proceeding via the intermediacy of a diazonium ion has also been 
reported. Thus, in the course of the preparation of an 1H-indazolone compound acting 
as norepiephedrine/serotonin reuptake inhibitor for the treatment of fibromyalgia, the 
construction of the 1H-indazolone core structure of precursor  has been accomplished 
via the decomposition of a diazonium ion and capture of the resulting aryl cation by 
an ortho-disposed hydrazide (Figure 20).132 
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Figure 20 
 
Reduction of a diazonium ion, or of a N-nitroso species, to the corresponding 
hydrazine and intramolecular reaction of the latter with an ortho-disposed carbonyl 
functionality is another way to reach 3-substituted-1Hindazoles. Following this 
protocol, 5-bromo and 5-methoxy-3-carboxy-1H-indazoles (Figure 21) have been 
prepared from properly substituted isatines .133 
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Figure 21 
 
Another example can be found in the work of Zhang et al.134 which, in the course of a 
study aimed at preparing bicyclic benzamides as novel 5-HT1F receptor agonists, 
have reported the preparation of 1H-indazole (Figure 22). It is worth noting that this 
example features an indole to indazole conversion135 and reduction of the diazo 
intermediate with SO2.136  
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Figure 22 
The synthesis of a series of 1H-indazol-3-ones with creation of the N-N bond has 
been achieved via the intramolecular trapping of an N-acylnitrenium intermediate by 
an ortho-disposed amino group137. Starting from an o-aminobenzamide the N-
acylnitrenium cation was best generated by action of the hypervalent iodine reagent 
PIFA in DCM at 0°C (Figure 23). 
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Figure 23 
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The chemistry of 2H-indazoles has not been explored as well as the chemistry of 1H-
indazoles. However, the discovery that N-2 substituted 2H-indazole compounds may 
exhibit biological activities has generated recent interest in their simple and efficient 
preparation. 
 
A synthesis of 2-aryl-2H-indazoles via a palladium-mediated intramolecular 
amination reaction of N-aryl-N-(obromobenzyl)-hydrazines has been reported by 
Song and Yee.138 The best conditions to effect the transformation are heating in 
toluene at 90°C for 15h in the presence of Pd(OAc)2 (5 mol%), dppf (7.5 mol%), and 
t-BuONa (15 0 mol%). Yields were comprised in the 50 to 60% range. The catalytic 
system is equally effective for electron-rich and electron-deficient substituent’s on 
both phenyl rings. In a mechanistic point of view the formation of the sp2 C-N bond is 
followed by the spontaneous oxidation of the dihydroindazole intermediates to give 
the 2-aryl-2H-indazole products (Figure 24). 
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R2= Me, CF3, Cl, CN
  
Figure 24 
 
Most 1,3,4-oxadiazoles are best obtained by synthesis from acyclic precursors. Such 
reactions are ‘one bond’ or ‘two bond’ cyclization. Different methods for the 
synthesis have been cited in literature.139-141  
Anil N. Mayekar et al142 reported a series of new 1,3,4 oxadiazole (Figure 25) 
derivatives having 6-bromonaphthalene moiety are synthesized a hydrazide was 
treated with various substituted aromatic acids in presence of POCl3 to give 2-{[(6-
bromo-2-naphthyl)oxy]methyl}-5-aryl-1,3,4-oxadiazole. 
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Figure 25 
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Chandrakantha, B. et al143 have synthesized oxadiazoles (Figure 26) by the reaction 
of hydrazide and aromatic acid in presence of POCl3. 
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Figure 26 
D. Ramesh and B. Sreenivasan144 have synthesized 1,3,4-oxadiazoles (Figure 27) 
from semicarbazide in presence of POCl3. 
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Figure 27 
 
K. Mogilaiah and B. Sakram145 have prepared 1,3,4-oxadiazole (Figure 28) from 
acetophenone-2-trifluoromethyl-1,8-naphthyridine-3-carbonyl hydrazone in presence 
of acetic anhydride. 
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Figure 28 
Yu Yuve et al146 have reported microwave assisted synthesis protocol with 91 % of 
the yield (Figure 29). 
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Figure 29 
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Silica sulfuric acid catalyst used for the rapid and ecofriendly synthesis of 1,3,4-
oxadiazoles (Figure 30) at ambient temperature by M. Dabiri et al.147 
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Figure 30 
 
A.K. Mishra et al148 have reported synthesis and antimicrobial activity of some newer 
oxadiazole/triazole derivatives (Figure 31) starting from 2-substituted-1H-
benzimidazole. 
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Figure 31 
Reid and Heindel et al149reported that the reaction of aryl acid hydrazide with CS2 
/KOH and hydrazine hydrate yielded triazoles (Figure 32).  
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Figure 32 
K. Paulvannam et al150 have developed an improved synthesis of 1,3,5-trisubstituted 
1,2,4-triazoles (Figure 33) via Ag2CO3 mediated cyclization of  triazenes. The 
reaction was complete within 3h and the products were isolated in moderate to high 
yields.  
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Figure 33 
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K. S. Bhat et al151 have synthesized 4-amino-3-(2,4-dichloro-5-fluorophenyl)1,2,4-
triazole-5-thiol (Figure 34) with the help of thiocarbohydrazide and 2,4 dichloro-5-
fluoro benzoic acid. 
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Figure 34 
 
Sumesh E. et al152 also synthesized triazole derivatives by the reaction of 4-hydroxy-
8-(trifluoromethyl)quinoline-3-carbohydrazide and give 1,2,4-triazole (Figure 35). 
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L. Labanauskas et al153 have  prepared  triazoles  (Figure 36)  by the addition reaction 
of  thiosemicarbazide  with substituted benzoyl chloride in the presence of pyridine. 
Then the substituted thiosemicarbazide cyclised in water in the presence of alkaline 
catalyst. 
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Figure 36 
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3.4   CURRENT RESEARCH WORK 
 
       Our group is involved in design, synthesis and biological screening of 
heterocyclic compounds. On conducting literature survey, it was found that 
tetrahydroindazole is not more explored though it has great importance in the field of 
medicinal chemistry. On the observation of medicinal importance of 
tetrahydroindazole, its derivatization is necessary.  
 
The 3-carboxamide derivatives of 1H- and 2H-indazole possess good medicinal 
values. We sought to develop some 3-carbohydrazide 4,5,6,7-tetrahydro-2H-indazole 
derivatives. As per mentioned in literature, ethyl-2-oxo-2-(2-oxocyclohexyl)acetate 
was prepared by reacting cyclohexanone and diethyl oxalate with the help of sodium 
ethoxide in ethanol at 0-5 °C. Subsequent treatment of ethyl-2-oxo-2-(2-
oxocyclohexyl)acetate with hydrazine hydrate in ethanol resulted into ethyl 4,5,6,7-
tetrahydro-2H-indazole-3-carboxylate, while without solvent in excess hydrazine 
hydrate on reflux resulted into 4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide.  
 
The synthesis of novel indazole bearing oxadiazole derivatives (PVP-3Aa-o) has been 
achieved by the reaction of hydrazide of 2H-indazole with acid in the presences of 
POCl3. However the reaction of hydrazide of 2H-indazole with carbon disulfide and 
base afforded the potassium salt of hydrazide which on reaction with hydrazine 
hydrate and followed by aldehyde afforded desired triazole derivatives (PVP-3Ba-o). 
All newly synthesized compounds were characterized by IR, Mass, 1H NMR, 13C 
NMR spectroscopy and elemental analysis and screened for antimicrobial activity. 
 
 
. 
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3.5. RESULTS AND DISCUSSION                   
Scheme:-1 Synthesis of substituted oxadiazole and triazole derivatives. 
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Table 1: Synthesis of substituted oxadiazole and triazole derivatives. 
 
Entry R Yield % M.P. oC 
PVP-3Aa 4-ClC6H4 90 180-182 
PVP-3Ab 4-CH3C6H4 91 176-178 
PVP-3Ac 2-CH3C6H4 84 186-188 
PVP-3Ad 3-ClC6H4 90 192-194 
PVP-3Ae 2-ClC6H4 86 187-189 
PVP-3Af 2-OHC6H4 90 183-185 
PVP-3Ag 2-OH,3-NO2C6H3 90 195-197 
PVP-3Ah 2-ClC7H6 86 188-190 
PVP-3Ai C7H6 89 185-187 
PVP-3Aj 3-NO2C6H4 89 195-197 
PVP-3Ak 4-NO2C6H4 88 201-203 
PVP-3Al C8H7 90 178-180 
PVP-3Am 4-OCH3C6H4 90 183-185 
PVP-3An 2-OH,4-NO2C6H3 87 186-188 
PVP-3Ao C6H5 85 195-197 
PVP-3Ba 2-ClC6H4 90 238-240 
PVP-3Bb 4-OHC6H4 90 240-242 
PVP-3Bc 4-OCH3C6H4 89 246-248 
PVP-3Bd 4-FC6H4 85 250-252 
PVP-3Be 4-ClC6H4 87 248-250 
PVP-3Bf 4-CH3C6H4 89 243-245 
PVP-3Bg 3-BrC6H4 90 257-259 
PVP-3Bh 3-OHC6H4 85 245-247 
PVP-3Bi 2-OHC6H4 88 256-258 
PVP-3Bj C6H5 90 260-262 
PVP-3Bk 4-NO2C6H4 90 248-250 
PVP-3Bl 3-NO2C6H4 89 249-251 
PVP-3Bm 3,4-di-OCH3C6H3 85 252-254 
PVP-3Bn 2-CH3C6H4 88 258-260 
PVP-3Bo 2,5-di-OCH3C6H3 90 254-256 
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In mechanism, the amine group acts as nucleophile which attack on carbonyl carbon 
of acetyl chloride and form iminium by removal of chloride. Followed by the proton 
migration and removal of water molecule it forms oxadiazole. 
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Figure 37: Proposed mechanism for the formation of oxadiazole 
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3.6.   ANTIMICROBIAL SENSITIVITY TESTING 
 
WELL DIFFUSION / AGAR CUP METHOD (Lt. General Raghunath D. 1998, 
Ashok Rattan, 1998; Patel R., Patel K. 2004,) 
In vitro effectivity of antimicrobial agents can be demonstrated by observing their 
capacity to inhibit bacterial growth on suitable media. The production of a zone 
depends on two factors namely bacterial growth and concentration of antimicrobial 
agent. The hole/well punch method was first used by Bennett. This diffusion method 
has proved more effective then many other methods. According to Lt. General 
Raghunath the well technique is 5-6 times more sensitive then using disk method. 
 
Principle  
 
When antimicrobial substance is added in agar cup (made in a medium previously 
inoculated with test organism) the redial diffusion of an antimicrobial agent through 
the agar, produces a concentration gradient. The test organism is inhibited at the 
minimum inhibitory concentration (MIC), giving rise to a clear zone of inhibition.  
 
Requirements 
 
1. Young broth culture of a standard test organism  
2. Sterile Mueller Hinton Agar plate 
3. Solution of antimicrobial substance 
4. Cup borer  
5. Alcohol etc. 
 
Inoculum preparation 
 
Inoculum was prepared by selecting 4-5 colonies from slope of stock culture of the 
indicator organism and emulsifying them in a suitable broth. The inoculated broth was 
incubated at 37ºC till it equals turbidity of a 0.5 McFarland standard. This happens in 
2-8 h. 
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Procedure 
 
1. Inoculate test organism on the top of Mueller Hinton Agar plate with help of 
sterile swab. (it can be inoculated in melted agar also ) 
2. The swab was dipped in the inoculum and surface of plate was streaked with 
swab. 
3. Streaking was repeated for 3 times and each time the plate was rotated at angle 
of 60º.  
4. Sterilize the cup-borer make four cups of the diameter of 8-10 mm. at equal 
distance in the plate previously inoculated with seed culture. 
5. The depth of well was 2.5-5.0 mm.  
6. The wells have been clearly punched so the surrounding medium is not lifted 
when the plug was removed out. 
7. The plates were incubated at 37ºC for 24 h. Then the zone of inhibition 
measured and the size of zone cited in table.  
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Antibiotic Sensitivity Assay 
 
(Concentration250/500/ 1000 µG/ml) 
Sr. 
No. 
COD
E No.
Pseudomonas 
aeruginosa 
Proteus 
vulgaris 
Escherichia  
coli 
Staphylococcu
s aureus 
Candida 
albicans 
  250 500 1000 250 500 1000 250 500 1000 250 500 1000 250 500 1000 
1.  3Aa 1.1 1.2 1.3 R 1 1.2 1.1 1.2 1.4 1.1 1.2 1.5 1.1 1.5 1.9 
2.  3Ab 1.3 1.4 1.9 1.3 1.7 2.1 1.2 1.5 2 1.1 1.5 1.9 1.1 1.4 1.6 
3.  3Ac 1.2 1.3 1.5 1.1 1.4 1.6 1.3 1.4 1.9 1.2 1.6 2 1.2 1.5 2 
4.  3Ad R R R 1.1 1.3 1.7 1.1 1.3 1.6 R R R 1.1 1.4 1.8 
5.  3Ae 1.4 1.6 2 1 1.2 1.4 R R R 1.1 1.2 1.5 1.2 1.5 2 
6.  3Af 1 1.1 1.3 R 1.1 1.3 R R R R 1 1.4 R 1.1 1.5 
7.  3Ag R 1 1.1 1.1 1.6 1.8 1.4 1.5 2 1.1 1.2 1.3 1.1 1.3 1.7 
8.  3Ah R R R 1.1 1.3 1.5 1.2 1.3 1.7 R 1 1.3 1 1.2 1.8 
9.  3Ai 1.1 1.2 1.5 1.2 1.4 1.7 1.3 1.5 2 1.1 1.2 1.5 1.1 1.2 1.7 
10.  3Aj 1.3 1.4 1.8 R 1.1 1.3 R 1 1 1.2 1.4 1.7 1 1.3 1.8 
11.  3Ak 1.3 1.5 1.7 R 1 1.2 1.1 1.3 1.6 1.1 1.3 1.5 1 1.2 1.5
12.  3Al 1.2 1.4 1.6 1.1 1.4 1.8 1.2 1.5 1.9 R 1.2 1.7 1.1 1.5 2
13.  3Am 1.4 1.6 2 1.3 1.7 2 1.1 1.3 1.5 R 1 1.2 R 1.1 1.4 
14.  3An 1.1 1.1 1.3 1.1 1.3 1.8 1.4 1.6 2 1.1 1.2 1.4 1 1.2 1.7 
15.  3Ao R R R R R R 1.2 1.5 1.7 1.6 1.8 1.4 1.5 2 1.1 
16.  3Ba 1.1 1.2 1.4 1 1.3 1.7 1.4 1.5 2 1.3 1.5 1.2 1.3 1.7 R 
17.  3Bb 1.3 1.4 1.8 1.2 1.5 1.9 1.2 1.7 2.1 1.4 1.7 1.3 1.5 2 1.1 
18.  3Bc 1.1 1.5 1.7 1.1 1.3 1.5 1.3 1.4 1.7 R 1.3 R 1 1 1.2
19.  3Bd 1.1 1.4 1.6 1 1.2 R 1.2 1.3 1.6 1.2 1.4 1.6 1.1 1.2 1.7 
20.  3Be 1.4 1.7 2 1.2 1.5 1.8 1.2 1.2 1.5 1.4 1.7 2.1 1 1.2 1.8 
21.  3Bf 1.3 1.6 2 1.3 1.6 2 R R R 1.1 1.8 2.3 1.1 1.4 1.8 
22.  3Bg 1.2 1.6 1.8 1.1 1.3 1.4 R R R 1.2 1.5 1.7 1.2 1.6 2.1 
23.  3Bh R 1 1.1 1 1.2 1.8 1.1 1.1 1.3 1.2 1.3 1.1 1.2 1.4 2 
24.  3Bi R 1.1 1.3 1.1 1.3 1.7 R 1.6 2 1 R 1 1 1.1 1.5 
25.  3Bj 1.1 1.4 1.7 1 1.1 1.3 1.1 1.1 1.3 1.2 1.5 1.1 1.2 1.3 1.5 
26.  3Bk 1.1 1.1 1.3 R 1.1 1.4 1.2 1.4 1.7 1.4 1.7 1 1.4 1.5 2 
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27.  3Bl 1.1 1.2 1.3 R 1 1.2 1.1 1.2 1.4 1.1 1.2 1.5 1.1 1.5 1.9 
28.  3Bm 1.3 1.4 1.9 1.3 1.7 2.1 1.2 1.5 2 1.1 1.5 1.9 1.1 1.4 1.6 
29.  3Bn 1.2 1.3 1.5 1.1 1.4 1.6 1.3 1.4 1.9 1.2 1.6 2 1.2 1.5 2
30.  3Bo 1.3 1.1 1.3 1.1 1.3 1.7 1.1 1.3 1.6 1.3 1.1 1.3 1.1 1.4 1.8 
31.  A 1.8 1.8 1.9 1.9 - 
32.  CPD 2.2 2.1 2.1 2.2 - 
33.  GF 1.8 1.9 2.0 2.0 - 
34.  GRF - - - - 2.6 
35.  FLC - - - - 2.8 
 
 
Note: Zone of inhibition interpretation is as follows. 
1. Zone SIZE <1.0 C.M.- RESISTENT(R)  
2. ZONE SIZE  1.0 To 1.5 – INTERMEDIATE 
3. ZONE SIZE >1.5 - SENSITIVE 
 
STD Antibiotic Sensitivity Assay Concentration 40 µG/ml 
 
         A: AMPICILLIN     
 CPD: CEFPODOXIME 
   GF: GATIFLOXACIN 
 GRF: GRESIOFULVIN 
  FLC: FLUCONAZOLE 
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 3.7.     CONCLUSION 
 
           In summary, we have described the synthesis of novel indazole bearing 
oxadiazole derivatives and triazole derivatives. The reaction of hydrazide of 2H-
indazole with substituted carboxylic acid in the presences of POCl3 afforded desired 
oxadiazole derivatives (3A). However the reaction of hydrazide of 2H-indazole with 
carbon disulfide and base afforded the potassium salt of hydrazide which on reaction 
with hydrazine hydrate and followed by aldehyde afforded desired triazole 
derivatives (3B) in excellent yields. All the synthesized compounds were evaluated 
for their antimicrobial activity. The investigation of antibacterial and antifungal 
screening data revealed that all the tested compounds PVP-3Aa-o and 3Ba-o showed 
moderate to potent activity. The compounds PVP-3Ab, 3Be and 3Bf showed 
comparatively good activity against all the bacterial strains. 
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3.8 EXPERIMENTAL SECTION 
 
     Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (400 MHz) and 13C (100 MHz) NMR spectra were recorded on a 
Bruker AVANCE II spectrometer in CDCl3. Chemical shifts are expressed in δ ppm 
downfield from TMS as an internal standard. Mass spectra were determined using 
direct inlet probe on a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were 
evaporated with a BUCHI rotary evaporator. Melting points were measured in open 
capillaries and are uncorrected.  
 
? General procedure for the synthesis 4,5,6,7-tetrahydro-2H-indazole-3-
carbohydrazide (3). 
 
            To the stirred solution of sodium ethoxide (0.2mol), a mixture of 
cyclohexanone (0.2 mol) and diethyl oxalate (0.2 mol) was added drop wise below 5-
10 ºC. Vigorous stirring was required to prevent complete solidification of the reaction 
mixture. After completion of the reaction. The reaction mixture was decomposed by 
the careful addition of cold dilute sulfuric acid solution. The ethyl 2-
ketocyclohexylglyoxalate separated as heavy oil. Ethyl 2-oxo-2-(2-oxocyclohexyl) 
acetate is added into access 80% hydrazine hydrate and refluxed for 5 to 6 h. The 
reaction mixture was allowed to cool at room temperature and the precipitate obtained 
was filtered, dried and recrystallized from ethanol white crystals. Yield-85%. 
 
? General procedure for the synthesis of 4,5,6,7-tetrahydro-3-(5-aryl-1,3,4-
oxadaizol-2-yl)-2H-indazole (3Aa-o). 
              Equimolar amount of 4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide and 
appropriate carboxylic acid were taken in POCl3. The reaction mixture was refluxed 
for 6 h. and allowed to cool at room temperature and poured into crushed ice and stand 
by over night. The solid was filtered, dried and recrystallized from ethanol to give 
analytical pure product in 85-90% yield.  
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? General procedure for the synthesis of 4-amino-5-(4,5,6,7-tetrahydro-2H-
indazole-3-yl)-4H-1,2,4-triazole-3-thiol 
            To a mixture of potassium hydroxide (0.15 mol) and 4,5,6,7-tetrahydro-2H-
indazole-3-carbohydrazide (0.1 mol) in methanol, carbon disulphide (0.15 mol) was 
added. This mixture was stirred for 12 h. It was than diluted with dry ether and thus 
the solid obtained was filtered and washed with ether and dried .There is a no need to 
further purify the salt for further reaction. A suspension of the potassium salt (0.1 
mol), hydrazine hydrate (0.2 mol) was refluxed with stirring for 3 h. The color of the 
reaction mixture changed to green, hydrogen sulfide was evolved and a homogeneous 
solution resulted. Dilute the solution with cold water and neutralized with glacial 
acetic acid, precipitated a white solid. The product was filtered, washed with cold 
water and crystallized from dioxane yield 80%          
 
? General procedure for the synthesis of 4-(arylideneamino)-5-(4,5,6,7-
tetrahydro-2H-indazole-3-yl)-4H-1,2,4-triazole-3-thiol (3Ba-o). 
            Equimolar amount of triazole and appropriate aldehyde were taken in 
methanol and added 2 drops of con. HCl as a catalyst. The reaction mixture was 
refluxed for 8 h. and allowed to cool at room temperature. The solid was filtered, 
dried and recrystallized from ethanol to give pure yellow crystals in 85-90% yield.  
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? Spectral data of the synthesized compounds 
 
3-(5-(4-chlorophenyl)-1,3,4,-oxadiazole-2-yl)-4,5,6,7-tetrahydro-2H-indazole 
(PVP-3Aa): Creamish solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3227, 3186, 
3078, 2941, 1668, 1579, 1467, 1249, 1161 cm-1; MS (m/z): 300 (M+); Anal. Calcd for 
C15H13ClN4O: C, 59.91; H, 4.36; N, 18.63; Found: C, 59.48; H, 4.15; N, 18.52. 
 
4,5,6,7-tetrahydro-3-(5-p-tolyl-1,3,4,-oxadiazole-2-yl)-2H-indazole (PVP-3Ab): 
Creamish solid; Rf 0.35 (6:4 hexane-EtOAc); IR (KBr): 3149, 2980, 2862, 1653, 1509, 
1461, 1237, 1051 cm-1; 1H NMR: δ 1.80 (m, 4H, 2xCH2),  2.39 (s, 3H, CH3), 2.69 (m, 
2H, CH2),  2.88 (m, 2H, CH2),  7.31-7.35 (d, 2H, Ar-H), 7.93-7.95 (d, 2H, Ar-H), 
10.58 (s, 1H, NH); 13C NMR: δ 21.22, 21.44, 21.67, 22.36, 22.82, 117.22, 120.92, 
126.84, 126.95, 129.71, 129.77, 133.15, 142.24, 142.46, 160.13, 163.93; MS (m/z): 
280 (M+); Anal. Calcd for C16H16N4O: C, 68.55; H, 5.75; N, 19.99; Found: C, 68.48; 
H, 5.65; N, 19.82. 
 
4,5,6,7-tetrahydro-3-(5-o-tolyl-1,3,4,-oxadiazole-2-yl)-2H-indazole (PVP-3Ac): 
Creamish solid; Rf 0.30 (6:4 hexane-EtOAc); IR (KBr):  3186, 3149, 3078, 2950, 
1668, 1579, 1467, 1161, 1030 cm-1; 1H NMR: δ 1.80 (m, 4H, 2xCH2), 2.68 (m, 2H, 
CH2),  2.73 (s, 3H, CH3), 2.87- 2.88 (m, 2H, CH2), 7.24 -7.28 (t, 1H, Ar-H), 7.32-7.41 
(m, 2H, Ar-H), 7.90 -7.92 (d, 1H, Ar-H), 10.28 (s, 1H, NH); MS (m/z): 280 (M+); 
Anal. Calcd for C16H16N4O: C, 68.55; H, 5.75; N, 19.99; Found: C, 68.58; H, 5.45; N, 
19.92. 
 
3-(5-(3-chlorophenyl)-1,3,4,-oxadiazole-2-yl)-4,5,6,7-tetrahydro-2H-indazole 
(PVP-3Ad): Creamish solid; Rf 0.29 (6:4 hexane-EtOAc) ; IR (KBr): 3207, 3123, 
2959, 1658, 1546, 1472, 1265, 1041 cm-1; MS (m/z): 300 (M+); Anal. Calcd for 
C15H13ClN4O: C, 59.91; H, 4.36; N, 18.63; Found: C, 59.78; H, 4.20; N, 18.52. 
 
3-(5-(2-chlorophenyl)-1,3,4,-oxadiazole-2-yl)-4,5,6,7-tetrahydro-2H-indazole 
(PVP-3Ae): Creamish solid; Rf 0.34 (6:4 hexane-EtOAc); IR (KBr): 3207, 3123, 
2959, 1668, 1526, 1265, 1049 cm-1; MS (m/z): 300 (M+); Anal. Calcd for 
C15H13ClN4O: C, 59.91; H, 4.36; N, 18.63; Found: C, 59.76; H, 4.18; N, 18.60. 
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2-(5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-1,3,4,-oxadiazole-2-yl)phenol (PVP-
3Af): yellow solid; Rf 0.32 (6:4 hexane-EtOAc); IR (KBr): 3207, 3123, 2990, 2862, 
1653, 1509, 1461, 1061 cm-1; MS (m/z): 282 (M+); Anal. Calcd for C15H14N4O2: C, 
63.82; H, 5.00; N, 19.85; Found: C, 63.78; H, 5.05; N, 19.82. 
 
2-(5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-1,3,4,-oxadiazole-2-yl)-6-nitrophenol 
(PVP-3Ag): Creamish solid; Rf 0.36 (6:4 hexane-EtOAc); IR (KBr):  3223, 3149, 
2990, 2862, 1653, 1509, 1437, 1061 cm-1; MS (m/z):327 (M+); Anal. Calcd for 
C15H13N5O4: C, 55.05; H, 4.00; N, 21.40; Found: C, 55.11; H, 4.05; N, 21.32. 
 
3-(5-(2-chlorobenzyl)-1,3,4,-oxadiazole-2-yl)-4,5,6,7-tetrahydro-2H-indazole 
(PVP-3Ah): Creamish solid;Rf 0.31 (6:4 hexane-EtOAc); IR (KBr): 3227, 3193, 
2966, 1628, 1522, 1456, 1217, 1041 cm-1; MS (m/z): 314 (M+); Anal. Calcd for 
C16H15ClN4O: C, 61.05; H, 4.80; N, 17.80; Found: C, 61.01; H, 4.75; N, 17.63. 
 
3-(5-benzyl)-1,3,4,-oxadiazole-2-yl)-4,5,6,7-tetrahydro-2H-indazol (PVP-3Ai): 
Creamish solid; Rf 0.33 (6:4 hexane-EtOAc); IR (KBr): 3227, 3173, 2989, 1648, 1586, 
1468, 1251, 1061 cm-1;  MS (m/z): 280 (M+); Anal. Calcd for C16H16N4O: C, 68.55; 
H, 5.75; N, 19.99; Found: C, 68.43; H, 5.65; N, 19.82. 
 
4,5,6,7-tetrahydro-3-(5-(3-nitrophenyl)-1,3,4,-oxadiazole-2-yl)-2H-indazole (PVP-
3Aj): Creamish solid; Rf 0.36 (6:4 hexane-EtOAc); IR (KBr): 3442, 3226, 3143, 2986, 
1642, 1566, 1447, 1241, 1051 cm-1;  MS (m/z): 311 (M+); Anal. Calcd for 
C15H13N5O3: C, 57.87; H, 4.21; N, 22.50; Found: C, 57.73; H, 4.14; N, 22.42. 
 
4,5,6,7-tetrahydro-3-(5-(3-nitrophenyl)-1,3,4,-oxadiazole-2-yl)-2H-indazole (PVP-
3Ak): Creamish solid; Rf 0.29 (6:4 hexane-EtOAc); IR (KBr): 3206, 3163, 2996, 
1672, 1566, 1478, 1241, 1049 cm-1;  MS (m/z): 311 (M+); Anal. Calcd for 
C15H13N5O3: C, 57.87; H, 4.21; N, 22.50; Found: C, 57.83; H, 4.18; N, 22.52. 
 
4,5,6,7-tetrahydro-3-(5-styryl-1,3,4,-oxadiazole-2-yl)-2H-indazole (PVP-3Al): 
Creamish solid; Rf 0.28 (6:4 hexane-EtOAc); IR (KBr): 3226, 3143, 2988, 1632, 1546, 
1424, 1231, 1061 cm-1;  MS (m/z): 292 (M+); Anal. Calcd for C17H16N4O: C, 69.85; 
H, 5.52; N, 19.17; Found: C, 69.73; H, 5.44; N, 19.12. 
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4,5,6,7-tetrahydro-3-(5-(4-methoxyphenyl)-1,3,4,-oxadiazole-2-yl)-2H-indazole 
(PVP-3Am): Creamish solid;Rf 0.30 (6:4 hexane-EtOAc);  IR (KBr): 3217, 3153, 
2950, 1613, 1539, 1431, 1061 cm-1;  MS (m/z): 296 (M+); Anal. Calcd for 
C16H16N4O2: C, 64.85; H, 5.44; N, 18.91; Found: C, 64.78; H, 5.35; N, 18.82. 
 
2-(5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-1,3,4,-oxadiazole-2-yl)-5-nitrophenol 
(PVP-3An): Creamish solid; Rf 0.32 (6:4 hexane-EtOAc);  IR (KBr): 3187, 3153, 
2980, 1623, 1569, 1431, 1051 cm-1;  MS (m/z): 327 (M+); Anal. Calcd for 
C15H13N5O4: C, 55.05; H, 4.00; N, 21.40; Found: C, 55.08; H, 4.05; N, 21.52. 
 
4,5,6,7-tetrahydro-3-(5-phenyl-1,3,4,-oxadiazole-2-yl)-2H-indazole (PVP-3Ao): 
Creamish solid; Rf 0.34 (6:4 hexane-EtOAc); IR (KBr): 3227, 3120, 2980, 1623, 1509, 
1461, 1051 cm-1; MS (m/z): 266 (M+); Anal. Calcd for C15H14N4O: C, 67.65; H, 5.30; 
N, 21.04; Found: C, 67.58; H, 5.25; N, 21.12. 
 
4-(2-chlorobenzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-
triazole-3-thiol (PVP-3Ba): yellow solid; Rf 0.53 (6:4 hexane-EtOAc); IR (KBr): 
3414, 3171, 3143, 2937, 2856, 1589, 1492, 1276, 1049 cm-1;  MS (m/z): 358 (M+); 
Anal. Calcd for C16H15 ClN6S: C, 53.55; H, 4.21; N, 23.42; Found: C, 53.46; H, 4.15; 
N, 23.32.  
 
4-(((3-mercato-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-triazol-4-
yl)imino) methyl)phenol (PVP-3Bb): yellow solid; Rf 0.54 (9:1Chloroform: 
Methanol); IR (KBr):  3394, 3115, 3068, 2989, 1648, 1597, 1458, 1261, 1061 cm-1; 1H 
NMR: δ 1.76- 1.81 (m, 4H, 2xCH2),  2.59 -2.67 (m, 4H, 2xCH2), 6.90- 6.95 (m, 2H, 
Ar-H), 7.65-7.74 (m, 2H, Ar-H), 9.80 (s, 1H, CH), 10.20 (s, 1H, OH), 13.62 (s, 1H, 
NH), 13.87 (s, 1H, SH); MS (m/z): 340 (M+); Anal. Calcd for C16H16N6OS: C, 56.45; 
H, 4.74; N, 24.69; Found: C, 56.43; H, 4.45; N, 24.62. 
 
4-(4-methoxybenzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-
1,2,4-triazole-3-thiol (PVP-3Bc): yellow solid; Rf 0.56 (9:1Chloroform: Methanol); 
IR (KBr): 3394, 3115, 2939, 2850, 1597, 1458, 1168, 1051 cm-1; 1H NMR: δ 1.72- 
1.79 (m, 4H, 2xCH2),  2.57 -2.65 (m, 4H, 2xCH2), 3.87 (s, 3H, OCH3), 6.99- 7.01 (d, 
2H, Ar-H), 7.82-7.87 (d, 2H, Ar-H), 9.33 (s, 1H, CH), 12.65 (s, 1H, NH), 13.87 (s,  
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1H, SH);   MS (m/z): 354 (M+); Anal. Calcd for C17H18N6OS: C, 57.61; H, 5.12; N, 
23.71; Found: C, 57.52; H, 5.15; N, 23.65. 
 
4-(4-fluorobenzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-
triazole-3-thiol (PVP-3Bd): yellow solid; Rf 0.54 (9:1Chloroform: Methanol); IR 
(KBr): 3414, 3252, 3173, 2919, 1586, 1478, 1241, 1051 cm-1; MS (m/z): 342 (M+); 
Anal.Calcd for C16H15FN6S: C, 56.13; H, 4.42; N, 24.54; Found: C, 56.20; H, 4.25; N, 
24.42. 
 
4-(4-chlorobenzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-
triazole-3-thiol (PVP-3Be): yellow solid; Rf 0.55 (9:1Chloroform: Methanol); IR 
(KBr): 3442, 3327, 3073, 2989, 1653, 1586, 1259, 1056 cm-1; 13C NMR: δ 20.10, 
20.83, 22.03, 22.47, 22.60, 22.74, 72.15, 115.24, 122.0, 127.68, 127.92, 128.22, 
128.37, 128.70, 128.77, 129.87, 130.76, 133.97, 134.02, 137.62, 140.66, 149.36, 
161.72, 164.29; MS (m/z): 358 (M+); Anal. Calcd for C16H15 ClN6S: C, 53.55; H, 
4.21; N, 23.42; Found: C, 53.48; H, 4.19; N, 23.32. 
 
4-((4-methylbenzylidene)amino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-
1,2,4-triazole-3-thiol (PVP-3Bf): yellow solid; Rf 0.51 (9:1Chloroform: Methanol); IR 
(KBr): 3422, 3317, 3073, 2939, 1586, 1427, 1276, 1067 cm-1;  MS (m/z): 338 (M+); 
Anal. Calcd for C17H18N6S: C, 60.33; H, 5.36; N, 24.83; Found: C, 60.30; H, 5.30; N, 
24.72. 
 
4-(3-bromobenzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-
triazole-3-thiol (PVP-3Bg): yellow solid; Rf 0.52 (9:1Chloroform: Methanol); IR 
(KBr): 3442,  3173, 2989, 2876, 1586, 1465, 1261, 1061 cm-1;  MS (m/z): 403 (M+); 
Anal. Calcd for C16H15 BrN6S: C, 47.65; H, 3.75; N, 20.84; Found: C, 47.58; H, 3.69; 
N, 20.82. 
 
3-(((3-mercato-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-triazol-4-
yl)imino) methyl)phenol (PVP-3Bh): yellow solid; Rf 0.52 (9:1Chloroform: 
Methanol); IR (KBr): 3393, 3327, 3173, 2989, 1586, 1487, 1256, 1044 cm-1;  MS 
(m/z): 340 (M+); Anal. Calcd for C16H16N6OS: C, 56.45; H, 4.74; N, 24.69; Found: C, 
56.35; H, 4.70; N, 24.72. 
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2-(((3-mercato-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-triazol-4-
yl)imino) methyl)phenol (PVP-3Bi): yellow solid; Rf 0.53 (9:1Chloroform: 
Methanol); IR (KBr): 3402, 3327, 3063, 2989, 2850, 1586, 1458, 1287, 1053 cm-1;  
MS (m/z): 340 (M+); Anal. Calcd for C16H16N6OS: C, 56.45; H, 4.74; N, 24.69; 
Found: C, 56.40; H, 4.68; N, 24.65. 
 
4-(Benzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-triazole-
3-thiol (PVP-3Bj): yellow solid; Rf 0. 54 (9:1Chloroform: Methanol); IR (KBr): 3327, 
3173, 2959,  1586, 1441, 1245, 1050 cm-1;  MS (m/z): 324 (M+); Anal. Calcd for 
C16H16N6S: C, 59.24; H, 4.97; N, 25.91; Found: C, 59.20; H, 4.89; N, 25.82. 
 
4-(4-nitrobenzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-
triazole-3-thiol (PVP-3Bk): yellow solid; Rf 0.53 (9:1Chloroform: Methanol); IR 
(KBr):  3397, 3173, 2939, 1586, 1492, 1241, 1068 cm-1;  MS (m/z): 369 (M+); Anal. 
Calcd for C16H15N7O2S: C, 52.02; H, 4.09; N, 26.54; Found: C, 51.90; H, 4.12; N, 
26.62. 
 
4-(3-nitrobenzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-1,2,4-
triazole-3-thiol (PVP-3Bl): yellow solid; Rf 0.53 (9:1Chloroform: Methanol); IR 
(KBr): 3414,  3173, 3142, 2989, 2856, 1586, 1256, 1061 cm-1;  MS (m/z): 369 (M+); 
Anal. Calcd for C16H15N7O2S: C, 52.02; H, 4.09; N, 26.54; Found: C, 51.98; H, 4.15; 
N, 26.42. 
 
4-(3,4-dimethoxybenzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-
1,2,4-triazole-3-thiol (PVP-3Bm): yellow solid; Rf 0.53 (9:1Chloroform: Methanol); 
IR (KBr): 3459, 3327, 3193, 2999, 1586, 1437, 1257, 1065 cm-1;  MS (m/z): 384 
(M+); Anal. Calcd for C18H20N6O2S: C, 56.23; H, 5.24; N, 21.86; Found: C, 56.12; H, 
5.15; N, 21.75. 
 
4-((2-methylbenzylidene)amino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-
1,2,4-triazole-3-thiol (PVP-3Bn): yellow solid; Rf 0.55 (9:1Chloroform: Methanol); 
IR (KBr): 3442, 3327, 3173, 2989, 1586, 1475, 1231, 1049 cm-1; MS (m/z): 338 (M+); 
Anal. Calcd for C17H18N6S: C, 60.33; H, 5.36; N, 24.83; Found: C, 60.20; H, 5.29; N, 
24.72. 
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4-(2,5-dimethoxybenzylideneamino)-5-(4,5,6,7-tetrahydro-2H-indazole-3-yl)-4H-
1,2,4-triazole-3-thiol (PVP-3Bo): yellow solid; Rf 0.53 (9:1Chloroform: Methanol); 
IR (KBr): 3459, 3327, 3193, 2999, 1648, 1586, 1437, 1051 cm-1;  MS (m/z): 384 
(M+); Anal. Calcd for C18H20N6O2S: C, 56.23; H, 5.24; N, 21.86; Found: C, 56.20; H, 
5.27; N, 21.85. 
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? Spectral representation of synthesized compounds 
 1H NMR spectrum of compound PVP-3Ab 
 
 
Expanded 1H NMR spectrum of compound PVP-3Ab 
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1H NMR spectrum of compound PVP-3Ac 
 
 
Expanded 1H NMR spectrum of compound PVP-3Ac 
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1H NMR spectrum of compound PVP-3Bb 
 
 
Expanded 1H NMR spectrum of compound PVP-3Bb 
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1H NMR spectrum of compound PVP-3Bc 
 
 
 
Expanded 1H NMR spectrum of compound PVP-3Bc 
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13C NMR spectrum of compound PVP-3Ab 
 
 
Expanded 13C NMR spectrum of compound PVP-3Ab 
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13C NMR spectrum of compound PVP-3Be 
 
 
Expanded 13C NMR spectrum of compound PVP-3Be 
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Mass Spectrum of compound PVP-3Aa 
 
 
Mass Spectrum of compound PVP-3Ac 
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Mass Spectrum of compound PVP-3Bc 
 
 
Mass Spectrum of compound PVP-3Bd 
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Mass Spectrum of compound PVP-3Bg 
 
 
IR Spectrum of compound of PVP-3Ac 
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IR Spectrum of compound of PVP-3Ba 
 
 
IR Spectrum of compound of PVP-3Bc 
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4.1     INTRODUCTION  
           
        Biginelli P. reported the synthesis of functionalized 3,4-dihydropyrimidin-2(1H)-
ones (DHPMs) via three-component condensation reaction of an aromatic aldehydes, 
urea and ethyl acetoacetate (Figure 1). In the past decade, this multicomponent 
reaction has experienced a remarkable revival, mainly due to the interesting 
pharmacological properties associated with this dihydropyrimidine scaffold.1  
H O
H2N
NH2
SH3C O
O
O +
H+
EtOH/Heat N
H
NH
H3C
O
O
S
R
R
 
Figure 1 
Biginelli reaction is not only important to synthesize analogs of DHPM ring using 
different building block as potent bioactive heterocycles, but diversed fused and non-
fused heterocycles can be synthesized by careful applications(Figure 2). 
? Various scaffolds derived from DHPMs 
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As displayed in above figure, it can be understood that a number of new moieties can 
be generated from DHPM ring.  
 
4.2   Pharmacological Profile 
 
        Kappe et al reported that N3-acylated DHPMs can be rapidly synthesized in a 
high throughput fashion by combining microwave-assisted acylations with 
microwave-assisted scavenging techniques. Scavenging experiments can be carried 
out employing either supported nucleophilic amine sequestration reagents or water.2 
N-acylated DHPMs are pharmacologically very important scaffolds as most of 
bioactive DHPMs are N-acylated. N-acylation of DHPM can be performed (Figure 3) 
as shown below.  
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Figure 3 
 
N3-Substituted DHPMs (Figure 4) have been identified to possess potent 
pharmacological profiles. Following compound exhibited high binding affinity and 
subtype selectivity for the cloned human R1a receptor.3 
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Figure 4 
 
Systematic modifications of above compounds led to identification of highly potent 
and subtype-selective compounds with high binding affinity (Ki ) 0.2 nM) for R1a 
receptor and greater than 1500-fold selectivity over R1b and R1d  adrenoceptors. The  
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compounds were found to be functional antagonists in human, rat, and dog prostate 
tissues (Figure 5, 6). 
 
NO2
N
H
NR''
O
R' O
N
H
N
Ph
CO2Me
O
       
N
H
NH2N
O
O
N
H
N
Ph
CO2Me
O
R
                       
Figure 5                                                                Figure 6 
 
Modifications to the C5 position also play important role in potency of DHPM ring. 
4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 
amide as selective R1A receptor subtype antagonists. In receptor binding assays, these 
types of compounds generally display Ki values for the R1a receptor subtype <1 nM 
while being greater than 100-fold selective versus the R1b and R1d receptor subtypes. 
(Figure 7).  Many of these compounds were also evaluated in vivo and found to be 
more potent than terazosin in both a rat model of prostate tone and a dog model of 
intra-urethral pressure without significantly affecting blood pressure.4 
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Figure 7 
 
Mithun Ashok et al5 have reported a new series of new 2-(arylidine)-5-(4-
methylthiophenyl)-6-carboethoxy-7-methyl-5H-thiazolo[3,2-a]pyrimidine-3(1H)-
ones. The newly synthesized compounds (Figure 8) were screened for their anti- 
bacterial and antifungal activities and have exhibited moderate to excellent growth 
inhibition of bacteria and fungi. 
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Hui Zhi et al6 have developed a novel AchE inhibitors. A docking screening model of 
AchE inhibitor was used to evaluate a series of 5H-thiazolo[3,2-a]pyrimidine 
derivatives (Figure 9). The virtual screening hits were analyzed in drug likeness and 
physic chemical features. Therefore were focused to those compounds. To investigate 
the relationship between the bioactivities and the structure, 10 target compounds with 
the 5H-thiazolo[3,2-a]pyrimidine scaffold were synthesized as potential AchE 
inhibitors. 
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4.3 Alternative synthetic routes for better yield and shorter reaction time to       
synthesize new analogs  
 
? Intramolecular Heck cyclization of DHPMs 
          The intramolecular Heck reaction can be observed in DHPM skeleton. The 
starting material for the intramolecular Heck reaction, DHPM was prepared by 
selective N3-acylation of 4-(o-bromophenyl)-dihydropyrimidone with acryloyl 
chloride7 (Figure 10). 
 
Chapter 4                                              Synthesis of functionalized thiazolopyrimidines 
140 
 
 
 
N
H
NH
O
O
O Br
N
H
N
O
O
O Br
OCl
O Et3N, MeCN
MW, 180 °C, 20 min+
 
 
Figure 10 
Applying intramolecular Heck reaction, tricyclic ring system can be obtained as 
shown below8 (Figure 11). 
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Figure 11 
 
The computational experiments reveal that the formation of a tricyclic ring system did 
not flatten out the overall geometry. On the contrary, the aryl ring was still locked in a 
pseudoaxial position, resembling other nonfused 4-aryl-dihydropyrimidines.9,10 In 
fact, here, (Figure 12) the intramolecular Heck strategy allows locking of the aryl 
ring in the proposed bioactive, that is, the pseudoaxial, orientation.11 
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Figure 12 
 
? N3-Arylation of DHPMs 
 
           N3-arylated DHPM analogues cannot be obtained by classical Biginelli 
condensation strategies involving N-arylureas. Here, the corresponding N1-substituted 
derivates will be formed exclusively.12,13  
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Wannberg et al reported protocol using concentrated mixture of 20 mol % of CuI as 
catalyst, 1.5 equiv of Cs2CO3 as base, and 5 mol equiv of DMF as solvent. The 
reactions were conducted at 180 °C for 40 min with a set of eight differently 
substituted aryl iodides (Figure 13). 
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Figure 13 
 
? Bicyclic systems derived from DHPMs 
  
            Many bicyclic systems can be synthesized from DHPM scaffold. 
Pyrazolo[4,3-d]pyrimidine derivatives synthesized by reacting sodium azide with N-
Me, 6-Br-Me DHPM. The possible mechanism of this transformation is shown in 
below and involves decomposition of the diazide to vinyl diazo derivative, which 
undergoes spontaneous 1,5-electrocyclization to 3H-pyrazole. Subsequent migration 
of the ester substituent from the tetrahedral carbon to N2 (thermal van Alphen-Hüttel 
rearrangement) yields pyrazolo[4,3-d]pyrimidine. The structure confirming the 
position of the ester group at N2 was established by an X-ray analysis.  
 
Use of the 4-chloroacetoacetate building block  in a Biginelli-type condensation is 
very useful to get variety of bicyclic systems. The resulting functionalized DHPM 
appeared to be an ideal common chemical template for the generation of a variety of 
interesting bicyclic scaffolds such as (Figure 14,15) furo[3,4-d]-pyrimidines, 
pyrrolo[3,4-d]pyrimidines, and pyrimido[4,5-d]pyridazines.a 
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Figure 15 
   
Solid-phase and solution-phase protocols for the synthesis of furo[3,4-d]pyrimidines, 
pyrrolo[3,4-d]-pyrimidines, and pyrimido[4,5-d]pyridazines are reported. The 
multistep solid-phase sequence involves the initial high-speed, microwave-promoted 
acetoacetylation of hydroxymethylpolystyrene resin with methyl 4-
chloroacetoacetate. The immobilized 4-chloroacetoacetate precursor was 
subsequently subjected to threecomponent Biginelli-type condensations employing  
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urea and a variety of aromatic aldehydes. The resulting 6-chloromethyl-functionalized 
resin-bound dihydropyrimidones served as common chemical platforms for the 
generation of the desired heterobicyclic scaffolds using three different traceless 
cyclative cleavage strategies. The corresponding furo[3,4-d]pyrimidines were 
obtained by microwave flash heating in a rapid, thermally triggered, cyclative release. 
Treatment of the chloromethyl dihydropyrimidone intermediates with a variety of 
primary amines followed by high-temperature microwave heating furnished the 
anticipated pyrrolo[3,4-d]pyrimidine scaffolds via nucleophilic cyclative cleavage. In 
a similar way, reaction with monosubstituted hydrazines resulted in the formation of 
pyrimido[4,5-d]pyridazines. All compounds (Figure 16) were obtained in moderate to 
good overall yields and purities.b  
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Figure 16 
 
Preparation of thiazolo[3,2-a]pyrimidine derivatives is very well reported in literature. 
Two approaches is generally employed for synthesis.  
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? Azole approach: 
          Various methods for (Figure 17) synthesis of thiazolo[3,2-a]pyrimidine 
derivatives using thiazole as starting material.  
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Figure 17 
 
Literature survey on synthetic methodology for thiazolo[3,2-a]pyrimidine derivatives 
can be summarized in chart 1 & 2 where various methods are illustrated for synthesis 
of this class of compounds.  
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Thiazolo[3,2-a]pyrimidine 2 was prepared in 30% yield by the reaction of 2-
aminothiazole 1 with ethyl cyanoacetate  in a sodium ethoxide/ethanol mixture or 
using polyphosphoric acid or acetic acid. However, oxothiazolopyrimidine 3 was 
obtained upon treatment with phosphorous pentoxide and methanesulfonic acid. 
 
The reaction of 1 with ethyl acetoactate at 140-150°C resulted in the formation of 
compound that was then converted to the Z-isomer upon heating at 250°C and 
cyclized to give 4. 2-Aminothiazole 5 cyclized with acetylacetone at l00"C, in the 
presence of methanesulfonic acid-phosphorus pentoxide or formic acid-phosphorus 
pentoxide, followed by treatment with 70% perchloric acid, to give the 
thiazolopyrimidin-4-ium salt 5. The ester 6 was obtained from 2-aminothiazole 1 with 
an excess of methyl methanetricarboxylate in 61 % yield. Cyclocondensation of 1 
with diethyl ethoxymethylene malonate in acetic acid followed by hydrolysis of the 
ester gave 7. Similarly, 2-aminothiazole 1 reacted with benzylidine in ethanol to give 
8. Stanovink et al., [13-171 reported the synthesis of a series of thiazolopyrimidine 
derivatives upon reacting 2-aminothiazole with a variety of different reagents. Thus, 
dimethylaminobut- 2-enoate (or pentenoate), reacted with 1 to give 
thiazolopyrimidines 23.14-27 
 
The reaction of 2-aminothiazole 1 with 2-hydropolyfluoroalk-2-enoate in basic 
medium gave two isomers, 7-oxo 2 and its isomeric 5-oxo 3. (Figure 18) The 
structure of both 2 and 3 was established through 1H NMR, 13C NMR and mass 
spectra28. 2-Aminothiazole derivatives, (R' = H, CO2Et; R2 = Ph, aryl, Me), reacted 
with the acetylenic derivative and ester derivative in ethanol and polyphosphoric acid, 
respectively, to give the isomeric oxothiazolopyrimidine derivatives 4 and 5, in 5-
32% and 8-97 % yield, respectively29. Condensation of 2-aminothiazole 1 in absolute 
ethanol with the sodium salt of ethyl oximinocyanoacetate gave after acidification 
(pH 6) with diluted hydrochloric acid, the nitroso derivative 6 in 92% yield30. 
Treatment of the 2-aminothiazaole derivatives 5 with the hydrazone derivatives gave 
the oxothiazolo [3,2-a] pyrimidine derivatives 7.31 
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Figure 18 
 
2-Amino-2-thiazoline reacted with 2-acylamino-3-dimethylamino-propenoates in 
acetic acid to yield 6-acylamino-5-oxo-2,3-dihydro-5-thiazolo[3,2-a]pyrimidines in 73 
and 12% yields, respectively32 (Figure 19).  
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Moreover, 2-amino-2-thiazoline reacted with an aromatic aldehyde and diethyl 
malonate, to give (Figure 20) a mixture of thiazolidino[3,2-a]pyrimidines. 
Furthermore, malononitrile reacted to give following product.33-34  
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Figure 20 
 
2-Amino-2-thiazoline reacted with potassium 2-ethoxycarbonyl-2-fluorovinyl 
alcoholate in a sodium methoxide/methanol mixture to give 6-fluoro-2,3-dihydro-5-
oxothiazolo[3,2-a]pyrimidine.35 (Figure 21)  
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2-(Methylthio)-2-thiazoline reacted with /3-alanine to give a 5-oxothiazolo[3,2-a]-
pyrimidine (Figure 22) derivative  in 23% yield.36 
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? Azine approach 
 
          Pyrmidinethione derivatives were alkylated with monochloroacetic acid or 
chloroacetyl chloride and then cyclized to give thiazolopyrimidine derivatives.37-50 
Thus, pyrimidinethione reacted in DMF37 or in an acetic anhydride/pyridine mixture39 
to give thiazolo-pyrimidines (Figure 23).  Alkylation in the presence of an aromatic 
aldehyde gave the ylidene. Similarly, pyrimidinethione derivatives reacted with 
monochloroacetic acid in acetic acid/acetic anhydride/sodium acetate mixture or with 
chloroacetyl chloride in dry dioxane to give the corresponding thiazolopyrimidines.41-
42 
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Treatment of mercaptopyrimidine derivative with 2-chloroethanol in DMF gave the 
asymmetrical thioether which underwent cyclization on refluxing with a mixture of 
acetic anhydride-pyridine, to give the oxothiazolopyrimidine.51 (Figure 24)   
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Figure 24 
1,3-dibromopropan-2-ol reacted with mercaptopyrimidine derivative to give product 
through the non isolated intermediates. (Figure 25) The same reaction product was 
obtained by reacting with I-bromomethyloxirane.52 
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Several derivatives of 4,5-disubstituted imidazole, 2,4,5-trisubstituted pyrimidine, 2-
substituted purine, thiazolo[3,2-a]purine, [1,3]thiazino[3,2-a]purine, thiazolo[2,3-
i]purine, [1,3]thiazino-[2,3-i]purine, and 6-substituted pyrazolo[3,4-d]pyrimidine 
were (Figure 26,27,28) synthesized and tested as inhibitors of the xanthine oxidase 
enzyme53. 
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Dihydropyrimidines are well-known calcium channel blockers. According to the 
literature analogous derivatives are anti-inflammatories. Thus Bo´szing and co-
workers decided to synthesize the pyrimidothiazines and assay these compounds for 
the same profile. Acute anti-inflammatory activity was tested by inhibition of the 
carrageenan-induced paw edema in rats.54 (Figure 29) 
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Adam et al filed US patent for phenyl substituted thiazolo pyrimidine derivatives 
synthesized from DHPM. (Figure 30) These compounds and their slats are novel and 
are distinguished by valuable therapeutic properties. Specifically it has been found 
that the compounds of general formula given below are metabotropic glutamate 
receptor antagonists. These compounds are capable of high affinity binding to group 
II mGluR receptors.55  
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Compounds displayed by general formulae given below exhibit excellent adenosine 
A3 receptor antagonism (Figure 31) where A is an optionally substituted benzene 
ring. B may be substituted and R1 is optionally substituted cyclic group.56 
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Amr, A. E. G. E. and Maigali, S. S. described the analgesic and antiparkinsonian 
activity of some thiazolopyrimidine derivatives as shown below. (Figure 32) Out of 
them compound of type III are potent antiparkinsonian agents.57 
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CDC25 phosphatases play critical roles in cell cycle regulation and are attractive 
targets for anticancer therapies. Several small non-peptide molecules are known to 
inhibit CDC25, but many of them appear to form a covalent bond with the enzyme or 
act through oxidation of the thiolate group of the catalytic cysteine. Matthieu Montes 
et al reported thiazolopyrimidine structure based compound (Figure 33) as CDC25 
phosphatases inhibitor.58 
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Helmut M. Hugel et al59 (Figure 34) have been developed the application of 
multicomponent reaction involving the combination of multiple starting materials 
with multiple functional groups leading to the higher efficiency and environmentally 
friendly construction of target molecules.  
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2-thioxopyrimidine derivatives were prepared by the Biginelli reaction protocol thus 
the 5 min MW irradiation of a 1,3-diphenyl-1,3-propanedione, arylaldehyde and 
thiourea in gl. acetic acid plus a few drops of cons. HCl gave the products in 75%-
80%  yields. The 2-thione DHPM were transformed into thiazolopyrimidines and 
pyrimidothiazine derivatives with bromo acids and MW irradiation. When compared 
to conventional heating the MW technology completed the two step synthesis much 
faster.   
 
I.V. Kulakov et al60 have synthesized thiazolo[3,2-a]pyrimidines by the reaction of 4-
aryl-substituted 3,4-dihydropyrimine(1H)-2-thiones and methyl chloroacetate in 
boiling toluene afford target molecule (Figure 35) in good yield. Their structures 
were shown by 1H NMR and X-ray crystallography.           
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4.4       CURRENT RESEARCH WORK 
 
             Importance of dihydropyrimidine ring to develop variety of bicyclic systems 
briefly surveyed in section 4.1. Reports reveals that N3-substitution in 
dihydropyrimidine ring is enhance therapeutic activity profile. Similarly, substitutions 
at C5 position may pay key role in activity profile. Thus, we have synthesized 
pyrimidine derivatives containing phenyl carbamoyl at C5 position. Further, thiazolo 
pyrimidine derivatives phenyl carbamoyl moiety at C5 position are synthesized and 
characterized. 
 
Thiazolo pyrimidine and pyrimido thiazine are very important bicyclic system in 
medicinal chemistry. Various synthetic routes have been reported in literature to 
synthesize these bicyclic systems. Utility of dihydropyrimidine ring to synthesize 
such bicyclic system can be used to obtain derivatives with phenyl carbamoyl as side 
chain on pyrimidine ring of bicyclic system. 
 
Dihydropyrimidine ring, substituted with phenyl carbamoyl side chain at C5 position, 
was synthesized by reacting acetoacetanilide, thiourea and aldehyde. This 
dihydropyrimidine ring was reacted with dihalo ketone to get fused bicyclic systems. 
The synthesis of thiazolo pyrimidine derivatives achieved by the reaction of 2-
thiodihydropyrimidine with chloro acetyl chloride. Various solvents were utilized as 
reaction media to get better results. Among them glacial acetic acid with sodium 
acetate as catalytic amount was succeeded to give better yield with shorten reaction 
time and easy in isolation of product. All the synthesized compounds were 
characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy. All the synthesized 
compounds were evaluated for their anti microbial activity. 
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4.5     RESULTS AND DISCUSSION 
 
Scheme:-1 Synthesis of substituted Thiazolopyrimidines. 
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Initially, the reaction of 4-methyl-3-oxo-N-arylpentanamide 1a-t with appropriate 
aldehyde 2a-t and thiourea in MeOH. Few drops of con. HCl were added to reaction 
mixture as a catalyst and was refluxed for 8-12 h. (Scheme 1) gives 1,2,3,4–
tetrahydro-6-isopropyl-N,4-diaryl-2-thioxopyrimidine-5-carboxamide 3a-t, When 3a-
t was reacted with chloro acetyl chloride (scheme 2) affords the 3,5-dihydro-7-
isopropyl-3-oxo-N,5-diaryl-2H-thiazolo[3,2-a]pyrimidine-6-carboxamide derivatives 
PVP-4a-t was obtained in excellent yield.     
   
The structures of 4a-t were established on the basis of their elemental analysis and 
spectral data (MS, IR, and 1H NMR). The analytical data for 3e revealed a molecular 
formula C22H25N3OS (m/z 379). The 1H NMR spectrum revealed a two singlet at δ = 
1.45-1.62 ppm assigned to isopropyl-CH3, a singlet at δ = 2.24 - 2.26 ppm assigned to 
the – ( 2xCH3 ) protons, a multiplet at δ = 3.85 ppm assigned to  the isopropyl-CH 
protons , a doublet at δ = 4.76 - 4.77 ppm assigned to the -CH protons, a multiplet at δ 
= 7.10 - 7.48 ppm assigned to the aromatic protons,  a doublet at δ = 8.86 - 8.87ppm  
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assigned to –NH protons, a singlets at δ = 8.93 ppm assigned to –NH protons, and one 
broad singlets at δ = 9.73 ppm assigned to -CONH groups. 
  
Table 1: Synthesis of substituted Thiazolopyrimidines. 
  
Entry R1 R2 Yield % M.P. 
PVP-4a 3-Cl,4-FC6H3 4-ClC6H4 90 260-262 
PVP-4b 4-ClC6H4 4-ClC6H4 91 258-261 
PVP-4c 4-FC6H4 4-ClC6H4 84 245-247 
PVP-4d 4-OCH3C6H4 4-OCH3C6H4 90 243-245 
PVP-4e 4-CH3C6H4 4-CH3C6H4 86 266-268 
PVP-4f 4-OCH3C6H4 4-FC6H4 90 268-270 
PVP-4g 3-Cl,4-FC6H4 C6H5 90 238-240 
PVP-4h C6H5 3,4-di- OCH3C6H3 86 248-250 
PVP-4i 4- BrC6H4 3,4-di- OCH3C6H3 90 256-258 
PVP-4j 4-ClC6H4 4-OCH3C6H4 91 236-238 
PVP-4k 4-FC6H4 4-FC6H4 88 226-228 
PVP-4l C6H5 C6H5 92 256-258 
PVP-4m 4-ClC6H4 4-CH3C6H4 90 264-266 
PVP-4n 2,5-di-CH3C6H3 4-OHC6H4 87 239-241 
PVP-4o 3-ClC6H4 4-CH3C6H4 85 241-243 
PVP-4p 4- BrC6H4 4-FC6H4 93 258-261 
PVP-4q 4-OCH3C6H4 4-NO2C6H4 90 250-252 
PVP-4r 4-ClC6H4 4-OHC6H4 89 256-257 
PVP-4s 4-FC6H4 2-OHC6H4 85 248-250 
PVP-4t 3-ClC6H4 3-ClC6H4 90 246-248 
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      The mechanism for the formation of DHPM involves acid catalyzed formation of 
an N- acylinium (4) ion intermediate from the aldehyde (1) and thiourea (2) 
precursors. Interception of the iminium ion by acetoacetanilidie, presumably through 
it’s active methylene produce an open chain uride (5) which subsequently cylices to 
hexahydropyrimidine (6). Acid catalyzed elimination of water from ultimately leads 
to the DHPM product (7).   
 
R2 CHO
H2N
S
NH2
N
OH
R2
H
NH2
S
N
H
R2
H
NH2
S
H+
-H2O
-H+
R1 N
H
OO
R2
O
NH
SH2N
R2
N
H
NH
S
HO
R2
N
H
NH
S
R2
N
NH
S:
H
Cl
OCl
-HCl
R2
N
N:
S
Cl OH
R2
N
N:
S
Cl O
H
-HCl
R2
N
N
S
O
-H2O
1
2
3
4
567
8 9
1011  
Figure 36: Proposed mechanism for the formation of Thiazolopyrimidine. 
 
The thio atom act as neucleophile and attack on methylene of chloro acetyl chloride 
and form (9) like product, which on acid catalyzed elimination of HCl leads the final 
compound thiazolopyrimidine (11). 
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4.6     ANTIMICROBIAL SENSITIVITY TESTING 
 
WELL DIFFUSION / AGAR CUP METHOD (Lt. General Raghunath D. 1998, 
Ashok Rattan, 1998; Patel R., Patel K. 2004,) 
In vitro effectivity of antimicrobial agents can be demonstrated by observing their 
capacity to inhibit bacterial growth on suitable media. The production of a zone 
depends on two factors namely bacterial growth and concentration of antimicrobial 
agent. The hole/well punch method was first used by Bennett. This diffusion method 
has proved more effective then many other methods. According to Lt. General 
Raghunath the well technique is 5-6 times more sensitive then using disk method. 
 
Principle  
 
When antimicrobial substance is added in agar cup (made in a medium previously 
inoculated with test organism) the redial diffusion of an antimicrobial agent through 
the agar, produces a concentration gradient. The test organism is inhibited at the 
minimum inhibitory concentration (MIC), giving rise to a clear zone of inhibition.  
 
Requirements 
 
1. Young broth culture of a standard test organism  
2. Sterile Mueller Hinton Agar plate 
3. Solution of antimicrobial substance 
4. Cup borer  
5. Alcohol etc. 
 
Inoculum preparation 
 
Inoculum was prepared by selecting 4-5 colonies from slope of stock culture of the 
indicator organism and emulsifying them in a suitable broth. The inoculated broth was 
incubated at 37ºC till it equals turbidity of a 0.5 McFarland standard. This happens in 
2-8 h. 
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Procedure 
 
1. Inoculate test organism on the top of Mueller Hinton Agar plate with help of 
sterile swab. (it can be inoculated in melted agar also ) 
2. The swab was dipped in the inoculum and surface of plate was streaked with 
swab. 
3. Streaking was repeated for 3 times and each time the plate was rotated at angle 
of 60º.  
4. Sterilize the cup-borer make four cups of the diameter of 8-10 mm. at equal 
distance in the plate previously inoculated with seed culture. 
5. The depth of well was 2.5-5.0 mm.  
6. The wells have been clearly punched so the surrounding medium is not lifted 
when the plug was removed out. 
7. The plates were incubated at 37ºC for 24 h. Then the zone of inhibition 
measured and the size of zone cited in table.  
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? Antibiotic Sensitivity Assay 
   
(Concentration250/500/ 1000 µG/ml) 
Sr. 
No. 
CODE 
No. 
Pseudomonas 
aeruginosa 
Proteus 
vulgaris 
Escherichia  
coli 
Staphylococcu
s aureus 
Candida 
albicans 
  250 500 1000 250 500 1000 250 500 1000 250 500 1000 250 500 1000 
1.  4a R R R R 1 1.3 1.2 1.4 2 R R R R R R 
2.  4b 1 1.1 1.2 1.2 1.5 1.7 1.2 1.6 1.9 R 1 1.2 R 1.1 1.4 
3.  4c R R 1.2 1.1 1.5 2 1.4 1.5 2.1 R 1.3 1.5 1.1 1.4 2 
4.  4d R R R 1 1.2 1.4 1.2 1.4 1.5 R R R 1 1.2 1.5 
5.  4e 1.2 1.3 1.5 R 1.1 1.3 1.3 1.4 1.7 1 1.2 1.5 1.1 1.4 2 
6.  4f 1.2 1.3 1.6 1.1 1.4 1.7 1.1 1.3 1.5 1 1.2 1.4 1.2 1.5 2 
7.  4g 1.3 1.5 1.8 R 1.2 1.5 1.2 1.2 1.6 1 1.2 1.3 1.1 1.2 1.6 
8.  4h 1.3 1.5 1.9 1 1.2 1.7 1.2 1.7 1.9 R 1.4 1.8 1.2 1.5 2 
9.  4i 1.2 1.4 1.7 1.3 1.5 1.9 1.3 1.6 2 R 1.1 1.2 1.1 1.3 1.8 
10.  4j 1.1 1.2 1.5 1 1.1 1.3 1.3 1.4 1.6 1.1 1.3 1.5 1.2 1.4 1.8 
11.  4k 1.9 1.2 1.7 2.1 R 1.1 1.2 2 R R R 1.1 1.2 1.4 1.7 
12.  4l 1.5 1.3 1.4 1.7 1.2 1.4 2 1.4 R R R 1.2 1.1 1.3 1.5 
13.  4m 1.3 1.2 1.3 1.6 1.2 1.3 1.7 1.8 1.1 1.1 1.3 R R 1.3 1.7 
14.  4n 1.8 1.2 1.2 1.5 1.1 1.3 1.5 1.7 R 1.6 2 R 1.2 1.5 2 
15.  4o 2 R R R 1.1 1.2 1.4 1.3 1.1 1.1 1.3 R R R R 
16.  4p 1.4 R R R 1.2 1.3 1.6 1.4 1.2 1.4 1.7 R R 1.2 1.5 
17.  4q 1.8 1.1 1.1 1.3 1.1 1.2 1.3 1.2 1.1 1.2 1.4 1.1 R 1 1.3 
18.  4r 1.7 R 1.6 2 1 1.3 1.5 2.1 1.2 1.5 2 1.1 R R R 
19.  4s 1.3 1.1 1.1 1.3 1.1 1.3 1.6 1.6 1.3 1.4 1.9 1.2 1.1 1.2 1.7 
20.  4t 1.4 1.2 1.4 1.7 1.3 1.5 1.9 1.7 1.1 1.3 1.6 R 1 1.2 1.8 
21.  A 1.8 1.8 1.9 1.9 - 
22.  CPD 2.2 2.1 2.1 2.2 - 
23.  GF 1.8 1.9 2.0 2.0 - 
24.  GRF - - - - 2.6 
25.  FLC - - - - 2.8 
 
Note: Zone of inhibition interpretation is as follows. 
 
1. ZONE SIZE <1.0 C.M.- RESISTENT(R)  
2. ZONE SIZE  1.0 To 1.5 – INTERMEDIATE 
3. ZONE SIZE >1.5 – SENSITV 
 
STD Antibiotic Sensitivity Assay Concentration 40 µG/ml 
     A: AMPICILLIN     
 CPD: CEFPODOXIME 
   GF: GATIFLOXACIN 
 GRF: GRESIOFULVIN 
  FLC: FLUCONAZOLE 
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4.7 CONCLUSION 
 
      In summary, we have described the synthesis substituted thiazolo pyrimidine 
derivatives in excellent yields. The reaction of various 2-thioxopyrimidine with 
chloro acetyl chloride (scheme 2) affords the 3,5-dihydro-7-isopropyl-3-oxo-N,5-
diaryl-2H-thiazolo[3,2-a] pyrimidine-6-carboxamide derivatives (PVP-4a-t) was 
obtained in excellent yield. All the synthesized compounds were characterized by IR, 
Mass, 1H NMR, 13C NMR spectroscopy. All the synthesized compounds were 
evaluated for their anti microbial activity. The investigation of antibacterial and 
antifungal screening data revealed that all the tested compounds PVP-4a-t showed 
moderate to potent activity. The compounds PVP-4c and 4m showed comparatively 
good activity against all the bacterial strains. 
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4.8      EXPERIMENTAL SECTION 
           Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (400 MHz) and 13C (100 MHz) NMR spectra were recorded on a 
Bruker AVANCE II spectrometer in CDCl3. Chemical shifts are expressed in δ ppm 
downfield from TMS as an internal standard. Mass spectra were determined using 
direct inlet probe on a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were 
evaporated with a BUCHI rotary evaporator. Melting points were measured in open 
capillaries and are uncorrected. 
 
? General synthesis of 2-thioxopyrimidines 3a-t. 
          A 100mL conical flask equipped with magnetic stirrer and septum was charged 
with a solution of 4-methyl-3-oxo-N-phenylpentanamide 1a-t, (0.01M), aldehyde 
(0.01M) and thiourea (0.015M) was dissolved in minimum quantity of methanol. It 
was than heated for 5-10 minutes to get the clear solution. Few drops of con. HCl 
were added to the reaction mixture as a catalyst. The reaction mixture was then 
refluxed in water bath for 6-12 h. The progress of reaction was monitored by thin 
layer chromatography. The reaction mixture was allowed to cool at room 
temperature. The solid separated upon cooling was filtered, washed with hot 
methanol and dried. Compounds were directly   used for the next step. 
 
? General procedure for the synthesis of substituted Thiazolopyrimidines 
PVP-4a-t. 
         To a well stirred mixture of compound 3a-t (10 mmol) and chloro acetyl 
chloride (10 mmol) were dissolved in glacial acetic acid with sodium acetate and 
refluxed for 6 h. The reaction was monitored with thin layer chromatography and 
after completion of the reaction, the reaction mixture was poured on crushed ice and 
was extracted with chloroform. The chloroform was removed in vacuum. The residue 
was dried and recrystallized from ethanol to afford analytically pure products PVP-
4a-t. 
. 
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? Spectral data of the synthesized compounds 
 
1,2,3,4-tetrahydro-6-isopropyl-2-thioxo-N,4-dip-tolylpyrimidine-5-carboxamide 
3e: White solid; Rf 0.60 (6:4 hexane-EtOAc); IR (KBr): 3373, 3072, 2895, 2828, 
1694, 1635, 1482, 1343, 1298 cm1;  1H NMR: δ ppm 1.45-1.62 ( d, 6H, 2 x iprCH3), 
2.24 - 2.26 ( s, 6H, 2 x CH3),  3.85 (m, 1H, iprCH), 4.76 - 4.77 (s, 1H, -CH), 7.10 - 
7.48 (m, 8H, Ar-H), 8.86 - 8.87 ( s, 1H, -NH), 8.93 (s, 1H, -NH), 9.73 (br, s, 1H, -
CONH); 13C NMR : 15.08, 19.28, 30.56, 31.27, 43.26, 54.35, 64.96, 116.38, 116.59, 
119.13, 119.77, 121.15, 127.50, 128.48, 132.74, 135.67, 137.97, 148.89, 152.11, 
154.53, 168.04, 169.67; MS (m/z): 379 (M+);  Anal. Calcd for C22H25N3OS: C, 69.62; 
H, 6.64; N, 11.07; Found: C, 69.58; H, 6.55; N, 11.05. 
 
N-(3-chloro-4-fluorophenyl)-5-(4-chlorophenyl)-3,5-dihydro-7-isopropyl-3-oxo-
2H-thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4a): yellow solid; Rf 0.80 (6:4 
hexane-EtOAc); IR (KBr): 3443, 3371, 3230, 3058, 1703, 1648, 1586, 1244, 1016 
cm-1; 1H NMR: δ 1.43-1.82 (d, 6H, 2 x iprCH3), 3.94 (m, 1H, iprCH), 4.12 (s, 2H, 
CH2), 5.59 (s, 1H, -CH), 7.20 (d, 2H, Ar-H,  j=9Hz), 7.36-7.42 (d, 4H, Ar-H, ,j=9Hz), 
7.90 (s, 1H, Ar-H),  10.18 (s, 1H, CONH); 13C NMR : 18.07, 20.45, 20.65, 30.51, 
45.06, 55.59, 114.28, 119.80, 121.69, 125.47, 128.64, 128.76, 132.61, 135.89, 138.42, 
167.19, 173.19; MS (m/z): 478(M+); Anal. Calcd for C22H18Cl2FN3O2S : C, 55.24; H, 
3.79; N, 8.78; Found: C, 55.18; H, 3.75; N, 8.62. 
 
N,5-bis(4-chlorophenyl)-3,5-dihydro-7-isopropyl-3-oxo-2H-thiazolo[3,2-a]pyrimi- 
dine-6-carboxamide (PVP-4b):  yellow solid; Rf 0.81 (6:4 hexane-EtOAc); IR 
(KBr): 3452, 3307, 3223, 2980, 1653, 1509, 1461, 1051 cm-1; 1H NMR: δ 1.60-1.82 
(d, 6H, 2 x iprCH3), 3.95 (m, 1H, iprCH), 4.12 (s, 2H, CH2), 5.57 (s, 1H, -CH), 7.18-
7.21 (d, 2H, Ar-H,  j=9Hz), 7.33-7.44 (d, 4H, Ar-H, ,j=9Hz), 7.58-7.60 (d, 2H, Ar-H), 
10.15 (s, 1H, CONH) ; MS (m/z): 460 (M+); Anal. Calcd for C22H19Cl2N3O2S: C, 
57.40; H, 4.16; N, 9.13; Found: C, 57.38; H, 4.12; N, 9.08. 
 
 5-(4-chlorophenyl)-N-(4-fluorophenyl)-3,5-dihydro-7-isopropyl-3-oxo-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4c): yellow solid; Rf 0.82 (6:4 
hexane-EtOAc); IR (KBr): 3412, 3317, 3253, 2950, 1613, 15039, 1431, 1041 cm-1; 1H 
NMR: δ 1.60-1.82 (d, 6H, 2 x iprCH3), 3.94 (m, 1H, iprCH), 4.11 (s, 2H, CH2), 5.57 
(s, 1H, -CH), 7.10-7.13 (d, 2H,  Ar-H, ,j=9Hz), 7.16-7.21 (d, 2H Ar-H, ,j=9Hz), 7.42- 
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7.44 (d, 2H, Ar-H, ,j=9Hz), 7.53-7.59 (d, 2H, Ar-H, j=9Hz), 10.05 (s, 1H, CONH) ; 
MS (m/z): 443(M+); Anal. Calcd for C22H18ClFN3O2S; C, 59.52; H, 4.31; N, 9.47; 
Found: C, 59.48; H, 4.25; N, 9.32. 
 
3,5-dihydro-7-isopropyl-N,5-bis(4-methoxyphenyl)-3-oxo-2H-thiazolo[3,2-
a]pyrimidine-6-carboxamide (PVP-4d): yellow solid; Rf 0.80 (6:4 hexane-EtOAc);  
IR (KBr): 3429, 3307, 3123, 2959, 1658, 1546, 1265, 1041 cm-1; MS (m/z): 451 (M+); 
Anal. Calcd for C24H25N3O4S: C, 63.84; H, 5.58; N, 9.31; Found: C, 63.68; H, 5.60; 
N, 9.42. 
 
3,5-dihydro-7-isopropyl-3-oxo-N,5-dip-tolyl-2H-thiazolo[3,2-a]pyrimidine-6-
carboxamide (PVP-4e): yellow solid; Rf 0.84 (6:4 hexane-EtOAc);  IR (KBr): 3335, 
3026, 2972, 2814, 1712, 1680, 1553, 1462, 1174, 1060 cm-1; MS (m/z): 419 (M+); 
Anal. Calcd for C24H25N3O2S: C, 68.71; H, 6.01; N, 10.02; Found: C, 68.81; H, 6.15; 
N, 10.12. 
 
5-(4-fluorophenyl)-3,5-dihydro-7-isopropyl-N-(4-methoxyphenyl)-3-oxo-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4f): 
yellow solid; Rf 0.79 (6:4 hexane-EtOAc); IR (KBr): 3462, 3307, 3223, 2990, 1653, 
1509, 1461, 1061 cm-1;  MS (m/z): 439 (M+); Anal. Calcd for C23H22FN3O3S: C, 
62.85; H, 5.05; N, 9.56; Found: C, 62.78; H, 5.10; N, 9.45. 
 
N-(3-chloro-4-fluorophenyl)-3,5-dihydro-7-isopropyl-3-oxo-5-phenyl-2H-                    
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4g): yellow solid; Rf 0.79 (6:4 
hexane-EtOAc);  IR (KBr): 3459, 3327, 3173, 2989, 1648, 1586, 1261, 1061 cm-1;  
MS (m/z): 443 (M+); Anal. Calcd for C22H19ClFN3O2S: C, 59.52; H, 4.31; N, 9.47; 
Found: C, 59.46; H, 4.40; N, 9.52. 
 
3,5-dihydro-7-isopropyl-5-(3,4-dimethoxyphenyl)-3-oxo-N-phenyl-2H-thiazolo 
[3,2-a]pyrimidine-6-carboxamide (PVP-4h): yellow solid; Rf 0.81 (6:4 hexane-
EtOAc); IR (KBr): 3449, 3227, 3193, 2966, 1628, 1522, 1217, 1041 cm-1; MS (m/z): 
451 (M+); Anal. Calcd for C24H25N3O4S: C, 63.84; H, 5.58; N, 9.31; Found: C, 63.74; 
H, 5.55; N, 9.35. 
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N-(4-fluorophenyl)-3,5-dihydro-7-isopropyl-5-(3,4-methoxyphenyl)-3-oxo-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4i): yellow solid; Rf 0.80 (6:4 
hexane-EtOAc);  IR (KBr): 3449, 3227, 3173, 2989, 1648, 1586, 1251, 1061 cm-1;  
MS (m/z): 530 (M+); Anal. Calcd for C24H24BrN3O4S: C, 54.34; H, 4.56; N, 7.92; 
Found: C, 54.23; H, 4.65; N, 7.82. 
 
N-(4-chlorophenyl)-3,5-dihydro-7-isopropyl-5-(4-methoxyphenyl)-3-oxo-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4j):  yellow solid; Rf 0.80 (6:4 
hexane-EtOAc);  IR (KBr): 3442, 3226, 3143, 2986, 1642, 1566, 1241, 1061 cm-1;  
MS (m/z): 455 (M+); Anal. Calcd for C23H23ClN3O3S: C, 60.59; H, 4.86; N, 9.22; 
Found: C, 60.63; H, 4.94; N, 9.12. 
 
N,5-bis(4-fluorophenyl)-3,5-dihydro-7-isopropyl-3-oxo-thiazolo[3,2a]pyrimidine-
6-carboxamide (PVP-4k): yellow solid; Rf 0.82 (6:4 hexane-EtOAc); IR (KBr): 
3459, 3252, 3143, 2919, 1648, 1586, 1241, 1051 cm-1;  MS (m/z): 427 (M+); Anal. 
Calcd for C22H19F2N3O2S: C, 61.81; H, 4.48; N, 9.83; Found: C, 61.83; H, 4.45; N, 
9.72. 
 
3,5-dihydro-7-isopropyl-3-oxo-N,5-diphenyl-2H-thiazolo[3,2-a]pyrimidine-6-      
carboxamide (PVP-4l): yellow solid; Rf 0.79 (6:4 hexane-EtOAc); IR (KBr): 3420, 
3226, 3143, 2988, 1632, 1546, 1231, 1061 cm-1;  MS (m/z): 391 (M+); Anal. Calcd for 
C22H21N3O2S: C, 67.50; H, 5.41; N, 10.73; Found: C, 67.43; H, 5.34; N, 10.62. 
 
N-(4-chlorophenyl)-3,5-dihydro-7-isopropyl-3-oxo-5-p-tolyl-2H-thiazolo[3,2-a] 
pyrimidine-6-carboxamide (PVP-4m):   
yellow solid; Rf 0.81 (6:4 hexane-EtOAc);  IR (KBr): 3412, 3317, 3253, 2950, 1613, 
1539, 1431, 1061 cm-1;  MS (m/z): 435 (M+); Anal. Calcd for C23H22ClN3O3S: C, 
62.79; H, 5.04; N, 9.55; Found: C, 62.68; H, 5.15; N, 9.52. 
 
3,5-dihydro-5-(4-hydroxyphenyl)-7-isopropyl-N-(2,5-dimethylphenyl)-3-oxo-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4n): yellow solid; Rf 0.82 (6:4 
hexane-EtOAc); IR (KBr): 3442, 3327, 3253, 2980, 1623, 1569, 1431, 1051 cm-1;  
MS (m/z): 435 (M+); Anal. Calcd for C24H25N3O3S: C, 66.18; H, 5.79; N, 9.65; 
Found: C, 66.10; H, 5.70; N, 9.52. 
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N-(3-chlorophenyl)-3,5-dihydro-7-isopropyl-3-oxo-5-p-tolyl-2H-thiazolo[3,2-
a]pyrimidine-6-carboxamide (PVP-4o): yellow solid; Rf 0.83 (6:4 hexane-EtOAc); 
IR (KBr): 3462, 3327, 3220, 2980, 1623, 1509, 1461, 1051 cm-1; MS (m/z): 316 (M+); 
Anal. Calcd for C16H20N4O3: C, 60.75; H, 6.37; N, 17.71; Found: C, 60.68; H, 6.55; 
N, 17.62. 
 
N-(4-bromophenyl)-5-(4-fluorophenyl)-3,5-dihydro-7-isopropyl-3-oxo-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4p): yellow solid; Rf 0.80 (6:4 
hexane-EtOAc); IR (KBr): 3442, 3327, 3173, 2989, 1653, 1586, 1261, 1061 cm-1;  
MS (m/z): 488 (M+); Anal. Calcd for C22H19BrFN3O2S: C, 54.11; H, 3.92; N, 8.60; 
Found: C, 54.16; H, 3.85; N, 8.62. 
 
3,5-dihydro-7-isopropyl-N-(4-methoxyphenyl)-5-(4-nitrophenyl)-3-oxo-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4q):: yellow solid; Rf 0.81 (6:4 
hexane-EtOAc);  IR (KBr): 3459, 3327, 3173, 2989, 1648, 1586, 1261, 1061 cm-1;  
MS (m/z): 466 (M+); Anal. Calcd for C15H17BrN4O2: C, 49.33; H, 4.69; N, 15.34; 
Found: C, 49.13; H, 4.45; N, 15.22. 
 
N-(4-chlorophenyl)-3,5-dihydro-5-(4-hydroxyphenyl)-7-isopropyl-3-oxo-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4r):  yellow solid; Rf 0.81 (6:4 
hexane-EtOAc); IR (KBr): 3459, 3327, 3193, 2999, 1648, 1586, 1261, 1061 cm-1;  
MS (m/z): 441 (M+); Anal. Calcd for C22H20ClN4O3S: C, 60.59; H, 4.56; N, 9.51; 
Found: C, 60.52; H, 4.65; N, 9.56. 
 
N-(4-fluorophenyl)-3,5-dihydro-5-(2-hydroxyphenyl)-7-isopropyl-3-oxo-2H-
thiazolo[3,2-a]pyrimidine-6-carboxamide (PVP-4s): yellow solid; Rf 0.83 (6:4 
hexane-EtOAc); IR (KBr): 3459, 3252, 3143, 2919, 1648, 1586, 1241, 1051 cm-1; MS 
(m/z): 425 (M+); Anal. Calcd for C22H20FN3O3S: C, 62.10; H, 4.74; N, 9.88; Found: 
C, 62.15; H, 4.65; N, 9.82. 
 
N,5-bis(3-chlorophenyl)-3,5-dihydro-7-isopropyl-3-oxo-2H-thiazolo[3,2-a]pyrim- 
idine-6-carboxamide (PVP-4t):  yellow solid; Rf 0.81 (6:4 hexane-EtOAc); IR 
(KBr): 3449, 3227, 3193, 2966, 1628, 1522, 1217, 1041 cm-1; MS (m/z): 460 (M+); 
Anal. Calcd for C16H19ClN4O2: C, 57.40; H, 4.16; N, 9.13; Found: C, 57.44; H, 4.10; 
N, 9.1 
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? Spectral representation of synthesized compounds 
 1H NMR spectrum of compound 3e 
 
 
Expanded 1H NMR spectrum of compound 3e 
 
NH ONHH3C
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1H NMR spectrum of compound PVP-4a 
 
 
Expanded 1H NMR spectrum of compound PVP-4a 
 
 
NH ONN
F Cl
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1H NMR spectrum of compound PVP-4b 
 
 
Expanded 1H NMR spectrum of compound PVP-4b 
 
 
 
NH ONNCl
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1H NMR spectrum of compound PVP-4c 
 
 
Expanded 1H NMR spectrum of compound PVP-4c 
 
 
NHO NNF
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13C NMR spectrum of compound PVP-4a 
 
 
Expanded 13C NMR spectrum of compound PVP-4a 
 
 
NH ONN
F Cl
 
Chapter 4                                              Synthesis of functionalized thiazolopyrimidines 
171 
 
 
 
13C NMR spectrum of compound PVP-3e 
 
 
Expanded 13C NMR spectrum of compound PVP-3e 
 
 
NH ONHH3C
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Mass spectrum of compound PVP-4c 
 
 
 
Mass Spectrum of compound PVP-4e 
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F
NH ONNH3C
 
Chapter 4                                              Synthesis of functionalized thiazolopyrimidines 
173 
 
 
 
Mass spectrum of compound PVP-4f 
 
 
Mass Spectrum of compound PVP-4g 
 
NH ONNH3CO
NHONF
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Mass Spectrum of compound PVP-4h 
 
 
IR Spectrum of compound PVP-4a 
 
 
NHON
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IR Spectrum of compound PVP-4e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NH ONNH3C
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5.1 INTRODUCTION  
        The condensation of a ring of 1,2,4-triazole and another one of pyrimidine gives 
rise to the formation of bicyclic heterocycles known as 1,2,4-triazolopyrimidines. Four 
different possibilities exist for the relative orientation of both rings, so four different 
isomeric families of compounds are defined: 1,2,4-triazolo[1,5-a]pyrimidine (Figure 
1) (1), 1,2,4-triazolo[1,5-c]pyrimidine (2), 1,2,4-triazolo[4,3-a]pyrimidine (3) and 
1,2,4-triazolo[4,3-c]pyrimidine (4). 
N
N N
N
NN N
N
N
N
N
N
NN
N
N
1
2
34
5
6
7 8
1
2
3
3 3
4
4 4
5
5 5
6
6 6
7
7 7
8
8 81 1
2 2
(1) 1,2,4-triazolo[1,5-a]pyrimidine (2) 1,2,4-triazolo[1,5-c]pyrimidine
(3) 1,2,4-triazolo[4,3-a]pyrimidine (4) 1,2,4-triazolo[4,3-c]pyrimidine  
Figure 1 
 
5.2    Pharmacological Profile 
         Among these isomeric families of compounds, 1,2,4-triazolo[1,5-a]pyrimidine 
derivatives are  thermodynamically more stable and, thus, the most studied ones,1 a 
few of them being commercially available. Revisions surveying the synthesis, 
reactivity, spectroscopic characterization and crystallographic studies of 1,2,4-
triazolo[1,5-c]pyrimidines,21,2,4-triazolo[4,3-a]pyrimidines 3 and 1,2,4-triazolo[4,3-
c]pyrimidines 4 have also been published. 
 
From the standpoint of biological activity, fused heteroaromatic systems are often of 
much greater interest than the constituent monocyclic compounds. Recently, 1,2,4-
triazolo[1,5-a]pyrimidines have aroused increasing attention from the chemical and 
biological view points, due to their diverse pharmacological activities, such as 
antitumor potency 5, 6 inhibition of KDR kinase,7 antifungal effect 8 and macrophage 
activation. 9 They have proved to be promising anticancer agents with dual 
mechanisms of tubulin polymerization promotion5,6 as well as cyclin dependent  
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kinases 2 inhibition. 10 Some examples of published derivatives of 1,2,4-triazolo[1,5-
a]pyrimidine with their biological activities are (Figure 2)  as following. 
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Figure 2 
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5.3     Reported synthetic strategies 
 
? Amino-1,2,4-triazole and 1,3-bifunctional synthons 
? Principle and Conditions 
 
            By far the most triazolo[1,5-a]pyrimidine synthesis are condensations of 
dinucleophilic 5-amino-1,2,4-triazoles with 1,3-bifunctional synthons as shown in the 
formation of triazolo[1,5-a]pyrimidine (15).21-24 New synthetic conditions recently 
described involve melting under microwave irradiation, a reaction that is 
environmental friendly and gives higher yields (Figure 3) than conventional heating in 
solvent.25 Furthermore, certain lithium 1,3-diketonates have proven to be better 
synthons than the corresponding diketones.26  
 
COOEt
OH3C
+
NHN
NH2N NH
N
N
N
O
H3C
(15)  
Figure 3 
Previous mechanistic conclusions have been confirmed by isolating stable 
intermediate 5-amino-1,2,4-triazole derivatives such as enamine (16) (Figure 4) on 
reacting 5-amino-1,2,4-triazoles with 3-ketovinyl ethers,27 3-ketoenamines,28 3-
ketoaldehydes,29 enamine-2-carboxylic esters 30 or ethoxymethylene malonates.31  
 
OEt
+
NHN
NH2N NH
HN
CO
N
N
Ar
(16)
Ar
O
EtOOC
EtOH
EtOOC
CH3CN /KF
N
N
N
N
Ar
EtOOC
 
Figure 4 
That means, the overall reaction starts with the interaction of the amino-1,2,4-
triazoleamino group and the enolic (or analogous) functionality of the three-carbon 
synthon. In the two-step examples, just mentioned, the first step proceeds under milder 
conditions (sometimes just in ethanol at room temperature), but the final Cyclization  
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(or the one-step reaction, if the intermediate is not trapped) requires stronger means 
(e.g., PPA or boiling acetic acid). Under extreme conditions, triazolylamide (17) was 
subject to flash vacuum pyrolysis between 300 and 450 ºC to give about 50% 
triazolo[1,5-a]pyrimidine (18) (Figure 5).32 Libraries of fused 3-aminopyrimidin-4-
ones (19) and other compounds were just recently prepared by the solid-phase and by 
the solution-phase parallel synthesis. 33 The latter method turned out to be 
advantageous with respect to yield and purity. 
 
COOEt
COOEt
+
NHN
NH2N N
H
HN
COOEt
N
N
O N
H
N
N
N
O
O
(17) (18)
COOEt
NMe2
AcHN NHN
NH2N
+ 1. AcOH
2. HCl
N
N
N
H
N
O
H2N
HCl
(19)  
Figure 5 
? Use of Modified 5-Amino-1,2,4-triazoles 
            Shows two parallel paths of pyrimidine ring annulations (Figure 6)  the 
conventional method, route A and a route B using a reactive amino-1,2,4-triazole 
derivative.34 Amidine (22), formed from 5-amino-1,2,4-triazole and DMF 
dimethylacetal, can be regarded as the result of incorporating one carbon of the three-
carbon synthon (20) into the 5-amino-1,2,4-triazole molecule; condensation with a 
reactive two-carbon component leads to target triazolo[1,5-a]pyrimidine (21).  
 
NC
NMe2
O
Ph
+
NHN
NH2N
A
BNC
O
Ph
+ NHN
NN
NMe2 N
N
N
NNC
Ph
(20)
(21)
(22)  
Figure 6 
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Path B also serves in confirming the structure of product (21). Similar syntheses of 7-
aryl and 7-heterocyclyl triazolo[1,5-a]pyrimidines have been described, 35-37 for 
example, that of an antipyrine derivative .38 
 
? The diversity of 1,3-bifunctional synthons  
            Examples of triazolo[1,5-a]pyrimidine (Figure 7)  synthesis published in the 
relevant period are listed in Table 1, arranged according to the bifunctional synthons 
used and to the substituents entering the positions 5 and 7. Triazolo[1,5-a]pyrimidines 
are included in reviews dealing with heterocyclic synthesis by the use of enamines,39 
enamine-2-carboxylic esters 40 and ketene mercaptals.41 
 
N
N N
N
1
2
34
5
6
7 8
 
Figure 7 
Table 1. Syntheses of triazolo [1, 5-a] pyrimidines from 1, 3-bifunctional synthons      
and  5-amino-1,2,4-triazoles. 
Bifunctional Synthons R-5b R-7b Bifunctional Synthons R-5b R-7b 
1,3-Dialdehyde 42 H H Enamine-2-carboxylate 59 H OH 
2-Formylacetal 43 H H Acetylenedicarboxylate 60 CO2Me OH 
1,3-Diacetal 44 H H 3-Ketocarboxylate 61 R OH
2-Formylvinyl ether 45 H H 3-Alkoxyacrylate 62 OH R 
2-Formylvinylchloride 46 H R Alkoxyalkylene malonate 63 R OH 
3-Iminiovinylchloride 47 H R 2-Chloroacrylate 64 OH R 
2-Formylenamine 48 H R Malonic ester 65 OH OH 
3-Iminioenamine 49 H R Malonyl chloride 66 OH OH 
3-Ketoaldehyde 50 R H 2-Acylketene mercaptal 67 SR R’ 
3-Ketoacetal 51 R H 2-Cyanoketene mercaptal 68 SR NH2 
3-Ketovinyl ether 52 H R Alkoxyalkylene cyanoacetate 69 R NH2 
3-Ketovinyl sulfone 53c R H Alkoxyalkylene malonitrile70 R NH2 
3-Ketoenamine 54 H R 2-Formylnitrile 71 H NH2 
1,3-Diketone 55 R R’ 2-Cyanoenamine 72 H NH2 
3-Ketoalkyne 56 Rd H Malonitrile 73 NH2 NH2 
2-Formylcarboxylate 57 R OH 2-Thiocarbamylcarboxylate 74 NHR OH 
2-Alkoxycarbonylacetal  58 OH H    
 
 
aor tautomeric form. bSubstituents on C-5 and C-7, respectively; R and R’ mean 
(possibly substituted) alkyl, aryl, heterocyclyl and H; OH means hydroxy or 
tautomeric oxo form. cAnd regioisomeric 7-R compound. dDeoxyaltrose derivative 
relating C-glycosides.75 
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In recent years, 3-ketoenamines have growing interest as building blocks for 7-aryl 
triazolo[1,5-a]pyrimidines (Figure 6 , Path A).76,77 They also serve to synthesize 7-
heterocyclyl triazolo [1,5-a]pyrimidines.78,79 In addition to usual N, N-dimethyl 
compounds also analogues having a free amino group can be used as in the synthesis 
of 7-trifluoromethyl derivatives.80 Enaminones can be formed in situ, for instance, 
from dimedone and DMF dimethylacetal. 81 
 
In the course of the cyclization of the stable tetrafluorobenzoyl derivative (23) (Figure 
8) fluorine at the o-position is involved in the reaction and is replaced to give 
trifluorobenzo triazolo[1,5-a]pyrimidine (24).82 Acetonyl is introduced as substituent 
into the 7-position by the use of triketone heptan-2,4,6-trione.83 
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Figure 8 
The electron acceptor tetracyanoethylene on interaction with amino-1,2,4-triazole first 
forms a charge transfer complex that after loss of hydrocyanic acid is transformed into 
dicyano triazolo[1,5-a]pyrimidine (25).84 Fusion of 1,4-naphthoquinone or indenone 
onto triazolo[1,5-a]pyrimidine can in a similar way be performed by the use of 2,3-
dicyano-1,4-naphthoquinone or dicyanomethylene indane-1,3-dione, respectively. 
Another indeno triazolo[1,5-a]pyrimidine is accessible from triketone 2- 
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acetylindane1,3-dione. 85 On the other hand, acetoacetic ester (26) with 5-amino-1,2,4-
triazole suffers ester group cleavage to form anilino triazolo[1,5-a]pyrimidine (27).86 
 
 
? Other pyrimidine ring synthesis 
             The annulation of pyrimidine onto the triazole ring can be accomplished by 
the use of heterocyclic precursors that can be regarded as masked 1,3-bifunctional 
reagents. This way, triacetic acid lactone (27) (Figure 9) reacts as a masked 1,3-
diketone and transforms 5-amino-1,2,4-triazole to triazolo[1,5-a]pyrimidine (28) 
together with ring isomer (29) and decarboxylation product (30). 87 Oxazolones play a 
similar part.88-90 Thus, enol ether (31) behaves as a masked 3-ethoxyacrylate and 
yields, through intermediate (32), benzamido TP (33) that, under harsher conditions, 
directly forms from compound. 30 
 
O
OH
O
+
N
N
N
N
CH3
H3C
NHN
NN
O
HOOC
NHN
NH2N
N
N
N
N
H3C
COOEt
N
N
N
N
H3C
COOEt
+
(27)
(28) (29)
(30)
O
N O
Ph
+
NHN
NH2N SCH3
EtOH
N
N
H
N
N
H
SCH3
O
N O
Ph
(31) (32)
AcOH AcOH
N
H
N
N
N
O
PhHNOC
SCH3
(33)
 
Figure 9 
 
 
 
 
 
 
Chapter 5                                             Synthesis of functionalized Triazolo pyrimidines 
186 
 
 
? 2-Hydrazinopyrimidines and one-carbon synthons 
            A second common triazolo[1,5-a]pyrimidine synthesis consists in the 
condensation of a C1-synthon with a 2-hydrazinopyrimidine derivative (e.g., 34, 
Figure 10) . A triazolo[4,3-a]-pyrimidine (35) initially forms that often can be 
isolated.91 Harsher conditions allow it to isomerize to the target triazolo[1,5-
a]pyrimidine (36) by Dimroth rearrangement.  
 
N
NH
NC
Ph
O
NH
NH2
HCOOH
N
H
N
NC
Ph
O
N
N
KOH (2%)
N
H
N
NC
Ph
O
N
N
(34) (35) (36)  
Figure 10 
? Other triazole ring synthesis 
            Most cyclization of 2,3-diaminopyrimidones (37)92 or corresponding 
quinazolones proceed with the participation of carboxylic acids or their derivatives 
(esters, anhydrides, chlorides, or orthoesters) as shown in (Figure 11). Noncyclized or 
saturated intermediates (38, 39) can frequently be found during synthesis of 
triazolo[1,5-a]pyrimidines .  
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5.4      CURRENT RESEARCH WORK 
 
           The biological importance of 1,2,4-triazolo[1,5-a]pyrimidines is well 
documented. Over the years, various substituted derivatives of these heterocycles have 
shown utility against a range of biological targets. For example, they have 
demonstrated activity against malaria and bronchospasm and shown activity as 
coronary vasodilators, antihypertensive agents, leishmanicides, antibiotics, adenosine 
A2a antagonists, immunosuppressants, antitumor agents, fungicides, xanthine oxidase 
inhibitors, and phosphodiesterase inhibitors.  
 
One of the synthetic pathways to 1,2,4-triazolo[1,5-a]pyrimidines is based on the 
Biginelli like cyclocondensation of aromatic aldehydes and acetoacetic acid 
derivatives with aminoazoles containing a guanidine fragment. There are literary data 
about the synthesis of triazolopyrimidines by treatment of 5-amino-1,2,4-triazole or 5-
aminotetrazole with aldehydes and ethyl acetoacetate or cyclic β-diketones 93. The 
cyclocondensations were realized by heating of the starting materials in ethanol with 
catalytic amounts of hydrochloric acid under reflux conditions 93a-c or using DMF as 
solvent. 93d-e The use of acetoacetamides in these or similar reactions has not been 
described. 
 
However, the existing methods are suffered with some drawbacks, such as yield, time, 
product isolation.Recognizing these facts, we have synthesised a new series of N-                        
cyclohexyl-4,7-dihydro-5-isopropyl-7-aryl-[1,2,4]triazolo[1,5-a]pyrimidine-6- 
carboxamide starting from, N-cyclohexyl-4-methyl-3-oxo-pentanamide.The newly 
synthesized compounds were characterized by IR, Mass, 1H NMR, 13C NMR 
spectroscopy and elemental analysis. All the synthesized compounds were evaluated 
for their antimicrobial activity. 
 
 
 
 
 
 
 
 
Chapter 5                                             Synthesis of functionalized Triazolo pyrimidines 
188 
 
 
 
5.5    RESULTS AND DISCUSSION      
                    
Scheme:-1 Synthesis of substituted triazolopyrimidines. 
NH
O
O
+
HO
R
HN N
NH2N
NH
O
N
H
N
N
N
R
DMF, Reflux
12-15 Min.
(1)
(2)
(3) (PVP-5a-o)
R= CH3, OCH3, Cl, F  
   
Initially, the reaction of N-cyclohexyl-4-methyl-3-oxo-pentanamide (1) with 
appropriate aldehyde (2) and aminoazole (3) was refluxed in 0.4 mL of DMF for 12-15 
min. After cooling, methanol (~10 mL) was added. The reaction mixture was allowed 
to stand overnight and then filtered to give the solid (scheme 1) affords the N-
cyclohexyl-4,7-dihydro-5-isopropyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-
carboxamide derivatives (PVP-5a-o) was obtained in excellent yield.       
 
The structures of (PVP-5a-o) were established on the basis of their elemental analysis 
and spectral data (MS, IR, and 1H NMR). The analytical data for 5a revealed a 
molecular formula C22H29N5O (m/z 379). The 1H NMR spectrum revealed a doublet at 
δ = 0.95-1.10 ppm assigned to isopropyl-CH3, a multiplet at δ = 1.17 - 1.58 ppm 
assigned to the – ( 5xCH2 ) protons, a singlet at δ = 2.23 ppm assigned to  the –CH3 a 
multiplet at δ = 3.18 - 3.28 ppm assigned to  the isopropyl-CH protons , a doublet at δ 
= 3.34 - 3.40 ppm assigned to the -CH protons, a singlet at δ = 6.25 ppm assigned to 
the -CH protons, a multiplet at δ = 6.98 - 7.10 ppm assigned to the aromatic protons, a 
singlet at δ = 7.57 ppm assigned to the -CH protons of triazoloring,  a singlet at δ = 
7.72 – 7.75 ppm assigned to -NH protons, a singlet at δ = 9.66 ppm assigned to –
CONH protons,  
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Table 1: Synthesis of substituted triazolopyrimidines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Entry R Yield % M.P. 
PVP-5a 4-CH3C6H4 92 252-254 
PVP-5b 4-ClC6H5 91 260-263 
PVP-5c 4-FC6H5 84 248-250 
PVP-5d 4-OCH3C6H5 90 245-247 
PVP-5e 3-BrC6H5 86 255-257 
PVP-5f 3,4-di-OCH3C6H3 92 259-261 
PVP-5g 3-ClC6H4 90 265-267 
PVP-5h C6H5 86 245-247 
PVP-5i 4-OHC6H5 93 242-244 
PVP-5j 2-ClC6H5 91 235-237 
PVP-5k 2- CH3C6H5 88 255-257 
PVP-5l 2-OHC6H5 92 257-259 
PVP-5m 3-NO2C6H5 90 260-262 
PVP-5n 4-NO2C6H5 87 262-264 
PVP-5o 3,5-di-OCH3C6H3 85 256-258 
 
Chapter 5                                             Synthesis of functionalized Triazolo pyrimidines 
190 
 
 
 
HN N
NH2N
HO
NHO
N
N
H2N
Pathway 1Pathway 2
HO
-2 H2O-H2O N
H
N
N
N
O
N
H
R
N
H
HN
N
N
O
N
H
O
O
N
H
R R
O
O
N
HR
 
Figure 11: Proposed mechanism for the formation of Triazolopyrimidine.  
          
                  The reaction mechanism of this three-component condensation is probably 
similar to the described 94 mechanism for the “classical” Biginelli reaction (Pathway 
1). The first step is a nucleophilic addition of N2 of the aminoazole to a carbonyl 
carbon of aldehyde, followed by subsequent cyclization with acetoacetamide to form 
the dihydropyrimidine ring. An alternate sequence is also possible and cannot be 
excluded 95 (Pathway 2), which is the initial formation of an enamine by reaction of 
aminoazole with the acetoacetamide followed by cyclocondensation. (Figure 11) The 
third alternative involving the formation of 2-benzylidene-N-cyclohexyl-4-methyl-3-
oxo-pentanamide derivatives as intermediates requires the presence of a strong base 96 
and is most likely not possible for the case described herein. 
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5.6     ANTIMICROBIAL SENSITIVITY TESTING 
 
WELL DIFFUSION / AGAR CUP METHOD (Lt. General Raghunath D. 1998, 
Ashok Rattan, 1998; Patel R., Patel K. 2004,) 
In vitro effectivity of antimicrobial agents can be demonstrated by observing their 
capacity to inhibit bacterial growth on suitable media. The production of a zone 
depends on two factors namely bacterial growth and concentration of antimicrobial 
agent. The hole/well punch method was first used by Bennett. This diffusion method 
has proved more effective then many other methods. According to Lt. General 
Raghunath the well technique is 5-6 times more sensitive then using disk method. 
 
Principle  
 
When antimicrobial substance is added in agar cup (made in a medium previously 
inoculated with test organism) the redial diffusion of an antimicrobial agent through 
the agar, produces a concentration gradient. The test organism is inhibited at the 
minimum inhibitory concentration (MIC), giving rise to a clear zone of inhibition.  
 
Requirements 
 
1. Young broth culture of a standard test organism  
2. Sterile Mueller Hinton Agar plate 
3. Solution of antimicrobial substance 
4. Cup borer  
5. Alcohol etc. 
 
Inoculum preparation 
 
Inoculum was prepared by selecting 4-5 colonies from slope of stock culture of the 
indicator organism and emulsifying them in a suitable broth. The inoculated broth was 
incubated at 37ºC till it equals turbidity of a 0.5 McFarland standard. This happens in 
2-8 h. 
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Procedure 
 
1. Inoculate test organism on the top of Mueller Hinton Agar plate with help of 
sterile swab. (it can be inoculated in melted agar also ) 
2. The swab was dipped in the inoculum and surface of plate was streaked with 
swab. 
3. Streaking was repeated for 3 times and each time the plate was rotated at angle 
of 60º.  
4. Sterilize the cup-borer make four cups of the diameter of 8-10 mm. at equal 
distance in the plate previously inoculated with seed culture. 
5. The depth of well was 2.5-5.0 mm.  
6. The wells have been clearly punched so the surrounding medium is not lifted 
when the plug was removed out. 
7. The plates were incubated at 37ºC for 24 h. Then the zone of inhibition 
measured and the size of zone cited in table.  
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? Antibiotic Sensitivity Assay 
   
(Concentration250/500/ 1000 µG/ml) 
Sr. 
No. 
COD
E No. 
Pseudomonas 
aeruginosa 
Proteus 
vulgaris 
Escherichia  
coli 
Staphylococcu
saureus 
Candida 
albicans 
  250 500 1000 250 500 1000 250 500 1000 250 500 1000 250 500 1000 
1.  5a 1.2 1.4 2 1.1 1.3 1.6 R R R R 1 1.2 R 1.2 1.5
2.  5b 1.2 1.3 1.7 1.1 1.4 1.6 R R R 1.2 1.3 1.6 1 1.3 1.8
3.  5c 1.5 1.3 1.5 R 1.1 1.4 1.1 1.2 1.3 R 1 1.2 1.1 1.5 2 
4.  5d 1.6 1.2 1.4 1 1.3 1.6 R R R 1.3 1.4 1.6 1.1 1.4 1.8
5.  5e 1.4 1.3 1.6 R 1.2 1.4 R R R 1.2 1.4 1.6 1 1.3 1.7
6.  5f 1.3 1.5 1.9 1 1.2 1.3 1.3 1.4 1.7 1.1 1.4 1.5 1.1 1.4 1.8
7.  5g 1.9 1.5 1.8 1.1 1.4 1.7 1.2 1.4 1.8 1.4 1.5 2 1.2 1.4 1.7
8.  5h 1.4 1.7 2 1.1 1.3 1.5 1.1 1.1 1.3 1.4 1.6 2 1.1 1.3 1.5
9.  5i 1.2 1.3 1.5 R R R R R R 1.3 1.4 1.7 R 1.3 1.7
10.  5j 1.7 1.9 2 1.8 1.8 2 1.1 1.8 1.8 1.5 1.7 1.9 1.8 1.8 2 
11.  5k 1.1 1.2 1.3 R 1 1.2 1.1 1.2 1.4 1.1 1.2 1.5 1.1 1.5 1.9
12.  5l 1.3 1.4 1.9 1.3 1.7 2.1 1.2 1.5 2 1.1 1.5 1.9 1.1 1.4 1.6
13.  5m 1.2 2 1.5 1.1 1.4 1.9 1.3 1.4 1.9 1.2 1.6 2 1.2 1.5 2 
14.  5n R R R 1.1 1.3 1.7 1.1 1.3 1.6 R R R 1.1 1.4 1.8
15.  5o 1.4 1.6 2 1 1.2 1.4 R R R 1.1 1.2 1.5 1.2 1.5 2 
16.  A 1.8 1.8 1.9 1.9 - 
17.  CPD 2.2 2.1 2.1 2.2 - 
18.  GF 1.8 1.9 2.0 2.0 - 
19.  GRF - - - - 2.6 
20.  FLC - - - - 2.8 
 
 
 
Note: Zone of inhibition interpretation is as follows. 
 
1. ZONE SIZE <1.0 C.M.- RESISTENT(R)  
2. ZONE SIZE  1.0 To 1.5 – INTERMEDIATE 
3. ZONE SIZE >1.5 - SENSITIVE 
 
STD Antibiotic Sensitivity Assay Concentration 40 µG/ml 
 
     A: AMPICILLIN     
 CPD: CEFPODOXIME 
   GF: GATIFLOXACIN 
 GRF: GRESIOFULVIN 
  FLC: FLUCONAZOLE 
 
 
Chapter 5                                             Synthesis of functionalized Triazolo pyrimidines 
194 
 
 
5.7 CONCLUSION 
 
       In summary, we have described the synthesis of 1,2,4-triazolo[1,5-a]pyrimidines 
derivatives in excellent yields. The reaction of N-cyclohexyl-4-methyl-3-oxo-
pentanamide (1) with appropriate aldehyde (2) and aminoazole (3) was refluxed in 
DMF affords the N-cyclohexyl-4,7-dihydro-5-isopropyl-7-phenyl-[1,2,4]triazolo[1,5-
a]pyrimidine-6-carboxamide derivatives was obtained in excellent yield. All the 
synthesized compounds are evaluated for their antimicrobial activity. The 
investigation of antibacterial and antifungal screening data revealed that all the tested 
compounds PVP-5a-o showed moderate to potent activity. The compounds PVP- 5j 
and 5l showed comparatively good activity against all the bacterial strains. 
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5.8   EXPERIMENTAL SECTION 
 
 Thin-layer chromatography was accomplished on 0.2-mm precoated plates of 
silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) 
or with an iodine vapor. IR spectra were recorded on a FTIR-8400 spectrophotometer 
using DRS prob. 1H (400 MHz) and 13C (100 MHz) NMR spectra were recorded on a 
Bruker AVANCE II spectrometer in CDCl3. Chemical shifts are expressed in δ ppm 
downfield from TMS as an internal standard. Mass spectra were determined using 
direct inlet probe on a GCMS-QP 2010 mass spectrometer (Shimadzu). Solvents were 
evaporated with a BUCHI rotary evaporator. Melting points were measured in open 
capillaries and are uncorrected. 
 
? General procedure for the synthesis of substituted Triazolopyrimidines 
5a-o.  
           A mixture of the aminoazole (0.01 mol), N-cyclohexyl-4-methyl-3-oxo-
pentanamide (0.01 mol) and an appropriate aromatic aldehyde (0.01 mol) was refluxed 
in 0.4 mL of DMF for 12-15 min. After cooling, methanol (~10 mL) was added. The 
reaction mixture was allowed to stand overnight and then filtered to give the solid 
triazolopyrimidine products PVP- 5a-o, which were crystallized from ethanol and 
subsequently dried in air. 
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? Spectral data of the synthesized compounds 
 
N-cyclohexyl-4,7-dihydro-5-isopropyl-7-p-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-
carboxamide(PVP-5a): White solid; Rf 0.64 (9:1Chloroform: Methanol); IR (KBr): 
3327, 3093, 2939, 1648, 1586, 1492, 1261, 1069 cm-1; 1H NMR: δ 0.95-1.10 (d, 6H, 2 
x iprCH3), 1.17-1.58 (m, 10H, 5 x CH2), 2.23 (s, 1H, CH3) 3.18-3.28 (m, 1H, iprCH), 
3.34-3.40 (s, 1H, CH),  6.25 (s, 1H, CH), 6.98-7.01 (d, 2H, Ar-H) 7.07-7.10 (d, 2H, 
Ar-H), 7.57 (s, 1H, CH) 7.72-7.75 (s, 1H, NH) 9.66 (s, 1H, CONH); 13C NMR: δ 
19.49, 19.74, 20.69, 24.60, 28.44, 30.52, 32.19, 47.51, 60.49, 102.81, 126.92, 128.64, 
137.01, 137.63, 141.85, 148.42, 149.30, 165.30 ; MS (m/z): 379 (M+); Anal. Calcd for 
C22H29N5O: C, 69.63; H, 7.70; N, 18.45; Found: C, 69.58; H, 7.65; N, 18.52. 
 
7-(4-chlorophenyl)-N-cyclohexyl-4,7-dihdro-5-isopropyl-[1,2,4]triazolo[1,5-
a]pyrimidine-6-carboxamide (PVP-5b): White solid; Rf 0.62 (9:1Chloroform: 
Methanol); IR (KBr): 3271, 3215, 3093, 3051, 2933, 2654, 1662, 1593, 1437, 1247, 
1076 cm-1; 13C NMR: δ 19.43, 19.74, 24.60, 28.54, 30.59, 32.15, 47.59, 60.09, 99.49, 
102.25, 128.09, 128.83, 132.75, 139.17, 142.17, 148.43, 149.68, 165.11, 177.08 ;  MS 
(m/z): 399 (M+); Anal. Calcd for C21H26ClN5O: C, 63.07; H, 6.55; N, 17.51; Found: C, 
63.10; H, 6.45; N, 17.42. 
 
N-cyclohexyl-7-(4-fluorophenyl)-4,7-dihydro-5-isopropyl-[1,2,4]triazolo[1,5-
a]pyrimidine-6-carboxamide (PVP-5c): White solid; Rf 0.60 (9:1Chloroform: 
Methanol); IR (KBr): 3300, 3215, 3093, 3051, 2933, 2674, 1662, 1593, 1437, 1297, 
1076 cm-1; 1H NMR: δ 1.009-1.114 (d, 6H, 2 x iprCH3), 1.19-1.56 (m, 10H, 5 x CH2), 
3.17-3.26 (m, 1H, iprCH), 3.31-3.42 (m, 1H, CH),  6.31 (s, 1H, CH), 7.09-721 (m, 4H, 
Ar-H), 7.59 (s, 1H, CH), 7.70-7.73 (s, 1H, NH), 9.73 (s, 1H, CONH);  MS (m/z): 383 
(M+); Anal. Calcd for C21H26FN5O: C, 65.78; H, 6.83; N, 18.26; Found: C, 65.68; H, 
6.75; N, 18.32. 
 
N-cyclohexyl-4,7-dihydro-5-isopropyl-7-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-
a]pyrimidine-6-carboxamide (PVP-5d): White solid; Rf 0.65 (9:1Chloroform:  
Methanol);IR (KBr): 3281, 3115, 3093, 3051, 2923, 2654, 1662, 1593, 1437, 1257, 
1061 cm-1;  MS (m/z): 396 (M+); Anal. Calcd for C22H29N5O2: C, 66.81; H, 7.39; N, 
17.71; Found: C, 66.78; H, 7.30; N, 17.62. 
 
 
Chapter 5                                             Synthesis of functionalized Triazolo pyrimidines 
197 
 
 
7-(3-bromophenyl)-N-cyclohexyl-4,7-dihdro-5-isopropyl-[1,2,4]triazolo[1,5-
a]pyrimidine-6-carboxamide (PVP-5e): White solid; Rf 0.61 (9:1Chloroform: 
Methanol); IR (KBr): 3291, 3215, 3093, 3021, 2933, 2654, 1662, 1593, 1437, 1247, 
1048  cm-1; MS (m/z): 444 (M+); Anal. Calcd for C21H26BrN5O: C, 56.76; H, 5.90; N, 
17.98; Found: C, 56.68; H, 5.85; N, 17.82. 
 
N-cyclohexyl-4,7-dihydro-5-isopropyl-7-(3,4-di-methoxyphenyl)-1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (PVP-5f):White solid; Rf 0.64 (9:1Chloroform: 
Methanol); IR (KBr): 3276, 3265, 3083, 3059, 2933, 2654, 1662, 1593, 1247, 1076  
cm-1;  MS (m/z): 425 (M+); Anal. Calcd for C23H31N5O3: C, 64.92; H, 7.34; N, 16.46; 
Found: C, 64.88; H, 7.25; N, 16.32. 
 
7-(3-chlorophenyl)-N-cyclohexyl-4,7-dihdro-5-isopropyl-[1,2,4]triazolo[1,5-a] 
pyrimidine-6-carboxamide (PVP-5g): yellow solid; Rf 0.64 (9:1Chloroform: 
Methanol); IR (KBr): 3271, 3215, 3093, 3045, 2933, 2854, 1662, 1518, 1492, 1244, 
1089 cm-1;  MS (m/z): 399 (M+); Anal. Calcd for C21H26ClN5O: C, 63.07; H, 6.55; N, 
17.51; Found: C, 63.13; H, 6.45; N, 17.52. 
 
N-cyclohexyl-4,7-dihydro-5-isopropyl-7-phenyl-[1,2,4]triazolo[1,5-a]pyrimidine-
6-carboxamide (PVP-5h): White solid; Rf 0.62 (9:1Chloroform: Methanol);IR (KBr): 
3300, 3215, 3093, 3051, 2933, 2654, 1662, 1593, 1437, 1247, 1056  cm-1; MS (m/z): 
365 (M+); Anal. Calcd for C21H27N5O: C, 69.01; H, 7.45; N, 19.16; Found: C, 69.10; 
H, 7.55; N, 19.03. 
 
N-cyclohexyl-4,7-dihdro-7-(4-hydroxyphenyl)-5-isopropyl-[1,2,4]triazolo[1,5-
a]pyrimidine-6-carboxamide (PVP-5i): White solid; Rf 0.62 (9:1Chloroform: 
Methanol); IR (KBr): 3261, 3215, 3073, 3051, 2933, 2634, 1672, 1593, 1437, 1247, 
1086  cm-1;  MS (m/z): 381 (M+); Anal. Calcd for C21H27N5O2: C, 66.12; H, 7.13; N, 
18.36; Found: C, 66.13; H, 7.15; N, 18.42. 
 
7-(2-chlorophenyl)-N-cyclohexyl-4,7-dihdro-5-isopropyl-[1,2,4]triazolo[1,5-
a]pyrimidine-6-carboxamide (PVP-5j): White solid; Rf 0.60 (9:1Chloroform: 
Methanol); IR (KBr): 3241, 3215, 3193, 3051, 2933, 2654, 1662, 1553, 1437, 1247,  
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1047 cm-1; MS (m/z): 399 (M+); Anal. Calcd for C21H26ClN5O: C, 63.07; H, 6.55; N, 
17.51; Found: C, 63.13; H, 6.48; N, 17.56. 
 
N-cyclohexyl-4,7-dihydro-5-isopropyl-7-o-tolyl-[1,2,4]triazolo[1,5-a]pyrimidine-6-
carboxamide(PVP-5k): White solid; Rf 0.64 (9:1Chloroform: Methanol);IR (KBr): 
3271, 3215, 3093, 3051, 2933, 2654, 1662, 1593, 1437, 1247, 1076 cm-1; MS (m/z): 
379 (M+); Anal. Calcd for C22H29N5O: C, 69.63; H, 7.70; N, 18.45; Found: C, 69.68; 
H, 7.75; N, 18.54. 
 
N-cyclohexyl-4,7-dihdro-7-(2-hydroxyphenyl)-5-isopropyl-[1,2,4]triazolo[1,5-a] 
pyrimidine-6-carboxamide (PVP-5l): White solid; Rf 0.62 (9:1Chloroform: 
Methanol); IR (KBr): 3301, 3215, 3073, 3041, 2933, 2664, 1682, 1593, 1437, 1247, 
1076 cm-1;  MS (m/z): 381 (M+); Anal. Calcd for C21H27N5O2: C, 66.12; H, 7.13; N, 
18.36; Found: C, 66.07; H, 7.16; N, 18.24. 
 
N-cyclohexyl-4,7-dihydro-5-isopropyl-7-(4-nitrophenyl)-[1,2,4]triazolo[1,5-a] 
pyrimidine-6-carboxamide (PVP-5m): White solid; Rf 0.60 (9:1Chloroform: 
Methanol); IR (KBr): 3271, 3093, 3051, 2933, 1662, 1593, 1437, 1247, 1057 cm-1;  
MS (m/z): 410 (M+); Anal. Calcd for C21H26N6O3: C, 61.45; H, 6.38; N, 20.47; Found: 
C, 61.38; H, 6.35; N, 20.52. 
 
N-cyclohexyl-4,7-dihydro-5-isopropyl-7-(3-nitrophenyl)-[1,2,4]triazolo[1,5-a] 
pyrimidine-6-carboxamide (PVP-5n): White solid; Rf 0.65 (9:1Chloroform: 
Methanol); IR (KBr): 3300, 3215, 3193, 3051, 2833, 2654, 1622, 1593, 1247, 1076 
cm-1;  MS (m/z): 410 (M+); Anal. Calcd for C21H26N6O3: C, 61.45; H, 6.38; N, 20.47; 
Found: C, 61.49; H, 6.28; N, 20.42. 
 
N-cyclohexyl-4,7-dihydro-5-isopropyl-7-(3,4-di-methoxyphenyl)-[1,2,4]triazolo 
[1,5-a]pyrimidine-6-carboxamide (PVP-5o):White solid; Rf 0.63 (9:1Chloroform: 
Methanol); IR (KBr): 3271, 3215, 3183, 3051, 2910, 2654, 1642, 1437, 1247, 1067 
cm-1; MS (m/z): 425 (M+); Anal. Calcd for C23H31N5O3: C, 64.92; H, 7.34; N, 16.46; 
Found: C, 64.83; H, 7.28; N, 16.42. 
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? Spectral representation of synthesized compounds 
1H NMR spectrum of compound PVP-5a 
 
 
Expanded 1H NMR spectrum of compound PVP-5a 
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1H NMR spectrum of compound PVP-5c 
 
 
Expanded 1H NMR spectrum of compound PVP-5c 
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13C NMR spectrum of compound PVP-5a 
 
 
 
Expanded 13C NMR spectrum of compound PVP-5a 
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13C NMR spectrum of compound PVP-5b 
 
 
 
Expanded 13C NMR spectrum of compound PVP-5b 
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Mass spectrum of compound PVP-5b 
 
 
 
Mass spectrum of compound PVP-5c 
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Mass spectrum of compound PVP-5f 
 
 
 
Mass spectrum of compound PVP-5i 
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Mass spectrum of compound PVP-5n 
 
 
IR spectrum of compound PVP-5b 
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IR spectrum of compound PVP-5g 
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Research Summary 
 
 
The work presented in the Thesis entitled “Studies on Pharmacologically active 
Heterocycles” can be summarized as below. 
 
Chapter 1, we have described the synthesis of substituted pyrimidine derivatives in 
excellent yields. The reaction of various ketene dithioacetals with guanidine nitrate 
in refluxing methanolic sodium methoxide or ethanolic sodium ethoxide affords the 
2-amino-4-isopropyl-6-alkoxy-N-arylpyrimidine-5-carboxamide derivatives with 
good yields. All the synthesized compounds were evaluated for their antimicrobial 
activity. The investigation of antibacterial and antifungal screening data revealed that 
all the tested compounds PVP-1a-t showed moderate to potent activity. The 
compounds PVP -1i, 1k and 1l showed comparatively good activity against all the 
bacterial strains. 
 
Chapter 2, we have demonstrated the synthesis substituted pyrazolopyridone 
derivatives in excellent yields. The reaction of various ketene dithioacetals with 
cyanoacetamide was afforded the pyridone derivatives with good yields in the 
presence of base. Sodium isopropoxide was found as an efficient base for the 
synthesis of pyridones. The pyridones were further reacted with hydrazine hydrate to 
furnished pyrazolopyridones in excellent yields with short reaction time. All the 
synthesized compounds were evaluated for their anti microbial activity. The 
investigation of antibacterial and antifungal screening data revealed that all the tested 
compounds PVP-2a-t showed moderate to potent activity. The compounds PVP- 2h 
and 2g showed comparatively good activity against all the bacterial strains. 
 
Chapter 3, we have explained the synthesis of novel indazole bearing oxadiazole 
derivatives and triazole derivatives. The reaction of hydrazide of 2H-indazole with 
substituted carboxylic acid in the presences of POCl3 afforded desired oxadiazole 
derivatives (3A). However the reaction of hydrazide of 2H-indazole with carbon 
disulfide and base afforded the potassium salt of hydrazide which on reaction with 
hydrazine hydrate and followed by aldehyde afforded desired triazole derivatives 
(3B) in excellent yields. All the synthesized compounds were evaluated for their 
antimicrobial activity. The investigation of antibacterial and antifungal screening  
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data revealed that all the tested compounds PVP-3Aa-o and 3Ba-o showed moderate 
to potent activity. The compounds PVP-3Ab, 3Be and 3Bf showed comparatively 
good activity against all the bacterial strains. 
 
Chapter 4, we have described the synthesis substituted thiazolo pyrimidine 
derivatives in excellent yields. The reaction of various 2-thioxopyrimidine with 
chloro acetyl chloride (scheme 2) affords the 3,5-dihydro-7-isopropyl-3-oxo-N,5-
diaryl-2H-thiazolo[3,2-a]pyrimidine-6-carboxamide derivatives (PVP-4a-t) was 
obtained in excellent yield. All the synthesized compounds were characterized by IR, 
Mass, 1H NMR, 13C NMR spectroscopy. All the synthesized compounds were 
evaluated for their anti microbial activity. The investigation of antibacterial and 
antifungal screening data revealed that all the tested compounds PVP-4a-t showed 
moderate to potent activity. The compounds PVP-4c and 4m showed comparatively 
good activity against all the bacterial strains. 
 
Chapter 5, we have described the synthesis of 1,2,4-triazolo[1,5-a]pyrimidines 
derivatives in excellent yields. The reaction of N-cyclohexyl-4-methyl-3-oxo-
pentanamide (1) with appropriate aldehyde (2) and aminoazole (3) was refluxed in 
DMF affords the N-cyclohexyl-4,7-dihydro-5-isopropyl-7-phenyl-[1,2,4]triazolo[1,5-
a]pyrimidine-6-carboxamide derivatives was obtained in excellent yield. All the 
synthesized compounds were evaluated for their antimicrobial activity. The 
investigation of antibacterial and antifungal screening data revealed that all the tested 
compounds PVP-5a-o showed moderate to potent activity. The compounds PVP- 5j 
and 5l showed comparatively good activity against all the bacterial strains. 
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